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ABSTRACT 
 
Steroid hormone receptors play a critical role in the growth and progression of hormone-
dependent cancers. This thesis aimed at identifying and characterizing new chemical entities 
with therapeutic potential in breast and prostate cancer treatment. Reported here are two 
inhibitors that antagonize androgen receptor (AR) function and one that suppresses estrogen 
receptor (ER) signaling. Moderate-to-high throughput screens of chemical libraries were 
designed and implemented to identify these inhibitors.  
 The most promising inhibitor of AR transactivation to have emerged from the rigorous 
screening process was CPIC (1-(3-(2-chlorophenoxy) propyl)-1H-indole-3-carbonitrile). CPIC is 
capable of potently and specifically reducing androgen-induced proliferation and gene 
expression in prostate cancer cells. CPIC also inhibited recruitment of androgen-bound AR to the 
DNA regulatory sites of target genes in multiple cell lines. CPIC exhibits a mode of action 
different from that of classical AR antagonists, bicalutamide or flutamide. Additionally, CPIC at 
nanomolar concentrations, but not bicalutamide, disrupts the amino-carboxyl (N/C) terminal 
interaction of AR, which is crucial for optimum androgen-mediated AR signaling.  
Also described here is a novel non-competitive inhibitor of AR action, AR54 (2-(pyrimidin-
2-ylthio)-1-(2,2,4-trimethyl-4-phenyl-3,4-dihydroquinolin-1(2H)-yl)ethanone). AR54 blocks 
prostate cancer cell proliferation by reducing AR mRNA levels and down-regulating AR protein 
levels. We have not yet determined whether AR54 reduces the production of AR transcripts or 
increases the rate of mRNA degradation. AR54 modestly inhibits both androgen-dependent and 
androgen-independent proliferation of 22Rv1 cells, a model for castration-recurrent prostate 
cancer.  
These novel small molecule inhibitors represent important new probes for understanding AR 
action. In addition, CPIC and its structural analogues have properties that make them suitable for 
further evaluation and development as therapeutics for aggressive late-stage prostate cancers 
resistant to current therapies. 
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CHAPTER 1 
BACKGROUND 
 
Androgen and estrogen receptors are key members of the steroid receptor family and 
unusual in their ability to stimulate cell growth in response to their respective steroid hormones. 
Since the discovery of the first steroid hormone receptor by Jenson and colleagues (1), this class 
of nuclear receptors has been understood to be key to life on earth as we know it. The steroid 
family of receptors comprise mainly of the androgen, estrogen, progesterone, glucocorticoid and 
mineralocorticoid receptors. Of these, androgen and estrogen receptors have been identified to be 
unusual in their ability to stimulate cell growth in response to binding their respective steroid 
hormones. This has great implications in the understanding of normal and diseased physiology. 
 
Androgen Receptor (AR) is a Class I member of the nuclear receptor (NR) superfamily of 
ligand-inducible transcription factors. This receptor contains an N-terminal transactivation 
domain (NTD, encoded by exon 1), the DNA binding domain (DBD, exons 2 and 3), a short 
hinge region (exon 4), and the C-terminal ligand-binding domain (LBD, exons 4–8) where the 
androgenic ligands testosterone and dihydrotestosterone (DHT) bind (Illustrated in Figure 1.1). 
When bound by androgens, AR undergoes a conformational change that permits nuclear 
translocation, DNA binding, and regulation of AR target genes (2). Whereas estrogen receptor 
interacts with coregulators via contact points in the LBD, AR interaction with coregulators 
occurs primarily via regions of the NTD (3). Along with influencing transcriptional regulation, 
the N-terminal domain also binds to the C-terminal domain in a phenomenon unique to the AR 
known as its N/C interaction (4). This intra-molecular interaction plays a role in the stabilization 
of the AR dimer complex and in stabilization of the ligand-AR complex by slowing the rate of 
ligand dissociation and decreasing receptor degradation. Androgens like testosterone and DHT 
induce the N/C interaction in full length AR, unlike antagonists like hydroxyflutamide (OHF) or 
bicalutamide (Bic). The N/C interaction is altered when AR is specifically bound to response 
elements on DNA, allowing coregulator binding (5). AR is a transcription factor that up or down 
regulates target genes in response to androgens (genomic action), facilitated largely by direct 
interactions between the AR DBD and androgen-responsive elements (ARE) at DNA regulatory 
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sites of androgen responsive genes. AR also has significant extranuclear functions resulting in 
transcription-independent steroid signaling.   
AR signaling is required for development of the normal prostate. In this tissue, the AR 
mediates androgenic signals that primarily arise from the testes and adrenal glands. Testosterone 
passively diffuses across the prostate cell membrane, where it is then converted to the more 
active metabolite DHT by the 5α-reductase enzyme. DHT binds to the AR LBD with high 
affinity, inducing conformational changes that lead to activation of the receptor. Extracellular 
peptide signals, such as growth factors and cytokines, can promote AR activity although not 
through the same ligand-binding mechanism as androgens. 
AR signaling is also required for development and progression of prostate cancer, even in 
the advanced stage of castration-resistant prostate cancer (CRPC) (6). CRPC may develop due to 
many causes including, (a) changes in the level of ligand in tumor tissue or presence of extra-
testicular androgens (7); (b) increased levels of the AR protein due to gene amplification or 
expression of splice variants (7-11); (c) activating mutations in the receptor that affect structure 
and function (12-14); (d) changes in coregulatory molecules including coactivators and 
FIGURE 1.1. Schematic representation of the domain and exon structure of androgen 
receptor gene. (Adapted from Gelmann E P, Journal of Clinical Oncology, 2002; 20.) 
ANDROGEN RECEPTOR GENE
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corepressors; and (e) factors that lead to activation of the receptor through cross-talk with 
kinases. Impeding AR signaling remains the main therapeutic objective. New drugs currently in 
clinical trials (15, 16) may offer modestly improved management of CRPC through antagonism 
of AR activity or blockage of extra-testicular androgen production. Ultimately, the identification 
of drugs that promote selective AR degradation may have the greatest impact on the continued 
action of AR in CRPC (8). 
 
Estrogen Receptor alpha (ERα) is also a steroid hormone receptor belonging to Class I of 
the NR superfamily of ligand-inducible transcription factors (9). The interaction of ERα with 
target gene promoters either can occur directly, through specific estrogen response elements 
(EREs), or indirectly through contacts with other DNA bound transcription factors such as AP1, 
SP1, or NF-κB. Once tethered to DNA, the receptor can either activate or repress target gene 
transcription by communicating with the general transcription apparatus (Fig 1.2). Two acidic 
activation domains mediate the ligand-dependent transcriptional activity of ERα, a constitutive 
activation function-1 (AF-1) in the N-terminus, and a hormone-dependent AF-2 located in the 
LBD with binding sites for co-regulator proteins. The ER N-terminus is able to activate gene 
transcription without ligand, but this activation is weak and more selective compared to the 
activation provided by the LBD. In addition to the above-described classic or ‘genomic’ ER 
action, a portion of the ER in the cell may initiate more rapid cellular signaling by direct 
interaction with components of growth factor signaling pathways in what is referred to as the 
‘non-genomic’ or extranuclear action of ER. The extranuclear actions of ER associated with cell-
surface membrane can be activated by estrogens as well as by selective estrogen-receptor 
modulators (SERMs) such as tamoxifen and raloxifene. Estrogenic compounds are classified as 
full agonists (estradiol), mixed antagonists (tamoxifen) or pure antagonists (ICI 182780), and this 
function is decided by ER interactions with various co-regulatory proteins in different tissue 
types. 
ERα action is essential for normal growth and development and is expressed in most 
physiological systems at low to moderate levels, with highest expression levels observed in the 
ovary, uterus, breast and pituitary gland. ERα is a key regulator of the cellular processes 
involved in the development and progression of a majority of breast cancers.  
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Inhibitors of ERα and AR action in Breast and Prostate Cancer - The central roles 
played by estrogen receptor α (ERα) and by androgen receptor (AR) in receptor dependent cases 
of breast and prostate cancer led to an intense effort to identify agents that modulate receptor 
activity. The availability of substantial information on the interaction of agonist ligands with 
ERα and AR led to a primary focus on identification of small molecules that act by competing 
with natural hormones for binding in the ligand-binding pocket of the receptors. This approach 
was followed by development of agents that act by inhibiting key enzymes in estrogen or 
androgen synthesis (aromatase inhibitors). While these approaches to development of clinically 
useful agents remain productive, as shown by recent development of an improved competitive 
ligand for androgens (MDV3100) (15) and an inhibitor of androgen production in prostate 
tumors (Abiraterone) (16), their current potential for illuminating novel mechanisms of ERα and 
AR action is limited.  
Our lab intended to focus on small molecule modulators of ERα and AR activity that act 
outside of the ligand-binding pocket. Some of the sites targeted in attempts to antagonize ER 
action in breast cancer are illustrated in Figure 1.3, and can be extrapolated to AR as well. In 
addition to direct interactions with various ligands, both receptors have an array of 
macromolecular interaction partners that can influence receptor activity (10) including DNA 
	  ESTROGEN  
RECEPTOR 
FIGURE 1.2. ER action at a responsive gene. (Adapted from A Prokesch and MA 
Lazar, Cell, 2011, 145:4, 499-501)	  
	   	   5 
	  
binding sites, proteins that tether receptors to DNA, coactivators and corepressors, chaperones, 
ubiquitin ligases, and diverse modifiers including kinases, phosphatases, methylases and 
acetylases. These interactions provide a wealth of targets that are being exploited by screens to 
identify small molecules that modulate ERα and AR activity (20-24). 
In considering efforts to identify small molecule modulators of ERα and AR, it is important 
to understand why it has been simpler to target binding of natural hormone ligands than to target 
other sites critical for receptor activity. The natural ligands are relatively small, and bind with 
very high affinity (low nM to sub nM) in a discrete binding pocket whose 3-dimensional 
structure has been solved. In contrast, most other ERα and AR interactions involve relatively 
large, often low affinity, macromolecular interfaces for which little or no structural information 
is available. Most current non-competitive small molecule modulators of ERα and AR were 
identified using screens based on known activities of the receptors, such as DNA binding or 
Figure 1.3: Schematic representation of some sites targeted by small molecules used to selectively 
block ERα action and breast cancer cell growth. DJ Shapiro et al., J Biol Chem, 2011,	  286:4043-8  
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coactivator binding. Although binding sites for many of these small molecules are, as yet, 
unknown, they target well-defined biological processes. 
Our lab has been involved in efforts to identify new small molecule inhibitors of AR and 
ERα action. We employed high-throughput screens (HTS) for this purpose and used different 
approaches for the two receptors. For ERα, we used a fluorescence anisotropy based microplate 
assay (FAMA) (25-27) to identify small molecule inhibitors that disrupt ERα binding to ERE 
containing DNA probes. This HTS identified TPBM as an inhibitor of ER action (20) and 
through lead optimization, we hit upon TPSF as a non-competitive inhibitor of ERα working at 
least in part by increasing ERα degradation (11). TPSF is described in Chapter 2 of this 
document. 
Although we performed a FAMA-based small-scale screen for identifying AR inhibitors, we 
found that there was poor translation of effective small molecules from in vitro assays to cell-
based assays for the AR. This motivated us to develop a luciferase-based screen for AR HTS. 
For this screen we used HeLa cells stably transfected to express high amounts of AR and a 
luciferase reporter under control of the prostate specific antigen (PSA) promoter sequence. We 
reasoned that using a cell line with high levels of AR protein and natural hormone, 
dihydrotestosterone (DHT), would help exclude weak-to-moderate competitive antagonists that 
inhibit the receptor by binding at its ligand-binding pocket. The screening methodologies I used 
are elaborated in Chapter 3.  
We are currently evaluating the properties of some leads from the AR HTS. Two lead 
inhibitors are described in detail in later chapters; CPIC (AR19), an antagonist of N-terminal 
AR activity, and AR54, a non-competitive small molecule that reduces AR transcripts. 
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CHAPTER 2 
A NONCOMPETITIVE SMALL MOLECULE INHIBITOR OF BREAST CANCER 
CELL GROWTH THAT ENHANCES PROTEASOME-DEPENDENT DEGRADATION 
OF ESTROGEN RECEPTOR ALPHA1¶ 
 
The mechanisms responsible for 17β-estradiol (E2)-stimulated breast cancer growth and 
development of resistance to tamoxifen and other estrogen receptor α (ERα) antagonists are not 
fully understood. We describe a new tool for dissecting ERα action in breast cancer, p-fluoro-4-
(1,2,3,6,-tetrahydro-1, 3-dimethyl-2-oxo-6-thionpurin-8-ylthio) (TPSF), a potent small-molecule 
inhibitor of estrogen receptor α, that does not compete with estrogen for binding to ERα. TPSF 
noncompetitively inhibits estrogen-dependent ERα-mediated gene expression with little 
inhibition of transcriptional activity by NF-κB, or the androgen or glucocorticoid receptor. TPSF 
inhibits E2-ERα-mediated induction of the proteinase inhibitor 9 (PI-9) gene, which is activated 
by ERα binding to estrogen response element DNA and the cyclin D1 gene which is induced by 
tethering ERα to other DNA-bound proteins. TPSF inhibits anchorage-dependent and anchorage-
independent E2-ERα stimulated growth of MCF-7 cells, but does not inhibit growth of ER-
negative MDA-MB-231 breast cancer cells. TPSF also inhibits ERα-dependent growth in 3 
cellular models for tamoxifen resistance: 4-hydroxytamoxifen-stimulated MCF7ERαHA cells 
that overexpress ERα, in fully tamoxifen-resistant BT474 cells that have amplified HER-2 and 
AIB1, and in partially tamoxifen-resistant ZR-75 cells. TPSF reduces ERα protein levels in 
MCF-7 cells and several other cell lines, without altering ERα mRNA levels. The proteasome 
inhibitor MG132 abolished down-regulation of ERα by TPSF. Thus, TPSF effects receptor 
levels at least in part due to its ability to enhance proteasome-dependent degradation of ERα. 
TPSF represents a novel class of ER inhibitor with significant clinical potential. 
                                                
1 This research was originally published in Journal of Biological Chemistry. 2010, 285(53): 41863-73. I thank my 
co-authors for their significant contributions to this work. 
¶ Disclosure: The University of Illinois at Urbana-Champaign has filed a novel use patent that claims TPSF. 
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INTRODUCTION 
Estrogen receptor α (ERα) is a well-studied member of the steroid/nuclear receptor family 
of transcription regulators. ERα acts in the nucleus to regulate gene expression by binding to 
estrogen response elements (EREs) and related DNA sequences (1-4) and through association 
with transcription factors bound at SP1 and AP-1 DNA binding sites (4-7). In response to high 
affinity estrogen binding, ERα dimerizes, binds to ERE DNAs and undergoes a conformational 
change in the ligand-binding domain that facilitates the recruitment of coactivators (8). Bound 
coactivators promote assembly of a multiprotein complex that enables chromatin remodeling and 
stabilization of an active transcription complex (9-11). In contrast, antagonist-occupied ERα 
recruits corepressors (12).  
At detection, growth of most human breast cancers depends on 17β-estradiol (E2) binding to 
ERα (13-16). Treatment strategies that inhibit estrogen-dependent breast cancer include selective 
ER modulators such as tamoxifen that binds in the ERα ligand-binding pocket, and aromatase 
inhibitors that block estrogen production. Nearly half of patients treated with aromatase 
inhibitors develop resistance (17). The long-term effectiveness of tamoxifen is limited by the 
development of resistance in nearly all patients with metastatic breast cancer and in ~40% of 
patients with primary breast cancers (18).  The development of resistance to current therapies 
underscores the need to develop new small molecule antagonists that act outside the ligand-
binding pocket of ERα. We recently described an in vitro high throughput screening strategy to 
identify small molecule inhibitors of ERα binding to DNA. We identified 8-
benzylsulfanylmethyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (TPBM) as a small molecule 
inhibitor of ERα binding to ERE DNA (19). Using a cell-based screen, we evaluated 
approximately 200 small molecules structurally related to TPBM, and identified butyrophenone, 
p-fluoro-4- (1,2,3,6, -tetrahydro-1, 3-dimethyl-2-oxo-6-thionpurin-8-ylthio) (TPSF) as a novel 
inhibitor of ERα >15-fold more potent than TPBM. Although structurally related to TPBM, 
TPSF exhibits an entirely different mode of action. While TPBM inhibits in vitro binding of E2-
ERα to a labeled ERE, TPSF does not. TPSF strongly reduces ERα levels in breast cancer cells, 
while TPBM has little or no effect on the level of ERα. Here we demonstrate the selectivity of 
TPSF and its ability to inhibit expression of an endogenous ERα regulated gene that contains 
EREs and a gene regulated by tethering of ERα through other proteins. We show that TPSF 
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inhibits anchorage-dependent and anchorage-independent growth of tamoxifen-sensitive and 
tamoxifen-resistant ERα-containing breast cancer cells and demonstrate that TPSF enhances 
proteosome-dependent degradation of ERα.  
 
EXPERIMENTAL PROCEDURES 
Cell Culture- Unless otherwise indicated, cells were maintained at 37˚C in 5% CO2 in 
growth medium containing 1% penicillin and streptomycin and fetal bovine serum (FBS) 
(Atlanta Biological, Atlanta, GA) or calf serum, and transferred to phenol-red free medium 
containing charcoal-dextran (CD) stripped serum at least 2 days prior to treatment with E2, 4-
hydroxytamoxifen (OHT) or TPSF. ERα positive MCF-7 and ER-negative MDA-MB-231, 
human breast cancer cells, were cultured in MEM supplemented with 10% calf serum and 
switched to MEM containing 5% CD-treated calf serum 3 or 4 days before the experiment. The 
medium was changed on day 2. Tet-inducible MCF7ERαHA cells were maintained in DMEM 
supplemented with 1 mM sodium pyruvate, 0.5 µg/ml puromycin and 10% FBS. Four days 
before the experiment, MCF7ERαHA cells were switched to the above medium without phenol 
red containing 10% 6X stripped CD-treated FBS, without puromycin (20-23). ZR-75 human 
breast cancer cells were maintained in MEM containing 10% calf serum and transferred to 
medium containing 10% CD-CS 4 days before the experiment. BT474 human breast cancer cells 
were maintained in improved MEM (iMEM) containing 10% FBS and transferred to phenol red-
free iMEM containing 10% CD-FBS 4 days before the experiment. T47D-KBluc breast cancer 
cells expressing an (ERE)3-luciferase reporter gene (24) were maintained in phenol red-free 
RPMI 1640 containing  2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM 
Hepes, pH 7.5, 1 mM sodium pyruvate, 10% FBS. Four days before induction with E2, cells were 
transferred to medium without phenol red, containing 10% 2X CD calf serum. T47D/A1-2 cells 
that stably express the glucocorticoid receptor (GR) and contain a mouse mammary tumor virus 
(MMTV)-luciferase reporter (25) were maintained in MEM supplemented with 10 mM HEPES, 
pH 7.4, 2 mM glutamine, 5% FBS and 0.2 mg/ml geneticin (G418). Four days before the 
experiment the cells were transferred to the above phenol red-free medium (phenol red- free) 
containing 10% 2X CD CS. HeLa-AR1C-PSA-Luc-A6 cells that stably express AR and a 
prostate-specific antigen (PSA)-Luc reporter were maintained in phenol-red free MEM 
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 10% FBS under selection with 
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0.1 mg/ml hygromycin B (Roche) and 0.5 mg/ml G418. Four days before the experiment cells 
were transferred to medium containing 10% 2X CD-CS.  
Fluorescence Anisotropy Assays- The fluorescence anisotropy microplate assay for 
analyzing binding of ERα to the fluorescein-labeled consensus ERE was as described (19).  
Competitive Radioligand Binding Assays-The relative binding affinity of TPSF for ERα 
and ERβ was determined in competitive radioligand binding assays using 2 nM 3H-E2 and a 
range of TPSF concentrations as described (26,27).  
Reporter Gene Assays-Reporter gene assays were performed to compare the ability of about 
200 compounds structurally related to TPBM (19) to inhibit estrogen-dependent transcription in 
T47D-KBluc breast cancer cells stably transfected to express an (ERE)3-Luc reporter (24). The 
ability of TPSF to inhibit AR and GR transcriptional activity was assayed in HeLa-AR1C-PSA-
Luc-A6 cells that stably express human AR and a PSA-Luc reporter, and in T47D/A1-2 cells that 
stably express GR and MMTV-Luc. Four days before each experiment, cells were switched to 
medium containing CD-treated serum as described above. HeLaAR-PSA-Luc cells (100,000 
cells/well) and T47DA/1-2 and T47D-KBluc cells (200,000 cells/well) were plated in 1 ml of 
media in 24-well plates. After 24 h the indicated concentrations of E2, dihydrotestosterone 
(DHT) or dexamethasone (Dex) in DMSO, or DMSO vehicle alone, with or without TPSF, were 
added to each well. After 24 h, cells were washed once with phosphate buffered saline and lysed 
in 100 µl of Passive Lysis Buffer (Promega, Madison WI). Luciferase activity was determined 
using BrightGlo firefly luciferase reagent from Promega (Madison, WI). 
Endogenous Gene Expression- MCF-7 cells and MCF7ERαHA cells were maintained for 4 
days in medium containing 5% 1X CD CS (MCF-7 cells) or 10% 6X stripped CD FBS 
(MCF7ERαHA cells). For assays of TPSF inhibition of PI-9 induction in MCF-7 cells, cells 
were preincubated for 24 h with TPSF and then maintained for 4 h with and without E2 and 
TPSF, or with vehicle alone. To induce ERα expression, MCF7ERαHA cells were maintained in 
medium containing 0.5 µg/ml doxycycline (Dox) for 24 h. E2 or OHT was added with or without 
TPSF and maintained for 24 h. For the induction of cyclin D1, 24 h after plating the cells, E2 
with and without TPSF was added and cells were maintained for 24 h. RNA was extracted and 
mRNA levels were measured by quantitative RT-PCR as described (19,28). Actin mRNA level 
is used as the qRT-PCR internal standard. Primers used in qRT-PCR were: ERα, Forward- 
5’GGAGACGGACCAAAGCCACT, Reverse- 5’TTCCCAACAGAAGACAGAAGATG; 
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Cyclin D1, Forward- 5’TCATGGCTGAAGTCACCTCTTGGT, Reverse- 
5’TCCACTGGATGGTTTGTCACTGGA; PI-9, Forward- 
5’TGGAATGAACCGTTTGACGAA, Reverse- 5’CATCTGCACTGGCCTTTGCT; IL-8’ 
Forward-5'GAGGGTTGTGGAGAAGTTTTTG, Reverse- 5'CTGGCATCTTCACTGATTCTT 
G; β-actin, Forward- 5’AAGCCACCCCACTTCTCTCTAA, Reverse- 
5’AATGCTATCACCTCCCCTGTGT. 
Cell Growth and Viability Assays-Cells were maintained in CD-treated serum for at least 4 
days prior to each experiment. To minimize cell aggregation, MCF-7 cells were harvested in 10 
mM HEPES, pH 7.4, 1 mM EDTA. Other cell lines were harvested in trypsin-EDTA. To assay 
anchorage-dependent cell growth, 1,000 cells/well were plated in a 96 well plate. For slow 
growing ZR-75 cells, 2,000 cells were plated/well. Cells were maintained in medium containing 
CD-treated serum for 24 h and the medium was then changed and E2 and DMSO vehicle or 
TPSF in DMSO was added. The medium was replaced after 2 days, except for BT474 cells 
whose medium was not changed. After 4 days, cell viability was determined using Promega 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison WI). 
To assay anchorage-independent cell growth in soft agar, 1% and 0.7% Select Agar 
(Invitrogen), were prepared in water and warmed at 40°C before use. 1.5 ml of 0.5% bottom agar 
diluted in medium was added to each well of a 6-well cell culture plate and allowed to solidify at 
room temperature. Top agar was prepared by dilution in warm medium containing the various 
treatments. MCF-7 cells were resuspended in 1.5 ml of 0.35% top agar at 5,000 cells/well and 
plated in 3 wells for each condition.  The plate was kept at room temperature for 30 min until the 
top agar solidified, then 0.5 ml of medium containing the respective treatments was added on top 
of the agar. Culture medium on top of the agar was changed every 3-4 days. Colonies were 
visible by 1 week and counted at day 16 using a dissecting microscope. Photographs of colonies 
were taken using a Zeiss AxioImager2 imaging system at 6X magnification. 
Western Blot-MCF-7 cells were plated at 200,000 cells/well in 6-well plates in MEM 
containing 5% 1X CD FBS. The medium was changed at day 2, and at day 4 the medium was 
replaced with fresh medium containing the indicated treatments. Whole cell extracts were 
prepared after 24 hours in 1XRIPA buffer (Millipore, CA) containing protease inhibitor cocktail 
(Roche, Germany). Extract (20 µg protein/lane) was run on 10% SDS-PAGE gels and transferred 
to nitrocellulose membranes. ER was detected using a 1:4,000 dilution of ERα antibody ER6F11 
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(Bio Care Medical, CA).  The blot was stripped for 25 min and reprobed using a 1:10,000 
dilution of β-actin monoclonal antibody (Sigma, Saint Louis MO). 
Statistical Analysis-Results are expressed as mean ± SEM of at least three independent 
experiments. Student’s t test was used for comparison of the means between two groups. 
Significance was established when p<0.05. The comparisons are described in the figure legends 
and are not shown in the body of the figures. 
 
RESULTS 
TPSF is a Structure-specific Inhibitor that Acts Outside of the Ligand-binding Pocket of 
ERα-We evaluated the ability of approximately 200 compounds structurally related to TPBM 
(Fig 2.1A), a first generation ERα inhibitor (19), to inhibit E2-ERα-mediated gene expression in 
ERα-positive T47D-KBluc human breast cancer cells containing (ERE)3-Luc (24). Of the 
compounds tested, TPSF  was ~16 fold more potent than TPBM in inhibiting ERα mediated 
gene expression (Fig 2.1B).  
To test whether TPSF is a structure-specific inhibitor, we compared the ability of TPSF to 
inhibit ERα mediated gene expression to the structurally similar small molecule 99676. TPSF 
differs from NSC 99676 by having hydrophilic C=O and F substitutions at the phenyl ring (Fig 
2.1A). The similar, but more hydrophobic, 99676 had an IC50 of 9 µM, and is ~13 fold less 
potent than TPSF (Fig 2.1B). The results suggest that TPSF is a structure-specific inhibitor of 
ERα and is not simply acting by promiscuous inhibition due to micelle formation. 
If TPSF inhibited ERα by competing with E2 for binding in the ligand-binding pocket of the 
receptor, increasing the E2 concentration should reduce the ability of TPSF to bind ERα and 
block its action. To test this, we varied the E2 concentration by 500 fold and tested the ability of 
TPSF to inhibit (ERE)3-Luc in T47D cells. Increasing the concentration of E2 from 0.2 nM to 
100 nM only slightly increased the IC50 for inhibiting E2-ERα-mediated transcription from 0.4 
µM; (Fig 2.1B, filled triangles), to 0.7 µM (Fig 2.1B, open triangles), suggesting TPSF acts 
outside the ERα ligand-binding pocket.  
If TPSF is a highly potent ERα ligand, it might retain the ability to inhibit ERα at 100 nM 
E2. To test whether TPSF binds in the ligand-binding pocket of ERα, the ability of TPSF to 
compete with radiolabeled E2 for binding to ERα was evaluated. In competitive radiometric 
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binding assays performed across a broad range of concentrations (26,27), TPSF had virtually no 
ability to compete with E2 for binding to ERα. With E2 set at 100%, TPSF had a relative binding 
affinity for ERα of ~0.001%, indicating that it is not a classical ligand that competes with E2 for 
binding in the ERα ligand-binding pocket.  
TPSF is a Specific Inhibitor of ERα  Transactivation-The ERα binding cleft for p160 
coactivator LxxLL motifs has been a major target for development of peptide and small molecule 
inhibitors (29-33). Although these inhibitors are effective in reporter gene assays in transfected 
cells, in general, they have not been shown to effectively inhibit expression of endogenous ER-
regulated genes in breast cancer cells. We therefore tested the ability of TPSF to inhibit the 
expression of the endogenous E2-inducible proteinase inhibitor 9 (PI-9) gene in MCF-7 cells. 
The serpin PI-9 is a tumor lethality factor (34-36) whose induction by estrogens enables breast 
cancer cells to evade apoptosis induced by the immune cells, cytotoxic T lymphocytes (CTLs) 
and natural killer (NK) cells (23,28,37). PI-9 also inhibits tumor necrosis factor-α (TNF-α) Fas 
and TRAIL mediated apoptosis (38,39). Induction of PI-9 results from direct binding of E2-ERα 
to EREs and ERE half sites (19,40,41). TPSF (IC50= 0.2 µM) potently inhibited E2-ERα-
stimulated induction of PI-9 mRNA (Fig 2.2A).  
To examine the ability of TPSF to inhibit E2-ERα induction of a gene regulated by tethering 
of E2-ERα through DNA-bound transcriptional regulators, we tested the effect of TPSF on 
induction of cyclin D1 mRNA. Cyclin D1 is thought to contribute to the growth of MCF-7 and 
other breast cancer cells (42-44) and to tamoxifen-stimulated growth of breast cancer cells (45). 
As previously reported (43,46), E2-ERα stimulated a 2-3 fold increase in cyclin D1 mRNA, that 
was blocked by 10 µM TPSF (Fig 2B). The data demonstrate that TPSF inhibits E2-dependent 
gene expression through mechanisms that include direct binding of ERα to EREs and through 
tethering of ERα to DNA-associated transcription regulators. 
Specificity of TPSF inhibition of E2-ERα mediated gene expression was evaluated by 
comparing the ability of TPSF to inhibit gene expression mediated by NF-κB (Fig 2.2C) and by 
other steroid receptors (Fig 2.2D). The NF-κB-regulated IL-8 gene was used to test specificity 
because many regulators and pathways including IκB and other kinases, the 
ubiquitin/proteasome pathway and nuclear/cytoplasmic shuttling all influence NF-κB activity 
(47). Analyzing the effect of TPSF on NF-κB is a good way to test whether TPSF acts as a 
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promiscuous inhibitor targeting diverse cell proteins and pathways. 30 µM TPSF had no effect 
on the NF-κB-mediated induction of IL-8 mRNA by TNF-α (Fig 2.2C). In the same breast 
cancer cells where TPSF inhibited E2-ERα induction of PI-9 mRNA (Fig 2.2A, IC50=0.2 µM), a 
>100 fold higher concentration of TPSF had no effect on NF-κB-mediated induction of IL-8 
mRNA by TNF-α (Fig 2.2C).  
To further evaluate the specificity of TPSF, we compared the ability of TPSF to inhibit ERα 
to its effect on the androgen receptor (AR) and glucocorticoid receptor (GR)-mediated activation 
of stably transfected reporter genes. AR was assayed in HeLa cells stably transfected to express 
AR and a prostate specific antigen (PSA)-luciferase reporter. TPSF only very weakly inhibited 
DHT-AR-mediated induction of the PSA-Luc reporter (IC50=33 µM, Fig 2.2D). GR was assayed 
in T47D cells stably transfected to express GR and an MMTV-Luc reporter (25). TPSF weakly 
inhibited GR activation of the MMTV-luc reporter in T47D cells (IC50=10 µM). Although T47D 
cells contain substantial levels of the progesterone receptor (PR), cross-talk between ERα and 
PR makes them unsuitable for assaying inhibitor specificity using PR. The ER antagonist 
faslodex/fulvestrant/ICI 182,780 inhibited PR induction of the endogenous alkaline phosphatase 
gene (Supplemental Fig S2.1). TPSF did not inhibit NF-κB and concentrations of TPSF required 
to inhibit AR (33 µM) and GR (10 µM) are far higher than the 0.2 and 0.4 µM TPSF required to 
inhibit the endogenous PI-9 gene and the stably transfected  (ERE)3-Luc reporter. At low 
concentrations, TPSF is a relatively specific ERα inhibitor. 
TPSF inhibits E2 and OHT-induced Gene Expression in Tamoxifen-stimulated 
MCF7ERαHA Cells-Development of resistance to tamoxifen, and other therapeutics that target 
ERα and estrogen production results in treatment failure in both primary and metastatic breast 
cancer. Recent studies show that tamoxifen-resistant breast cancer cells that retain dependence 
on ERα for growth lose their dependence on SRC3 and other p160 coactivators for E2-ERα 
mediated gene transcription (22,48). We explored the ability of TPSF to inhibit E2 and OHT-
dependent gene expression in tamoxifen-resistant cells that are less dependent on p160 
coactivators for transactivation.  
MCF7ERαHA cells are an MCF-7-breast cancer cell line engineered to increase ERα 
expression in response to Doxycycline (Dox) (20,22). In Dox-induced MCF7ERαHA cells 
overexpressing ERα, tamoxifen and 4-hydroxytamoxifen (OHT) are potent ERα agonists (22,23) 
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and increase ERα-mediated gene expression independent of SRC3 (22). Because OHT stabilizes 
ERα against degradation, while E2 down-regulates ERα (23,37), ERα levels are ~4 times higher 
in OHT treated MCF7ERαHA cells than in cells treated with E2. The elevated level of ERα in 
OHT-treated MCF7ERαHA cells compared to cells treated with E2 renders OHT more effective 
than E2 in inducing PI-9 gene expression and more difficult to inhibit. 10 µM TPSF inhibited E2-
ERα (Fig 2.3A) and OHT-ERα induction of PI-9 mRNA (Fig 2.3B). This indicates that TPSF is 
an inhibitor of both E2-ERα and OHT-ERα mediated gene expression in cells where tamoxifen 
is a full agonist.  
TPSF Inhibits Estrogen-dependent Growth of MCF-7 Cells and Exhibits Low Toxicity in 
ERα  Negative MDA-MB-231 Cells-To determine whether TPSF specifically inhibits ERα-
dependent growth of breast cancer cells with minimal nonspecific cell toxicity, we tested TPSF 
inhibition of cell growth in MCF-7 cells and ERα negative MDA-MB-231 human breast cancer 
cells. Compared to MCF-7 cells in estrogen-depleted medium, both 1 pM and 10 pM E2 
stimulated a 4-5 fold increase in cell number after 4 days (Fig 2.4 and data not shown). TPSF 
elicited a dose-dependent inhibition of estrogen-dependent growth of MCF-7 cells (IC50= 2 µM) 
and completely blocked E2-dependent growth at 7.5 µM (Fig 2.4, filled circles). However, TPSF 
did not inhibit E2-independent cell growth (Fig 2.4, compare 7.5 and 10 µM TPSF, filled circles 
to no E2 or TPSF, open circle). TPSF did not inhibit growth of ERα negative MDA-MB-231 
cells at all concentrations, including 30 µM (Fig 2.4, filled triangles). To rule out the possibility 
that MDA-MB-231 cells are unusually resistant to TPSF or other ERα inhibitors, we compared 
the effects of TPSF and OHT on the growth of MDA-MB-231 cells. TPSF was less toxic to ER 
negative MDA-MB-231 cells than OHT (Supplemental Fig S2.2). The results suggest that TPSF 
specifically inhibits ERα-mediated growth of breast cancer cells with low nonspecific toxicity in 
ERα negative cells.  
TPSF Inhibits Anchorage-independent Growth of MCF-7 and BT474 Cells-The capacity 
for anchorage-independent growth is a hallmark of cancer cells. Growth in soft agar is often used 
to evaluate anchorage-independent growth of human breast cancer cells. We tested the ability of 
TPSF to inhibit E2-stimulated growth of MCF-7 cells in soft agar. MCF-7 cells grown in medium 
containing E2 formed large colonies after 16 days. Addition of 10 µM TPSF completely inhibited 
growth of MCF-7 cells in soft agar (Fig 2.5 A). When colonies in equal areas of the soft agar 
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plate were counted, the E2 treated plate had 30 colonies >0.5 mm in diameter, whereas there 
were no colonies >0.5 mm in diameter in the E2 and TPSF treated plate. Similar results were 
obtained with the tamoxifen-resistant BT474 cells as well (Fig 2.5 B). The data indicate that 
TPSF inhibits estrogen-stimulation of anchorage-dependent (Fig 2.4) and anchorage-independent 
(Fig 2.5) growth of breast cancer cells.  
TPSF Inhibits E2-ERα-dependent Growth of Tamoxifen-resistant Breast Cancer Cells- 
The ability of TPSF to inhibit E2-ERα-dependent cell growth was tested using human cell 
models of tamoxifen-resistant breast cancer. ZR-75 cells are usually reported as partially 
tamoxifen and OHT-resistant (49-51), while BT474 cells are fully tamoxifen-resistant and 
contain amplified expression of HER2 and AIB1 (52,53). TPSF inhibited E2-ERα-dependent 
growth of BT474 and ZR-75 cells with near maximal inhibition at 5 µM TPSF (Fig 2.6). Since 
TPSF has minimal nonspecific toxic effects, cell numbers after TPSF treatment were not zero 
and represented cells plated at day zero plus E2-ERα-independent cell growth over the 4 days. 
TPSF IC50 values were 0.9 µM for slow-growing ZR-75 cells and 1.6 µM for BT474 cells. The 
lower levels of ERα in ZR-75 compared to MCF-7 cells (54), may be responsible for the greater 
potency of TPSF in ZR-75 cells. Some tamoxifen-resistant breast cancers regress after tamoxifen 
withdrawal, suggesting tamoxifen stimulates tumor growth (45,55-57). The MCF7ERαHA cell 
line is a model for tamoxifen-stimulated breast cancer, where tamoxifen and OHT act as full 
agonists (Fig 2.3) (23,37). In MCF7ERαHA cells treated with Dox, overexpression of ERα 
increased E2-independent ERα-mediated cell growth, which was modestly increased by 1 pM E2 
with and without 5 µM OHT, and was inhibited by 5 µM TPSF (Supplemental Fig S2.3). Table 1 
summarizes the effect of TPSF on gene expression and cell growth. 
TPSF and TPBM have Different Modes of Action-Our data show that TPSF is a potent and 
selective inhibitor ER-stimulated gene expression and breast cancer cell growth. We therefore 
began to assess how TPSF might exert its actions. We used our fluorescence anisotropy 
microplate assay (FAMA) (19,58,59) to compare the ability of TPSF and TPBM to inhibit 
binding of purified ERα to a fluorescein-labeled consensus ERE (flcERE). When polarized light 
excites the flcERE, most of the emitted light is depolarized because of rapid rotational diffusion 
of the flcERE that results in its position being largely randomized at the time of emission. 
Binding of the larger ERα protein to the flcERE slows rotation of the flcERE, increasing the 
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likelihood that the complex is in the same plane at emission and excitation. Interaction of ERα 
with the flcERE increases fluorescence polarization (FP)/fluorescence anisotropy (FA).  
We compared the ability of TPBM and TPSF to inhibit binding of ERα to the flcERE. 
Consistent with our recent report (19), TPBM inhibited binding of E2-ERα to the ERE (Fig 
2.7A). Surprisingly, even at 30 µM, TPSF had no effect on binding of E2-ERα to the flcERE 
(Fig 2.7A). Thus, in a direct in vitro assay containing only E2-ERα, the flcERE, TPSF did not 
inhibit binding of ERα to an ERE.  
We next compared the effects of TPSF and TPBM on the intracellular levels of E2-ERα in 
MCF-7 cells. TPBM, at 5-20 µM, had little or no effect on the level of E2-ERα. In contrast, TPSF 
elicited a concentration-dependent reduction in E2-ERα levels, with 10 µM TPSF decreasing the 
level of E2-ERα by ~4 fold (Fig 2.7B). TPSF also reduced E2-ERα levels in T47D breast cancer 
cells (Fig 2.7C). Since TPSF had very little or no effect on the levels of AR and GR (Supplemental 
Fig S2.4), TPSF selectively down-regulates the level of ERα. The results indicate that TPBM and 
TPSF have distinct modes of action, and that TPSF is not simply a more potent version of TPBM.  
TPSF Does Not Alter the Level of ER mRNA-TPSF might reduce ERα levels by decreasing 
transcription, or by destabilizing ERα mRNA. To test for effects of TPSF at the mRNA level, we 
examined the effect of TPSF on ERα levels in HeLa cells that stably express ERα mRNA from a 
CMV promoter. TPSF retained the ability to down-regulate ERα protein from the CMV promoter 
and from the 2 kb ERα mRNA coding region that lacks ~4 kb of 5’ and 3’ untranslated region (Fig 
2.8A). TPSF had no effect ERα mRNA levels in MCF-7 cells (Fig 2.8B). Taken together the results 
suggest that TPSF down-regulates ERα protein levels through mechanisms that are independent of 
the level of ERα mRNA.  
The Proteasome Inhibitor MG132 Blocks the Down-regulation of ERα  by TPSF- To 
further examine the effects of TPSF we determined the time course of TPSF down-regulation of 
ERα. Consistent with a TPSF-induced increase in proteasome-dependent degradation of ERα, 
there was a progressive decrease in ERα protein levels after 6-8 h (Fig 2.9A). To examine this 
further we tested the ability of the proteasome inhibitor MG132 to block the effects of TPSF. 
Compared to E2 alone, TPSF reduced ER levels, and the TPSF-mediated reduction in ERα levels 
was completely blocked by MG132 (Fig 2.9B). Efforts to examine the effect of TPSF on 
ubiquitination of ERα in MCF-7 cells were complicated by the use of endogenous untagged 
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endogenous ubiquitin and because E2 down-regulates ER and influences its degradation. The 
data suggests that much of TPSFs effectiveness as an ER inhibitor resides in its ability to 
enhance proteasome-mediated degradation of ERα. 
TPSF Does Not Enhance ERα  Degradation by Reducing the Level of the Muc1 
Oncoprotein- Kufe and coworkers reported that the cytoplasmic domain of the Muc1 
oncoprotein binds ERα and stabilizes ERα against degradation; which contributes to enhanced 
ERα transactivation and the estrogen-dependent growth of breast cancer cells. Although the 
mechanism by which Muc1 influences ER degradation is unknown, knockdown of Muc1 with 
RNAi enhanced degradation of ERα, and inhibited ERα-mediated transactivation and growth of 
ER positive breast cancer cells (60). Because the effects of TPSF and RNAi knockdown of Muc1 
protein are similar, we tested whether TPSF influenced the level of the Muc1 cytoplasmic 
domain. Using the same antibody used by by Kufe and coworkers, TPSF did not alter the level of 
the Muc1 cytoplasmic domain (Supplemental Fig S2.5), indicating that the reduction in ERα 
levels elicited by TPSF was likely independent of the level of Muc1.  
 
DISCUSSION 
Specificity and Toxicity of TPSF- An optimal small molecule inhibitor of E2-ERα action 
and growth of breast cancer cells will exhibit specificity for ERα and low nonspecific toxicity. 
Independent testing of TPSF at concentrations up to 10 µM against a panel of 60 cancer cell lines 
at the National Cancer Institute Developmental Therapeutics Program demonstrated that TPSF is 
generally not toxic to cancer cells (testing was terminated because <6 of the 60 cell lines showed 
50% inhibition of cell growth at 10 µM TPSF). In agreement with this, we provide evidence that 
TPSF selectivity targets E2-ERα-dependent cell growth, with little effect on ERα-independent 
cell growth. After 4-days of treatment, E2 increased MCF-7 cell number by ~4 fold, which 
corresponds to a doubling time of ~1 day with E2 and ~2 days without E2. The number of cells 
treated with 7.5 µM and 10 µM TPSF was similar to that seen without E2. In addition, studies 
using ER-negative MDA-MB-231 cells showed 30 µM TPSF was not toxic. The ability of 10-20 
µM OHT to induce apoptosis of MDA-MB-231 cells suggests that these cells are not especially 
resistant to nonspecific toxic effects. Over several decades, tamoxifen has displayed an excellent 
safety profile in humans. The toxicity of OHT is used only to demonstrate that MDA-MB-231 
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cells remain susceptible to cell death and that the failure of TPSF to damage the cells is therefore 
due to low toxicity, rather than resistance of these cells to cell death.  
Several lines of evidence support the specificity of TPSF for ERα. For example, NF-κB is 
regulated by a variety of signaling mechanisms that include the ubiquitin/proteasome pathway, 
nuclear/cytoplasmic shuttling, IκB and other kinases and acetylases, (47). In MCF-7 cells, TNF-
α activation of NF-κB in MCF-7 cells increases IL-8 mRNA levels by ~50 fold. The absence of 
an effect of 30 µM TPSF on TNF-α induction of IL-8 mRNA suggests that TPSF does not 
exhibit nonspecific effects on these diverse cell pathways.  
TPSF specificity for ERα was also demonstrated relative to other steroid receptors. TPSF 
strongly down-regulated the level of ERα, but had very little or no effect on the levels of AR and 
GR. TPSF was a more potent inhibitor of transactivation by ERα than by AR or GR. We have 
identified other compounds that inhibit AR and GR under the same assay conditions (data not 
shown), suggesting that the failure of low concentrations of TPSF to inhibit transactivation by 
AR and GR was not due to assay conditions. The partial inhibition of GR and AR by higher 
concentrations of TPSF will not impede future animal or human studies. Two recently described 
AR inhibitors being tested for prostate cancer therapy, harmol and pyrvinium (61) were strong 
inhibitors of GR but were used with some success as AR inhibitors in studies in mice (61). 
Mifepristone (RU-486), a classical PR antagonist that also inhibits GR, has been used in long-
term clinical studies without significant GR-related pathology (62,63).  
Our initial ER inhibitor, TPBM, has proven useful as a selective inhibitor of the binding of 
E2-ERα to cellular genes (64,65). The identification of a new coactivator binding surface on AR 
using moderate potency (IC50 ~50 µM) small molecule inhibitors of AR selected by screening 
(66), that are unrelated to TPSF, also supports the utility of small molecule inhibitors as probes 
to understand the mechanisms of steroid receptor action.  
Inhibition of Gene Expression by TPSF- ERα activates gene expression by direct binding 
to ERE-related DNA sequences and by tethering to DNA-associated transcription factors. Our 
studies indicate that both of these mechanisms are inhibited by TPSF. TPSF inhibited the 
induction of PI-9 mRNA by E2-ERα and by OHT-ERα. PI-9 gene expression induced by E2: 
ERα results from binding to two adjacent ER binding sites in the PI-9 promoter region (40,41). 
Induction of PI-9 may be a mechanism by which estrogens enable breast cancers to evade 
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immune surveillance and apoptosis (23,37). PI-9 inhibits granzyme B and cytotoxic T 
lymphocyte and natural killer and cell mediated apoptosis of target cancer cells (23,28,37), and 
caspase 8-dependent apoptosis induced by TNF-α-family members (38,39). Expression of PI-9 is 
associated with a poor prognosis in some cancers (34-36,67).  
Cyclin D1 plays a key role in cell cycle progression and is induced by tethering E2-ERα to 
transcription factors bound at SP1 sites (46). Cyclin D1 induction is proposed to play a role in 
estrogen-dependent growth of breast cancer cells (42,43,45). Consistent with TPSF as a broad 
spectrum ERα inhibitor, 10 µM TPSF abolished E2 induction of cyclin D1 mRNA, but did not 
reduce the level of cyclin D1 mRNA much below the basal (-E2) level. Inhibition of E2-ERα-
dependent MCF-7 cell growth by 10 µM TPSF is consistent with a role for cyclin D1 in 
estrogen-stimulated growth of breast cancer cells. Our work extends earlier studies 
demonstrating that nearly complete loss of cyclin D1 following RNAi knockdown reduces 
growth of MCF-7 cells in medium containing estrogen (68).  Because TPSF specifically targets 
the ERα-regulated component of target gene expression, and did not influence basal gene 
expression, TPSF may be a promising new probe to help clarify the role of ERα regulation of 
specific genes in growth of breast cancer cells.     
TPSF is Effective in Tamoxifen-stimulated and Tamoxifen-resistant Breast Cancer Cells-
Development of resistance to tamoxifen and other endocrine therapies is a multifactorial clinical 
challenge in the treatment of breast cancer. A therapeutically useful small molecule inhibitor of 
ERα should inhibit the growth of a primary tumor as do tamoxifen and its active metabolite 
OHT, and also inhibit growth of tumor cells with acquired resistance to tamoxifen. Tamoxifen-
resistant tumors can be grouped into three broad classes. Some tumors become independent of 
ERα for growth and may be unaffected by therapies that target ERα. Others tumors remain 
dependent on E2 and ERα for growth. A third group loses estrogen-dependence but requires ERα 
for growth. The mechanisms involved in resistance to endocrine therapy are diverse. For 
example, ERα transactivation in tamoxifen-resistant cell lines may depend on as yet unidentified 
coregulators, or may be independent of the p160 coactivators (22,48).  
One proposed mechanism for tumor resistance to antagonists is the overexpression of steroid 
receptors. Overexpression of AR was suggested as an important mechanism of resistance to 
endocrine therapy in castration-recurrent prostate cancer (69). A subset of breast cancers that 
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contain high levels of ERα are often refractory to tamoxifen therapy (70-72). In MCF7ERαHA 
cells that overexpress ERα, tamoxifen and OHT are full agonists and induce PI-9 expression. In 
MCF7ERαHA cells maintained in the presence of OHT, levels of ERα are >10 times higher than 
in wild-type MCF-7 cells maintained in the presence of E2 (37). In cells expressing high levels of 
ERα, 10 µM TPSF inhibited both E2-ERα and OHT-ERα induction of PI-9 mRNA.  
Clinical specimens of tamoxifen-resistant metastatic breast cancer can be difficult to obtain 
(73). We and others (49) have therefore evaluated ERα inhibitors using stable breast cancer cell 
lines resistant to tamoxifen. TPSF inhibited E2-ERα-dependent growth of ZR-75 human breast 
cancer cells (IC50=0.9 µM), whose slow growth is only weakly stimulated by E2 and are partially 
resistant to tamoxifen and OHT (49,74). In contrast to OHT, TPSF blocked the growth of 
MCF7ERαHA cells that are tamoxifen-resistant because they overexpress ERα. TPSF inhibited 
E2-ERα-dependent growth of BT474 cells, which contain amplified HER2 and AIB1 and are 
fully tamoxifen resistant in cell culture (49) and in xenograft studies (52). Thus, TPSF is 
effective in cells that become tamoxifen-resistant through different mechanisms. 
Small Molecules Inhibitors of ERα-TPSF is structurally distinct from disulfide benzamide 
(DIBA), a zinc-chelator that acts outside the ERα ligand-binding pocket. DIBA promotes an 
ERα conformation conducive to the antagonist activity of OHT in tamoxifen-resistant cell lines. 
However, 5 µM DIBA inhibited the growth of ZR-75 cells by ~20% but did not inhibit the 
growth of tamoxifen-resistant BT474 cells (49). In contrast, growth of both ZR-75 cells and 
BT474 cells was inhibited by TPSF (IC50s=0.9 and 1.6 µM, respectively). Since TPSF does not 
compete with E2 for binding to ER in a direct binding assay or in transactivation, TPSF is not a 
classical antagonist ligand and is distinct from known ERα inhibitors. 
Fulvestrant is a high affinity ER ligand with nearly pure antagonist activity. Although 
fulvestrant is used therapeutically to treat advanced breast cancer, its use is limited by the fact 
that it can require several months for fulvestrant to reach a therapeutic level in serum (75). It has 
been known for many years that fulvestrant and related compounds, such as ICI 162,380 enhance 
the degradation of ERα (76,77), although the mechanisms are not known. Recent solution of the 
structure of fulvestrant bound to the ligand binding domain of ERα suggests that fulvestrant 
binding may distort ERα structure so that a few hydrophobic amino acids are exposed near the 
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surface, perhaps triggering recognition of ERα as a misfolded protein and rapid degradation (8). 
While this is an attractive hypothesis, this idea has not been tested in experiments.  
Structurally-related TPBM and TPSF Elicit Different Effects- Because ERα and other 
steroid receptors exhibit a high level of conformational flexibility small molecules can elicit 
quite different conformations when they interact with ERα. For example, binding of E2 or OHT 
in the ERα ligand-binding pocket resulted in functionally distinct agonist and antagonist 
conformations (8). Thus, binding of structurally related ERα inhibitors TPBM (19), and the more 
potent TPSF, may cause distinct ERα conformations that are associated with different modes of 
action. The different actions of TPBM and TPSF are illustrated in Fig 2.10. TPBM, inhibited E2-
ERα binding to ERE DNA in vitro, but had no effect on the intracellular level of ERα. In 
contrast, TPSF had no effect on binding of E2-ERα to ERE DNA, but elicited a concentration-
dependent reduction in ERα protein levels. TPSF also reduced the ERα protein level in our 
HeLa-ERα cells that stably express FLAG tagged ERα from a cytomegalovirus promoter that 
drives transcription of the ~2,000 nucleotide ERα cDNA (76) and did not reduce the level of 
ERα mRNA. Thus, at least part of the inhibitory effect of TPSF appears to reflect its ability to 
down-regulate ERα protein. E2-ERα induction of PI-9 mRNA and of the stably transfected 
(ERE)3-Luc reporter is inhibited by TPSF with IC50s of 0.2 µM and 0.7 µM, respectively, with 
only a modest effect on ERα levels. It is possible that regulation of some genes is more sensitive 
to small changes ERα levels. Another possibility is that low concentrations of TPSF did not 
saturate ERα. Under these conditions, ERα may assume a transient TPSF-induced conformation 
sufficient to alter ERα function and inhibit E2-ERα-mediated transactivation at PI-9 and (ERE)3-
Luc, whereas higher concentrations of TPSF may be required for an effect on levels of ERα.  
In conclusion, TPSF is a potent and specific small molecule inhibitor of ERα that blocks 
ERα-mediated gene expression and estrogen dependent growth of tamoxifen-sensitive and 
tamoxifen-resistant human breast cancer cells. TPSF inhibition of ERα is consistent with a role 
for estrogen induction of cyclinD1 in triggering the growth of breast cancer cells. TPSF 
represents a novel compound with potential for treating breast cancer and for probing the 
mechanisms of ER action.  
 
 
24 
 
REFERENCES: 
1. O'Lone, R., Frith, M. C., Karlsson, E. K., and Hansen, U. (2004) Genomic targets of 
nuclear estrogen receptors Mol Endocrinol 18, 1859-1875 
2. Carroll, J. S., and Brown, M. (2006) Estrogen receptor target gene: an evolving concept 
Mol Endocrinol 20, 1707-1714 
3. Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., 
Shao, W., Hestermann, E. V., Geistlinger, T. R., Fox, E. A., Silver, P. A., and Brown, M. 
(2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range 
regulation requiring the forkhead protein FoxA1 Cell 122, 33-43 
4. Jakacka, M., Ito, M., Weiss, J., Chien, P. Y., Gehm, B. D., and Jameson, J. L. (2001) 
Estrogen receptor binding to DNA is not required for its activity through the nonclassical 
AP1 pathway J Biol Chem 276, 13615-13621 
5. Safe, S. (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen 
receptor-Sp1 interactions Vitam Horm 62, 231-252 
6. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., and 
Webb, P. (2000) Estrogen receptor pathways to AP-1 J Steroid Biochem Mol Biol 74, 
311-317 
7. Qin, C., Singh, P., and Safe, S. (1999) Transcriptional activation of insulin-like growth 
factor-binding protein-4 by 17beta-estradiol in MCF-7 cells: role of estrogen receptor-
Sp1 complexes Endocrinology 140, 2501-2508 
8. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and 
Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and 
the antagonism of this interaction by tamoxifen Cell 95, 927-937 
9. Glass, C. K., and Rosenfeld, M. G. (2000) The coregulator exchange in transcriptional 
functions of nuclear receptors Genes Dev 14, 121-141 
10. McKenna, N. J., and O'Malley, B. W. (2002) Minireview: nuclear receptor coactivators--
an update Endocrinology 143, 2461-2465 
11. McKenna, N. J., and O'Malley, B. W. (2002) Combinatorial control of gene expression 
by nuclear receptors and coregulators Cell 108, 465-474 
 
 
25 
12. Shang, Y., and Brown, M. (2002) Molecular determinants for the tissue specificity of 
SERMs Science 295, 2465-2468 
13. Henderson, B. E., and Feigelson, H. S. (2000) Hormonal carcinogenesis Carcinogenesis 
21, 427-433 
14. Deroo, B. J., and Korach, K. S. (2006) Estrogen receptors and human disease J Clin 
Invest 116, 561-570 
15. Fabian, C. J., and Kimler, B. F. (2005) Selective estrogen-receptor modulators for 
primary prevention of breast cancer J Clin Oncol 23, 1644-1655 
16. Katzenellenbogen, B. S., Montano, M. M., Ekena, K., Herman, M. E., and McInerney, E. 
M. (1997) William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action 
and resistance in breast cancer Breast Cancer Res Treat 44, 23-38 
17. Anderson, H., Bulun, S., Smith, I., and Dowsett, M. (2007) Predictors of response to 
aromatase inhibitors J Steroid Biochem Mol Biol 106, 49-54 
18. Jordan, V. C. (2001) The past, present, and future of selective estrogen receptor 
modulation Ann N Y Acad Sci 949, 72-79 
19. Mao, C., Patterson, N. M., Cherian, M. T., Aninye, I. O., Zhang, C., Montoya, J. B., 
Cheng, J., Putt, K. S., Hergenrother, P. J., Wilson, E. M., Nardulli, A. M., Nordeen, S. K., 
and Shapiro, D. J. (2008) A new small molecule inhibitor of estrogen receptor alpha 
binding to estrogen response elements blocks estrogen-dependent growth of cancer cells 
J Biol Chem 283, 12819-12830 
20. Fowler, A. M., Solodin, N., Preisler-Mashek, M. T., Zhang, P., Lee, A. V., and Alarid, E. 
T. (2004) Increases in estrogen receptor-alpha concentration in breast cancer cells 
promote serine 118/104/106-independent AF-1 transactivation and growth in the absence 
of estrogen Faseb J 18, 81-93 
21. Jiang, X., Patterson, N. M., Ling, Y., Xie, J., Helferich, W. G., and Shapiro, D. J. (2008) 
Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and 
block killing of breast cancer cells by immune cells Endocrinology 149, 5366-5373 
22. Fowler, A. M., Solodin, N. M., Valley, C. C., and Alarid, E. T. (2006) Altered target gene 
regulation controlled by estrogen receptor-alpha concentration Mol Endocrinol 20, 291-
301 
 
 
26 
23. Jiang, X., Ellison, S. J., Alarid, E. T., and Shapiro, D. J. (2008) Interplay between the 
levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, 
proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells 
Oncogene 26, 4106-4114 
24. Wilson, V. S., Bobseine, K., and Gray, L. E., Jr. (2004) Development and 
characterization of a cell line that stably expresses an estrogen-responsive luciferase 
reporter for the detection of estrogen receptor agonist and antagonists Toxicol Sci 81, 69-
77 
25. Nordeen, S. K., Kuhnel, B., Lawler-Heavner, J., Barber, D. A., and Edwards, D. P. 
(1989) A quantitative comparison of dual control of a hormone response element by 
progestins and glucocorticoids in the same cell line Mol Endocrinol 3, 1270-1278 
26. Carlson, K. E., Choi, I., Gee, A., Katzenellenbogen, B. S., and Katzenellenbogen, J. A. 
(1997) Altered ligand binding properties and enhanced stability of a constitutively active 
estrogen receptor: evidence that an open pocket conformation is required for ligand 
interaction Biochemistry 36, 14897-14905 
27. Katzenellenbogen, J. A., Johnson, H. J., Jr., and Myers, H. N. (1973) Photoaffinity labels 
for estrogen binding proteins of rat uterus Biochemistry 12, 4085-4092 
28. Jiang, X., Orr, B. A., Kranz, D. M., and Shapiro, D. J. (2006) Estrogen induction of the 
granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by 
cytotoxic T lymphocytes and natural killer cells Endocrinology 147, 1419-1426 
29. Chang, C., Norris, J. D., Gron, H., Paige, L. A., Hamilton, P. T., Kenan, D. J., Fowlkes, 
D., and McDonnell, D. P. (1999) Dissection of the LXXLL nuclear receptor-coactivator 
interaction motif using combinatorial peptide libraries: discovery of peptide antagonists 
of estrogen receptors alpha and beta Mol Cell Biol 19, 8226-8239 
30. Chang, C. Y., Norris, J. D., Jansen, M., Huang, H. J., and McDonnell, D. P. (2003) 
Application of random peptide phage display to the study of nuclear hormone receptors 
Methods Enzymol 364, 118-142 
31. Gunther, J. R., Moore, T. W., Collins, M. L., and Katzenellenbogen, J. A. (2008) 
Amphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid 
receptor coactivator interaction ACS Chem Biol 3, 282-286 
 
 
27 
32. LaFrate, A. L., Gunther, J. R., Carlson, K. E., and Katzenellenbogen, J. A. (2008) 
Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for 
the estrogen receptor Bioorg Med Chem 16, 10075-10084 
33. Norris, J. D., Paige, L. A., Christensen, D. J., Chang, C. Y., Huacani, M. R., Fan, D., 
Hamilton, P. T., Fowlkes, D. M., and McDonnell, D. P. (1999) Peptide antagonists of the 
human estrogen receptor Science 285, 744-746 
34. ten Berge, R. L., de Bruin, P. C., Oudejans, J. J., Ossenkoppele, G. J., van der Valk, P., 
and Meijer, C. J. (2003) ALK-negative anaplastic large-cell lymphoma demonstrates 
similar poor prognosis to peripheral T-cell lymphoma, unspecified Histopathology 43, 
462-469 
35. ten Berge, R. L., Meijer, C. J., Dukers, D. F., Kummer, J. A., Bladergroen, B. A., Vos, 
W., Hack, C. E., Ossenkoppele, G. J., and Oudejans, J. J. (2002) Expression levels of 
apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma 
Blood 99, 4540-4546 
36. van Houdt, I. S., Oudejans, J. J., van den Eertwegh, A. J., Baars, A., Vos, W., 
Bladergroen, B. A., Rimoldi, D., Muris, J. J., Hooijberg, E., Gundy, C. M., Meijer, C. J., 
and Kummer, J. A. (2005) Expression of the apoptosis inhibitor protease inhibitor 9 
predicts clinical outcome in vaccinated patients with stage III and IV melanoma Clin 
Cancer Res 11, 6400-6407 
37. Jiang X, P., N, Ling, Y, Xie, J, Helferich,W, Shapiro, DJ. (2008) The soy phytoestrogen, 
genistein, blocks killing of breast cancer cells by immune cells. Submitted for publication  
38. Kummer, J. A., Micheau, O., Schneider, P., Bovenschen, N., Broekhuizen, R., Quadir, 
R., Strik, M. C., Hack, C. E., and Tschopp, J. (2007) Ectopic expression of the serine 
protease inhibitor PI9 modulates death receptor-mediated apoptosis Cell Death Differ 14, 
1486-1496 
39. Cunningham, T. D., Jiang, X., and Shapiro, D. J. (2007) Expression of high levels of 
human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated 
cytotoxicity Cell Immunol 245, 32-41 
40. Krieg, A. J., Krieg, S. A., Ahn, B. S., and Shapiro, D. J. (2004) Interplay between 
estrogen response element sequence and ligands controls in vivo binding of estrogen 
receptor to regulated genes J Biol Chem 279, 5025-5034 
 
 
28 
41. Krieg, S. A., Krieg, A. J., and Shapiro, D. J. (2001) A unique downstream estrogen 
responsive unit mediates estrogen induction of proteinase inhibitor-9, a cellular inhibitor 
of IL-1beta- converting enzyme (caspase 1) Mol Endocrinol 15, 1971-1982 
42. Musgrove, E. A., Lee, C. S., Buckley, M. F., and Sutherland, R. L. (1994) Cyclin D1 
induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to 
complete the cell cycle Proc Natl Acad Sci U S A 91, 8022-8026 
43. Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. 
G., Hinds, P. W., Dowdy, S. F., Brown, M., and Ewen, M. E. (1997) Cyclin D1 
stimulation of estrogen receptor transcriptional activity independent of cdk4 Mol Cell 
Biol 17, 5338-5347 
44. Sabbah, M., Courilleau, D., Mester, J., and Redeuilh, G. (1999) Estrogen induction of the 
cyclin D1 promoter: involvement of a cAMP response-like element Proc Natl Acad Sci U 
S A 96, 11217-11222 
45. Kilker, R. L., and Planas-Silva, M. D. (2006) Cyclin D1 is necessary for tamoxifen-
induced cell cycle progression in human breast cancer cells Cancer Res 66, 11478-11484 
46. Castro-Rivera, E., Samudio, I., and Safe, S. (2001) Estrogen regulation of cyclin D1 gene 
expression in ZR-75 breast cancer cells involves multiple enhancer elements J Biol Chem 
276, 30853-30861 
47. Chen, L., Fischle, W., Verdin, E., and Greene, W. C. (2001) Duration of nuclear NF-
kappaB action regulated by reversible acetylation Science 293, 1653-1657 
48. Naughton, C., MacLeod, K., Kuske, B., Clarke, R., Cameron, D. A., and Langdon, S. P. 
(2007) Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine 
resistance Mol Endocrinol 21, 2615-2626 
49. Wang, L. H., Yang, X. Y., Zhang, X., An, P., Kim, H. J., Huang, J., Clarke, R., Osborne, 
C. K., Inman, J. K., Appella, E., and Farrar, W. L. (2006) Disruption of estrogen receptor 
DNA-binding domain and related intramolecular communication restores tamoxifen 
sensitivity in resistant breast cancer Cancer Cell 10, 487-499 
50. Coradini, D., Biffi, A., Cappelletti, V., and Di Fronzo, G. (1995) Influence of different 
combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer 
cell lines Cancer Detect Prev 19, 348-354 
 
 
29 
51. Arteaga, C. L., Koli, K. M., Dugger, T. C., and Clarke, R. (1999) Reversal of tamoxifen 
resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming 
growth factor-beta J Natl Cancer Inst 91, 46-53 
52. Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., and Osborne, C. K. 
(2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular 
target for overcoming endocrine resistance Clin Cancer Res 10, 331S-336S 
53. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., 
Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. (1997) AIB1, a steroid 
receptor coactivator amplified in breast and ovarian cancer Science 277, 965-968 
54. Reese, J. C., and Katzenellenbogen, B. S. (1992) Examination of the DNA-binding 
ability of estrogen receptor in whole cells: implications for hormone-independent 
transactivation and the actions of antiestrogens Mol Cell Biol 12, 4531-4538 
55. Howell, A., Dodwell, D. J., Anderson, H., and Redford, J. (1992) Response after 
withdrawal of tamoxifen and progestogens in advanced breast cancer Ann Oncol 3, 611-
617 
56. Canney, P. A., Griffiths, T., Latief, T. N., and Priestman, T. J. (1987) Clinical 
significance of tamoxifen withdrawal response Lancet 1, 36 
57. Ishii, Y., Waxman, S., and Germain, D. (2008) Tamoxifen stimulates the growth of 
cyclin D1-overexpressing breast cancer cells by promoting the activation of signal 
transducer and activator of transcription 3 Cancer Res 68, 852-860 
58. Wang, S., Zhang, C., Nordeen, S. K., and Shapiro, D. J. (2007) In vitro fluorescence 
anisotropy analysis of the interaction of full-length SRC1a with estrogen receptors alpha 
and beta supports an active displacement model for coregulator utilization J Biol Chem 
282, 2765-2775 
59. Wang, S. Y., Ahn, B. S., Harris, R., Nordeen, S. K., and Shapiro, D. J. (2004) 
Fluorescence anisotropy microplate assay for analysis of steroid receptor-DNA 
interactions Biotechniques 37, 807-808, 810-807 
60. Wei, X., Xu, H., and Kufe, D. (2006) MUC1 oncoprotein stabilizes and activates 
estrogen receptor alpha Mol Cell 21, 295-305 
 
 
30 
61. Jones, J. O., Bolton, E. C., Huang, Y., Feau, C., Guy, R. K., Yamamoto, K. R., Hann, B., 
and Diamond, M. I. (2009) Non-competitive androgen receptor inhibition in vitro and in 
vivo Proc Natl Acad Sci U S A 106, 7233-7238 
62. Ramondetta, L. M., Johnson, A. J., Sun, C. C., Atkinson, N., Smith, J. A., Jung, M. S., 
Broaddus, R., Iyer, R. B., and Burke, T. (2009) Phase 2 trial of mifepristone (RU-486) in 
advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal 
sarcoma Cancer 115, 1867-1874 
63. Grunberg, S. M., Weiss, M. H., Russell, C. A., Spitz, I. M., Ahmadi, J., Sadun, A., and 
Sitruk-Ware, R. (2006) Long-term administration of mifepristone (RU486): clinical 
tolerance during extended treatment of meningioma Cancer Invest 24, 727-733 
64. Pan, Y. F., Wansa, K. D., Liu, M. H., Zhao, B., Hong, S. Z., Tan, P. Y., Lim, K. S., 
Bourque, G., Liu, E. T., and Cheung, E. (2008) Regulation of estrogen receptor-mediated 
long range transcription via evolutionarily conserved distal response elements J Biol 
Chem 283, 32977-32988 
65. Powell, E., Wang, Y., Shapiro, D. J., and Xu, W. Differential requirements of Hsp90 and 
DNA for the formation of estrogen receptor homodimers and heterodimers J Biol Chem 
285, 16125-16134 
66. Estebanez-Perpina, E., Arnold, A. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, 
R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., Webb, P., and Fletterick, R. J. 
(2007) A surface on the androgen receptor that allosterically regulates coactivator 
binding Proc Natl Acad Sci U S A 104, 16074-16079 
67. ten Berge, R. L., Oudejans, J. J., Ossenkoppele, G. J., and Meijer, C. J. (2003) ALK-
negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic 
aspects--a review J Pathol 200, 4-15 
68. Grillo, M., Bott, M. J., Khandke, N., McGinnis, J. P., Miranda, M., Meyyappan, M., 
Rosfjord, E. C., and Rabindran, S. K. (2006) Validation of cyclin D1/CDK4 as an 
anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of 
cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 
expression Breast Cancer Res Treat 95, 185-194 
 
 
31 
69. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. 
G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen 
therapy Nat Med 10, 33-39 
70. Lewis, J. S., and Jordan, V. C. (2005) Selective estrogen receptor modulators (SERMs): 
mechanisms of anticarcinogenesis and drug resistance Mutat Res 591, 247-263 
71. Thorpe, S. M., Christensen, I. J., Rasmussen, B. B., and Rose, C. (1993) Short 
recurrence-free survival associated with high oestrogen receptor levels in the natural 
history of postmenopausal, primary breast cancer Eur J Cancer 29A, 971-977 
72. Romain, S., Chinot, O., Guirou, O., Soulliere, M., and Martin, P. M. (1994) Biological 
heterogeneity of ER-positive breast cancers in the post-menopausal population Int J 
Cancer 59, 17-19 
73. Abukhdeir, A. M., Vitolo, M. I., Argani, P., De Marzo, A. M., Karakas, B., Konishi, H., 
Gustin, J. P., Lauring, J., Garay, J. P., Pendleton, C., Konishi, Y., Blair, B. G., Brenner, 
K., Garrett-Mayer, E., Carraway, H., Bachman, K. E., and Park, B. H. (2008) Tamoxifen-
stimulated growth of breast cancer due to p21 loss Proc Natl Acad Sci U S A 105, 288-
293 
74. Hoffmann, J., Bohlmann, R., Heinrich, N., Hofmeister, H., Kroll, J., Kunzer, H., 
Lichtner, R. B., Nishino, Y., Parczyk, K., Sauer, G., Gieschen, H., Ulbrich, H. F., and 
Schneider, M. R. (2004) Characterization of new estrogen receptor destabilizing 
compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer J Natl 
Cancer Inst 96, 210-218 
75. Robertson, J. F. (2007) Fulvestrant (Faslodex) -- how to make a good drug better 
Oncologist 12, 774-784 
76. Cheng, J., Zhang, C., and Shapiro, D. J. (2007) A functional Serine-118 phosphorylation 
site in estrogen receptor alpha is required for down-regulation of gene expression by 
17beta-estradiol and by 4-hydroxytamoxifen. Endocrinology In Press 
77. Reese, J. C., and Katzenellenbogen, B. S. (1991) Differential DNA-binding abilities of 
estrogen receptor occupied with two classes of antiestrogens: studies using human 
estrogen receptor overexpressed in mammalian cells Nucleic Acids Res 19, 6595-6602 
 
 
 
 
32 
CHAPTER ACKNOWLEDGEMENTS: I am most grateful to Ms. K. Carlson and Prof. J. 
Katzenellenbogen who performed the determination of the relative binding affinity of TPSF, Dr. 
Z. Erdogan for much helpful advice on MCF-7 cell growth assays, Dr. B. Huang for important 
advice on growth of MCF-7 cells in soft agar, Prof. F. Wang for use of his microphotography 
system, Prof. E. Alarid who provided the MCF7ERαHA cells, and Prof. A. Nardulli who 
provided the MDA-MB-231 cells.  
 
 
33 
TABLES & FIGURES 
 
Table 2.1 
Summary of IC50 values (µM) for inhibition of gene expression and growth of ERα positive and 
ERα negative human breast cancer cells* 
 
* IC50 values were calculated from data in Figs. 1,2,4 and 6 by curve fitting using SigmaPlot.  
IC50(µM)
Gene 
Expression
Reporter assays in T47D 
stable lines
ER 0.7
AR 34
GR 10
qRT-PCR in MCF-7 cells
Endogenous 
PI-9 0.2
NF-κB >>30
Cell Growth
ERα
positive 
breast 
cancer 
cell lines
Tam sensitive MCF-7 2
Partially Tam 
resistant ZR-75 0.9
Tam resistant BT474 1.6
ER negative cell lines MDA-MB-231
>30 
(0% 
inhibition)
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 Figure 2.1 
 
FIGURE 2.1. Structure-specific inhibition of E2-ERα-mediated gene expression by TPSF.  
A. Structures of three ERα inhibitors. TPBM is a recently described ERα inhibitor (19). TPSF is 
butyrophenone, p-fluoro-4-(1,2,3,6,-tetrahydro-1, 3-dimethyl-2-oxo-6-thionpurin-8-ylthio and is 
known also as theophylline, 8-(3-p-fluorobenzoylpropyl)thio-6-thio-). NSC-99676 is similar to 
TPSF except TPSF has C=O and F substitutions at the phenyl ring. B. Potency and efficacy of 
TPSF (triangles), TPBM (squares) and 99676 (circles). Inhibition of E2-ERα activation of ERE-
Luc was evaluated in dose-response studies of T47D (ERE)3-Luc cells maintained in 0.2 nM E2 
(filled triangles, squares and circles) or 100 nM E2 (open triangles) with the indicated 
concentrations of TPBM, TPSF, or 99676 present for 24 h prior to assay. Activity of the reporter 
in the presence of the tested concentration of E2 with DMSO and no inhibitor was set to 100%. 
Data are the average of 3 experiments ± SEM. IC50s were calculated by curve fitting using Sigma 
Plot. 
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Figure 2.2 
 
FIGURE 2.2. TPSF specifically inhibits expression of endogenous ER-regulated genes.  
A. TPSF inhibits E2 induction of PI-9 mRNA. For studies of PI-9 mRNA (filled squares), MCF-7 
cells were incubated for 24 h with the indicated concentrations of TPSF and maintained for 4 h 
in 10 nM E2 and TPSF. PI-9 mRNA was quantitated by RT-PCR as described (23). B. TPSF 
inhibition of E2-ERα induction of cyclin D1 mRNA. MCF-7 cells were plated and 24 h later 
treated with ethanol and DMSO vehicles, 10 nM E2, or 10 nM E2 and 10 µM TPSF. After 24 h, 
RNA was extracted and cyclin D1 mRNA levels measured by qRT-PCR. The level of cyclin D1 
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mRNA in the vehicle only sample was set to 1. Fold induction of cyclin D1 in the presence of 10 
µM TPSF was significantly different from the control (p < 0.05 using Student’s t test). C. TPSF 
does not inhibit NF-κB induction of IL-8 mRNA. MCF-7 cells were maintained for 24 h in 
medium without TNF-α or with 10 ng/ml TNF-α with and without 30 µM TPSF, harvested and 
IL-8 mRNA levels determined by qRT-PCR. D. Dose-response studies of inhibition of ERα, AR 
and GR transactivation. For each receptor, induction of luciferase reporter gene expression (AR 
and GR), or endogenous PI-9 mRNA (ER), in the presence of an appropriate ligand with DMSO 
minus TPSF was set to 100%. Cells were incubated for 24 h with 0.2 nM E2 for ERα, (filled 
squares), 5 nM Dex for GR, (filled triangles), 1 µM DHT for AR (filled circles) and the indicated 
concentrations of TPSF. Data are the average ± SEM for 3 experiments.  
Experimental Data in Figure 2.2 A, B: NM Kretzer 
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Figure 2.3 
 
FIGURE 2.3. TPSF inhibits E2 and OHT-induced gene expression in a tamoxifen-stimulated 
cell line. A and B. MCF7ERαHA cells maintained in 6X CD-FBS (22,37) were treated for 24 h 
with 0.5 µg/ml Dox to induce ERα expression (37) and A. 100 pM E2 or B. 500 pM OHT and 10 
µM TPSF as indicated. PI-9 mRNA levels were measured by qRT-PCR. PI-9 mRNA in control 
MCF7ERαHA cells not treated with Dox, E2 or OHT was set equal to 1. The high level of ERα 
in Dox-treated cells results in ligand-independent transactivation of PI-9 (37). Data are the 
average, with the range shown, for 2 experiments for E2 and 3 experiments ± SEM for OHT.  
Experimental Data in Figure 2.3: NM Kretzer
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Figure 2.4 
 
FIGURE 2.4. Inhibition of E2-ERα-dependent breast cancer cell growth by TPSF. MCF-7 
and MDA-MB-231 cells were maintained for 4 days in 5% CD-CS and 1,000 MCF-7 cells 
(circles) or MDA-MB-231 cells (triangles) were plated per well in 96 well plates. After 24 h, the 
medium was changed to 5% CD-CS with 1 pM E2 (filled circles or triangles) or without E2 (open 
circle and open triangle) and DMSO vehicle and the indicated concentrations of TPSF. Medium 
was replaced after 2 days and cells were assayed with MTS after a total of 4 days. Cell number 
was determined using a standard curve of cell number versus absorbance based on plating a 
known number of cells and assaying using MTS. Each data point is the average of 8 wells ± 
SEM. The percentage of cells present after 4 days with E2 and without TPSF was set equal to 
100. By curve fitting in Sigma Plot, the IC50 for inhibition of E2-dependent growth of MCF-7 
cells by TPSF was 2 µM.  
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Figure 2.5 
 
FIGURE 2.5. TPSF inhibits growth of MCF-7 and BT474 cells in soft agar. 5,000 MCF-7 
cells (A) or BT474 cells (B) were plated into top agar containing 1 pM E2, E2 + 10 µM 
hydroxytamoxifen (OHT) or E2 + 10 µM TPSF as described in Materials and Methods. After 16 
days of culture for MCF-7 cells and 28 days for BT474 cells, colonies were photographed at 5x 
magnification and counted. Photographs are representative of the entire plate and of duplicate 
experiments.  
 
A 
B 
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Figure 2.6 
 
 
FIGURE 2.6. TPSF inhibits E2-ERα-dependent growth of tamoxifen-resistant BT474 and 
ZR-75 cells. Cells were maintained in medium containing 10% CD-FBS (ZR-75) (triangles) or 
10% CD-CS (BT474) (circles) with or without 100 pM E2 and the indicated concentrations of 
TPSF. Viable cells were measured by comparison to a standard curve of cell number versus 
absorbance using the MTS assay. Data represents the average of at least 4 wells. IC50s for TPSF 
inhibition of cell growth were calculated by curve-fitting using Sigma Plot. Although some 
portion of ZR-75 cell growth is likely ERα-independent, to calculate the IC50 using Sigma Plot, 
we used the conservative assumption that all cell growth beyond the 2,000 ZR-75 cells plated 
was E2-ERα-dependent growth and thus subject to inhibition by TPSF.  
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Figure 2.7 
 
FIGURE 2.7. Different modes of 
action of TPSF and TPBM. A. 
TPSF does not inhibit binding of E2-
ERα to the flcERE. FAMA was 
performed as described (19) in the 
presence of increasing 
concentrations of TPSF and 5 µM 
TPBM. Consistent with our detailed 
dose-response study (19), 5 µM 
TPBM inhibited binding of TPBM 
to the flcERE by ~60%. Data were 
plotted with the change in anisotropy 
for binding of E2-ERα to the flcERE 
in the absence of small molecule 
inhibitors set to 100% (actual 
anisotropy: flcERE: 44 mA units; 
E2-ERα-flcERE: 81 mA units). Data 
are the average + SEM of 4 
experiments. The difference between 
5 µM TPSF and the control (no 
inhibitor) was not significant 
(p>0.05). The data for 5 µM TPBM 
was significantly different from both 
the control and from 5 µM TPSF 
(p<0.01 using Student’s t test) B. 
TPSF decreases ERα levels. MCF-7 
cells were cultured in 5% CD-calf 
serum for at least 2 days and maintained in +/- E2 and the indicated concentrations of TPSF or 
TPBM for 24 h. Lysates were then analyzed for ERα by Western blot using 8 µg protein/lane, 
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with actin as internal standard. Data are from the 3 independent western blots and are presented 
as mean ± SEM. Quantitation of ERα and actin was by PhosphorImager analysis. The value for 
ERα/actin in the absence of E2 was set equal to 1. C. T47D cells were maintained in the absence 
or presence of E2 and the indicated concentrations of TPSF, harvested, and analyzed by western 
blot as described for panel B.  
Experimental Data in Figure 2.7 B, C: C Mao 
 
Figure 2.8 
 
FIGURE 2.8. TPSF does not alter the level of ERα  mRNA. A. Western blot of HeLa-ER cells 
extract. HeLa cells stably transfected to express functional wild-type ERα (76) were maintained 
in MEM+10% FBS. Four days before the cells were plated in 6-well plates at 50,000 cells/well 
in MEM + 10% 1X CD-FBS. The medium was changed after 2 days and on day 4 replaced with 
fresh medium containing 10 nM E2 in DMSO, or DMSO and the indicated concentration of 
TPSF.  After 24 h, the cells were harvested and extracts prepared as described in Material and 
Methods. B. Effect of TPSF on ERα mRNA levels in MCF-7 cells. Cells were maintained 4 days 
in MEM + 5% 1X CD-FBS as described in Material and Methods. Then cells were then 
maintained for 24h in medium containing 10 nM E2 in DMSO or DMSO with or without 10 µM 
TPSF and ER mRNA levels determined by qRT-PCR as described in Material and Methods. 
Data were the average of 3 experiments ± SEM. 
Experimental Data in Figure 2.8: C Mao 
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Figure 2.9 
 
FIGURE 2.9. The proteasome inhibitor MG132 blocks degradation of ERα  by TPSF. A. 
Time course of the effect of TPSF on ER levels. MCF-7 cells were plated as described in 
Materials and Methods. After 4 days in MEM + 5% 1X CD-FBS, the medium was replaced with 
medium containing 10 nM E2 with or without 10 µM TPSF. Cells were harvested at the indicated 
times and extracts prepared and ERα protein levels determined by western blot as described in 
Materials and Methods. B. MG132 reverses the down-regulation of ER by TPSF.  Cells were 
treated as in panel A and maintained for 24 h in medium containing 10 nM E2 with or without 10 
µM and 10 µM MG132. Preparation of cell extracts and western blotting were as described in 
Materials and Methods. 
Experimental Data in Figure 2.9: C Mao 
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Figure 2.10 
 
 
 
FIGURE 2.10.  
Schematic representation of the different modes of action of TPSF and TPBM. 
 
 
45 
SUPPLEMENTAL FIGURES 
Supplemental Figure 2S.1 
SUPPLEMENTAL FIGURE 2S.1. The ER inhibitor ICI 182,780, decreases PR-mediated 
gene expression in T47D cells. In panel A before plating the cells were maintained in full serum 
(5% FBS) that contains some estrogen. In panel B the cells were depleted of estrogen by 4 days 
in medium containing 5%1X CD-FBS. A. 24 h after plating 2.5 nM or 500 nM progesterone (P4) 
was added with or without 1 µM ICI 182,780. B. After 24 h cells were maintained in medium 
with or without 5 nM progesterone (P4) and 1 µM ICI 182,780. Alkaline phosphatase assay. 
After 24 h in the indicated treatment, the cells were washed once with PBS, lysed in 100 µl of 
buffer (20 mM potassium phosphate, pH 7.8, 5 mM MgCl2, 0.5% Triton X-100, frozen. Lysate 
was stored at –70˚. 5 µl of supernatant was removed and assayed in a 96 well plate in 25 µl of 
assay buffer (100 mM diethanolamine, pH 9.5, 1 mM MgCl2, 0.4 mM CSPD (substrate, Applied 
Biosystems/Tropix) and 1X Emerald ll enhancer (Applied Biosystems/Tropix). After 1 h at room 
temp., luminescence in the visible (emission max. 542 nM) was read for 1 sec. Data were the 
average of 3 experiments ± SEM. 
Experimental Data in Supplemental Figure 2S.1: IO Aninye 
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Supplemental Figure 2S.2 
 
SUPPLEMENTAL FIGURE 2S.2. TPSF does not exhibit nonspecific toxic effects in ERα  
negative MDA-MB-231 cells. Cell maintenance, growth and plating were as described in the 
Fig 2.4 legend. The indicated concentrations of OHT (filled triangles) and TPSF (filled circles) 
and 1 pM E2 were added and cell number was determined using MTS and a standard curve. Cell 
number in the absence of TPSF or OHT was set as 100%. Data were the average of 3 
experiments ± SEM. 
Experimental Data in Supplemental Figure 2S.2: NM Kretzer 
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Supplemental Figure 2S.3 
 
 
SUPPLEMENTAL FIGURE 2S.3. TPSF but not OHT inhibits E2-ERα-dependent growth of 
MCF7ERαHA cells. MCF7ERαHA cells were maintained for 4 days in 6x CD-FBS (22,37), 
seeded into 12 well plates with or without 0.5 µg/ml Dox , 1 pM E2, 5 µM OHT and 5 µM TPSF, 
grown for 4 days and assayed using MTS and a standard curve for cell number. Cells in ethanol 
and DMSO vehicle alone were set to 100%. Data represent the average of 3 experiments + SEM. 
The difference between the cells incubated with TPSF + E2 + Dox and cells in OHT + E2 + DOX 
was significant (P <0.05 using Student’s t test). 
Experimental Data in Supplemental Figure 2S.3: IO Aninye 
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Supplemental Figure 2S.4 
 
 
SUPPLEMENTAL FIGURE 2S.4. TPSF has little or no effect on levels of AR and GR. To 
test the selectivity of TPSF for down-regulation of ERα, we evaluated the effect of 5 µM and 10 
µM TPSF on the levels of AR and GR. The cell lines used and cell growth conditions were those 
employed in the dose-response studies evaluating effects of TPSF on gene expression (Fig 2D). 
Cells were maintained in medium containing or lacking dexamethasone (panel A) or DHT (panel 
B) and 0, 5 or 10 µM TPSF for 24 hours. Extracts were prepared and analyzed on separate gels 
for AR and GR levels by western blotting. Total protein (12 µg for AR and 40 µg for GR) was 
fractionated on 10% polyacrylamide gels and AR and GR levels determined by western blot. The 
antibody used to detect AR was AR441 monoclonal antibody used at 1:1000 dilution 
(NeoMarkers, Freemont, CA). The GR antibody was MA1-510 monoclonal antibody (Thermo 
Scientific, Rockford, IL) used at 1:1000 dilution. Data is representative of at least 2 gels for each 
sample.  
Experimental Data in Supplemental Figure 2S.4: IO Aninye, MC Cherian and C Mao 
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Supplemental Figure 2S.5 
 
 
SUPPLEMENTAL FIGURE 2S.5. TPSF does not down-regulate the level of Muc1. MCF-7 
cells were maintained and plated as described in Materials and Methods. After 4 days in MEM + 
5% 1X CD-FBS, the medium was replaced with medium with or without 10 nM E2 and with or 
without 10 µM TPSF. Cells were harvested at 24 h extracts prepared and Muc1 detected using 
Muc1 specific antibody (60). The actin samples were run on a separate gel.  
Experimental Data in Supplemental Figure 2S.5: C Mao 
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CHAPTER 3 
HIGH-THROUGHPUT SCREENING FOR IDENTIFYING INHIBITORS OF 
ANDROGEN RECEPTOR ACTION 
 
Prostate cancer (PCa) is one of the leading causes of male mortality in the United States 
with more than 240,000 diagnosed cases predicted for 2012 alone (1). Androgens working 
through androgen receptor (AR) are fundamental to the growth and proliferation of prostate 
cancers. AR is the best-studied and most targeted biomarker of this type of cancer. Early stage 
tumors undergo remission with surgical or chemical castration, sometimes combined with 
radiation. The primary line of defense upon diagnosis of prostate cancer includes treatments that 
reduce circulating levels of androgens (androgen ablation) such that the stimulation of 
proliferation by androgen-bound AR is inhibited and the tumor regresses. Often, androgen 
deprivation therapy includes the use of antiandrogens (bicalutamide, hydroxyflutamide, 
nilutamide) to directly antagonize AR transactivation. But about 25% of the patients diagnosed 
with PCa develop ‘resistance’ to current treatments that aim at androgen ablation. These tumors 
called castration-recurrent prostate cancer (CRPC) are highly malignant, able to grow in low 
circulating androgens or even anti-androgens. Treatment options for these aggressive tumors are 
limited. Androgen ablation is not a cure for prostate cancer, but instead has an anti-proliferatory 
effect on advanced prostate cancer. Eventually a fatal form of cancer will remerge in the castrate 
environment, in which AR is reactivated by poorly understood molecular mechanisms that 
enable the tumor to be castration-recurrent. However, androgen receptor continues to play a 
central role in CRPC progression. 
My goal was to use high-throughput screening (HTS) to identify new small molecule 
inhibitors of AR action that have the potential for therapeutic use in CRPC. As AR in the 
castration-recurrent phenotype is unaffected by classical ligand antagonists, I wanted these 
inhibitors to preferentially act outside of the ligand-binding domain (LBD) of AR. With this idea, 
a moderate-scale screen (~12,000 small molecules) was set up using the fluorescence anisotropy 
microplate assay (FAMA) developed previously in our lab (2, 3). Small molecules may inhibit 
the macromolecular surfaces involved in DNA binding of steroid receptors, by either physically 
occupying the contact interface, or by altering protein conformation and are detectable by a 
change in fluorescence anisotropy. Later, a higher-throughput screening was set up and 
implemented using a stable HeLa cell line expressing androgen-induced, AR-mediated luciferase 
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reporter. This chapter details the various screening methodologies developed for the 
identification of small molecule inhibitors of AR action reported in this thesis.  
 
(I) FAMA FOR IDENTIFYING INHIBITORS OF AR BINDING TO DNA 
Previously it was thought that because protein-DNA and most protein-protein interfaces are 
large, they were poor targets for HTS to identify small molecule inhibitors. But we had 
considerable success in using FAMA to identify inhibitors of estrogen receptor binding to 
estrogen responsive element constructs (4). These inhibitors were also able to disrupt these 
complexes and interrupt transactivation of target genes in MCF-7 as seen in RT-PCR and 
chromatin immunoprecipitation assays. A similar approach was used to identify AR inhibitors.  
Briefly, small biomolecules such as short DNA fragments tumble rapidly in solution due to 
their increased entropy. If these biomolecules are labeled with a fluorescent dye, a beam of 
polarized light passing through this solution will be mostly depolarized and light is detected at 
both the parallel and perpendicular detectors. When a second biomolecule known to interact with 
the first is introduced into this solution, the ensuing complex rotates more slowly in solution due 
to its conformational change and the light emitted is more polarized. An inhibitor of this 
interaction would in principle result in less polarized (more depolarized) emissions, without 
exhibiting any intrinsic fluorescence (Fig 3.1). We rule out ligand-exchange in these assays, as 
the amount of DHT added in the reaction buffer is substantial, DHT is the most effective ligand 
known for AR. Moreover, the AR protein was purified with DHT.  
I used full-length flag-tagged AR expressed and purified from baculovirus cultures by our 
collaborator Dr. Elizabeth M. Wilson (UNC, Chapel Hill). I successfully applied FAMA to the 
binding of AR to three fluorescein-labeled palindromic androgen response elements (ARE), the 
fl-cARE, fl-c3ARE and fl-PRE/GRE. The assay is done in a total volume of 20 µl in 96-well 
micro-plates. Increasing concentrations of AR are incubated with 1 nM of the fluorescein-labeled 
probe, for 10-15 minutes at room temperature in the dark prior to measuring the 
polarization/anisotropy. The assay binding buffer contains: 20 mM Tris-Cl pH 7.5, 100 mM KCl, 
2 mM dithiothreitol (DTT), 10% glycerol, 0.25 µg/µl bovine serum albumin (BSA), 0.2 mM 
EDTA and 10 ng of non-specific DNA, poly (dI:dC). These conditions were shown to abolish 
non-specific binding. The dilution buffer for AR was similar, with 5 µM ZnCl2 for stabilizing the 
zinc-finger motifs within the AR DNA-binding domain (DBD) and 1 µM dihydrotestosterone 
(DHT) to keep the receptor ligand-bound and hence stable for longer periods of time (5). The 
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fluorescence anisotropy is measured as a ‘change in anisotropy’ in milli-anisotropy (mA) units, 
representing the difference between anisotropy values measured at each concentration of AR and 
values measured in the wells with free probe. An approximate KD (dissociation constant) was 
determined as the receptor concentration at which 50% of the probe was bound. AR bound to the 
three probes with an apparent KD ~25 nM in 100 mM salt, which is thought to be a 
physiologically relevant salt concentration (Fig. 3.2).  
I used 1 nM fl-cARE for the screen with 45 nM AR, which results in at least 80% of 
maximal binding. The test compounds in each plate were added at a final concentration of 2.5 
µM using a 100 nl pin-spotter (VP Scientific) and incubated for 15 minutes before measuring the 
fluorescence anisotropy using the BMG Pherastar (excitation wavelength 495 nm, emission 
wavelength 520 nm). Z’-factor of the screen was calculated to be 0.8 using the formula given 
below, which is characteristic of robust assays whose precision and dynamic range is suitable for 
HTS development.  
 
 
 
 
where STDsample and Meansample are the sample mean and standard deviation from the mean, 
STDP and MeanP are the mean and standard deviation of the negative control wells on the plate.  
The actual primary screen of ~12,000 small molecules was relatively small and was 
performed within a week, with help from Dr. Chengjian Mao. Fig 3.3 represents a typical plate 
from the screen. % Inhibition of each compound was calculated as  
 
 
 
where xwell is the change in anisotropy measured for each compound in a well and ẌP is the 
change in anisotropy measured in the control wells (DMSO) containing AR: flcARE.  
The most dramatic increases or decreases in anisotropy were observed in wells with 
compounds that exhibit intrinsic fluorescence. These were eliminated on the basis of increased 
deviation of % fluorescence intensity when compared to control wells containing DMSO. On an 
average 3-4 inhibitors were identified per plate of small molecules. The ~200 molecules 
identified as inhibitors in the first round of screening were used in the secondary screening 
% Inhibition = 1 –  ( xwell – ẌP) 
    (ẌP) 
	  
Z’-factor = 1–    3 * (STDsample +  STDP) 
       | Meansample – MeanP| 
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assays including dose-response curves. Specificity of the small molecules for AR was tested by 
determining the effect on estrogen and progesterone receptors binding to their respective 
response elements in FAMA. Molecules that showed high potency and specificity were then 
utilized in cell-based androgen-mediated luciferase assays and in androgen-dependent prostate 
cancer cell proliferation assays.  
To our great disappointment, most specific inhibitors of AR:ARE in FAMA when tested in 
cell-based assays showed no or low inhibition of androgen-induced AR-mediated luciferase 
activity. Only one inhibitor showed any inhibition of AR in a dose-responsive manner and 
translated well into a cell-based assay system. The structure of this small molecule, #4457, is 
illustrated in Fig 3.4A and it specifically and potently inhibited AR-ARE interaction (Fig 3.4B). 
#4457showed some dose-dependent inhibition of androgen-induced AR-mediated luciferase 
reporter in HeLa cells (Fig 3.4C). But a closer look at the compound revealed that it is a TNT 
derivative and thus challenging for chemists to synthesize more of the compound or make 
analogues for structure-activity relationship study. We decided not to pursue this compound, 
instead planned to perform an unbiased cell-based screen. 
I also investigated ~180 small molecules that were structurally similar to the ER inhibitor 
identified using FAMA (TPBM, (4)) and conducted structure-activity relationship studies with 
all the steroid receptor activated luciferase reporter systems. This was performed in hopes of 
identifying potent and specific small molecule inhibitors that may inhibit AR action. Two of 
these inhibitors, #95869 and #95899, performed with reasonable specificity and potency in cell-
based luciferase reporter assays, induced using 10 nM DHT (Fig 3.5A). But in radio-ligand 
competition assays, these compounds were found to be competitive antagonists that worked less 
well than bicalutamide (Fig 3.5B). Since the main purpose of the screen was to identify potent 
non-competitive inhibitors of AR action for potential use in a castrate-recurrent environment, the 
inhibitors identified so far were underwhelming and hence not pursued any further.  
There are two basic approaches to HTS. A small library can be screened and candidate 
molecules subject to further study by combinatorial synthesis of related compounds and further 
evaluation and testing. This is what I had hoped to do with the moderate-scale fluorescence 
anisotropy screen, but the results were not ideal. Alternatively, a much larger library can be 
screened with the hope that individual hits will be identified with better potency, efficacy and 
specificity. So I decided to use this second approach by utilizing the ~160,000 small molecules 
in the chemical libraries at the HTS facility on this campus. I hoped that this type of large screen 
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in an AR-regulated luciferase-reporter system is more likely to generate strong lead compounds 
capable of crossing the cell membrane for inhibition of AR action.   
 
(II) CELL-BASED HIGH-THROUGHPUT SCREENING FOR IDENTIFYING 
INHIBITORS OF ANDROGEN RECEPTOR ACTION 
Cell-based assays combine the biological complexity of live cell responses with the 
scalability and process adaptation of HTS. The application of cell-based assays in HTS is an 
inherently challenging operation. The large biological complexity and high degree of crosstalk 
between integrated signaling pathways predispose cell-based assays to more false positives than 
biochemical assays (6).  The high biological complexity also increases potential sources of noise 
and variability that can lead to deterioration of assay performance to levels unacceptable for 
HTS. These factors include variations in cell plating, differential cell growth and response, 
uneven response across plates, plate-to-plate variability, and edge effects.  
The feasibility of performing a cell-based high-throughput screen was tested extensively 
before set-up. To overcome well-to-well variability that could arise if aspiration steps are 
performed from well containing cells, we compared two different set-ups for screening in 384-
well plates.  
In testing a large number of compounds for AR-mediated transactivation and for toxicity of 
the hits, it would be simplest to add the cells and the small molecules to the wells at the same 
time. The more traditional alternative we previously used involved plating the cells, waiting for 
them to attach and grow for 24 hours, and then adding the compound. But this results in 
significant additional labor and poses evaporation problems because of the very small volume of 
medium in the wells. Method 1 involves plating the cells one day prior to compound addition 
and aspirating the excess media from the cells after 24 hours of incubation with small molecules. 
If aspiration caused cells to dislodge from the bottom of wells, we felt that this step could 
increase the number of false positives.  
In method 2, cells are delivered after the compound and no medium aspirations are required 
after cell addition, thus reducing the chances of variability due to cell number. A hit map of 
results from a test plate comparing the two above methods is illustrated in Fig 3.6. Inhibition of 
transactivation and toxicity of the small molecules were similar when the compounds were added 
along with the cells and when the compounds were added after the cells had had a day to attach 
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and recover. Thus we chose method 2 for large-scale screening of the ~160,000 small molecules 
in the library. 
 
Careful consideration was given to way to reduce ‘edge effect’. Thermal gradients are 
greatest in the edge wells of plates, and they result in uneven distribution of the cells on the well 
bottoms. The uneven cell distribution in turn affects cell adhesion and morphology, and response 
to test compounds. After adding the cells, the plates were arranged in the 37°C, 5% CO2 
incubator in single files across each shelf (rather than stacks) and care was taken not to open the 
incubators until the end of the 24 hour period. This seems to help in maintaining equal volumes 
in wells across the plate. Due to the way the chemical libraries are set-up, the edge columns and 
rows of plates had to be evaluated in the assay.  
  
MATERIALS AND METHODS 
Screening libraries- The main library we screened was the ChemBridge MicroFormatTM 
library, which was pre-plated in 10 mM stocks in DMSO. We also included two smaller libraries, 
Cells added to 384-well plates and incubated 
for 24 hours
Add media with 5nM hormone (DHT)
Deliver compounds  to cells with pin-spotter.
Each well: 2,400cells, 5nM DHT, 10uM compound
Incubate 24 hours
Aspirate excess media from the cells and  
freeze the plates.
Thaw plates and assay using 5µl BrightGlo
Luciferase reagent per well.
Deliver 80µl media per well to 384-well plates
Deliver compounds  to wells with pin-spotter, 
20µM final concentration.
Remove 70µl media and deliver cells in 10µl media 
with 10nM DHT. 
Each well: 2,400cells, 5nM DHT, 10uM compound
Incubate 24 hours
Freeze the plates.
Thaw plates and assay using 5µl BrightGlo
Luciferase reagent per well.
Method 1 Method 2
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the Marvel library1, containing ~9,700 small molecules (4, 7, 8) and the HTSF library, an in-
house compound library.  
Cell lines- Our collaborators at the University of North Carolina, Chapel Hill, developed 
two stable cell lines in HeLa cells for this study. HeLa-AR1C-PSA-ARE-Luc-A6 (HeLaA6) 
cells (9) that stably express androgen receptor (AR) and a prostate-specific antigen (PSA)-Luc 
reporter were maintained in MEM supplemented with 10 mM HEPES, 1% penicillin- 
streptomycin (P/S), 10% FBS, and under selection with 0.2 mg/ml hygromycin B and 0.5 mg/ml 
G418. HeLaA6 cells express considerably more AR protein when compared to prostate cancer 
cell lines like LNCaP or LAPC4. (Fig 3.7) In this regard, they behave more like castration-
resistant prostate cancers (CRPCs). HeLa-AR3A-PSA-ARE-Luc-13 (HeLa13) cells that stably 
express AR and a PSA-Luc reporter were maintained in MEM supplemented with 10 mM 
HEPES, 1% penicillin- streptomycin (P/S), 10% FBS, and under selection with 0.1 mg/ml 
hygromycin B and 0.5 mg/ml G418. HeLa13 cells express AR protein levels similar to LNCaP 
cells (Fig 3.7).  
T47D-KBluc breast cancer cells expressing an (ERE)3-luciferase reporter gene (10) were 
maintained in RPMI 1640 containing 10% FBS. T47D/(A1-2) cell line that stably express the 
glucocorticoid receptor (GR) and contain a mouse mammary tumor virus (MMTV)-luciferase 
reporter (11) were maintained in MEM, 5% FBS and 0.2 mg/ml geneticin (G418).  
LNCaP cells were maintained in phenol-red free RPMI 1640 with 10% fetal bovine serum 
(FBS; Atlanta Biological, GA). Cells were transferred to RPMI 1640 containing 5% CD 
(charcoal-dextran stripped) FBS at least 3 days prior to plating for an experiment. 
Reporter Gene Assays- For the primary screen 2,400 HeLaA6 cells were added per well of 
384-well plates and treated with 5 nM DHT and 7.1 µM compound. For the secondary screen, we 
seeded 2,400 HeLaA6 cells or 4,500 HeLa13 cells per well of 384-well plates. At least 3 days 
before each experiment, cells were switched to medium containing CD-treated FBS as described 
above. For the ER luciferase assays, T47D-KBluc cells were plated at 8,000 cells/well and 
induced with 5 nM estradiol (E2). Similarly, T47DA/1-2 cells were used to assay the effects of 
compounds on the glucocorticoid receptor (GR). After 24 hours of incubation with the 
compound and respective hormone or other ligands, cells were lysed partially by freeze-thaw and 
assayed using 5 µl per well of BrightGlo reagent (Promega, Madison WI). Unless otherwise 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 The Marvel library was developed at the University of Illinois by Dr. K. Putt and Professor P.J. Hergenrother. 
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stated, total DMSO (vehicle) concentration in the assays was maintained between 0.1-0.5 
percent. 
Cell Growth and Toxicity Assays- At least 3 days prior to plating, LNCaP cells were 
maintained in medium containing 5% CD-FBS while DU145 cells were maintained in their 
growth medium. For all cell lines, 2,000 cells/well was added to 96-well plates and allowed to 
attach for 1 day. Cells were added with treatment medium containing the indicated 
concentrations of hormone and small molecule and incubated for 3-4 days. Cell viability (MTS) 
assays were carried out using the CellTiter 96 Aqueous One Solution cell proliferation assay 
(Promega). 
Luciferase-enzyme activity assay- To test whether small molecule leads obtained from the 
AR screen were inhibitors of luciferase enzyme, we performed assays using QuantiLum 
recombinant luciferase protein (Promega). For each 10 µl assay in a 384-well plate, 0.05 ng of 
luciferase protein in 5 µl buffer was incubated with 10 µM small molecule. After 10 minutes, 5 
µl BrightGlo was added and luciferase activity was measured.  
 
PRIMARY HIGH-THROUGHPUT SCREENING 
Screening Method- The primary HTS was conducted at the High Throughput Screening 
Facility (HTSF) using robotic equipment. Prior to each experimental batch, HeLaA6 cells were 
grown in multiple flasks in MEM + 10% FBS. The day before the plating the cells, 70 µl of 
MEM + P/S was added to each well of 30-60 white 384-well plates under sterile conditions with 
a Matrix WellMate 8-channel dispenser. Using a pin-spotter (V&P Scientific Inc.) mounted on a 
Matrix Platemate-Plus, 100 nl of 10 mM compound in DMSO from each plate of the library was 
transferred to the assay plates and mixed. DMSO was added to the positive and negative control 
wells (2x16 wells). 60 µl was aspirated out automatically using Matrix Platemate-Plus, such that 
10 µl of the medium containing 14.2 µM compound was left behind in each well. Cells were 
trypsinized into MEM+ 10% FBS, 10 nM DHT was added and plated at 2,400 cells/well in 10 µl 
volume in a sterile environment. Each well thus contained 2,400 cells, 5 nM DHT and 7.1 µM 
compound in 20 µl of MEM + 5% FBS. The cells were incubated at 37°C in 5% CO2 for 24 
hours and then frozen at -20° C for at least 6 hours before reading the luciferase activity. We 
believe that the freeze-thaw cycle facilitates cell lysis. Plates were brought to room temperature 
along with the reconstituted BrightGlo reagent (Promega) and 5 µl of BrightGlo was added per 
well. This mix was incubated 15 minutes at room temperature for increasing cell lysis and 
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release of luciferase enzyme, and then luminescence was read  the Analyst HT (Molecular 
Devices).  
Analysis- Data from the screen was analyzed using Microsoft Excel. The top 50 and bottom 
50 luciferase values of every plate was discounted in the calculation of the average plate value so 
that the average used in the calculation of % activity of each well is not biased towards activators 
or inhibitors. % Activity was calculated using the formula  
 
 
 
where Lucwell is the optical units measured from any given well, Lucplate average is the average 
calculated discounting the top 50 and bottom 50 values. The effect of each compound on 
luciferase activity was determined by comparison to the positive and negative control wells of 
each plate. Compounds showing > 50% luciferase inhibition were selected for further study in 
the secondary screen. Approximately 3000 compounds were selected. A schematic of the various 
steps leading to the identification and characterization of ‘lead’ AR inhibitors are illustrated as a 
flowchart in Fig 3.8. 
Note: Although I used what seems like an arbitrary value of >50% inhibition as a metric to 
peg a compound well as a ‘hit’, it was > 3 times the standard deviation of the controls. Later 
these values were crosschecked using the strictly standardized median deviation (SSMD*) 
method, which scores inhibitors from a range of poor (scores = 0, corresponding to no effect) to 
very strong (score ≤ -5, corresponding to greater than 99 percent confidence interval). It was 
determined that all the hits identified from any plate corresponded to scores between -1.5 and -3, 
which corresponds to 87-99 percent confidence intervals respectively (6).  
 
SECONDARY HIGH-THROUGHPUT SCREENING 
A. To verify the ~3,000 primary hits and test them for potency, efficacy, specificity and toxicity 
we needed to perform a large number of assays. A secondary screen library was created by 
manually picking 1 µl of each hit from a 1 mM copy of the original 10 mM library (a process 
known as cherry picking). This new library was then diluted in Hanks Balanced Salt Solution 
(HBSS) and MEM (no serum) just before use. A final concentration of 8 µM of each compound 
was used in all assays. Secondary screening involved repeating the primary screen in HeLaA6 
cells as well as other stringent tests.  
% Luciferase Activity =    (Lucwell – Lucplate average)  x 100 
     Lucplate average 
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B. We also selected 160 compounds from the primary screening to make a second secondary 
screening library, by manually picking 1 µl from the original 10 mM library. This was due to the 
inconsistencies we noticed after the first round of secondary screening and realization that data 
from assays performed using the 1 mM copy library was significantly different from those 
obtained from the original 10 mM compound library. Multiple freeze-thaw cycles had apparently 
further diluted the 1 mM library (as water is absorbed by DMSO at ambient temperatures). 
Screening method- Secondary screening assays were performed in much the same way as 
primary screening in 384-well plates. Luciferase inhibition by compounds acting through AR in 
HeLaA6, HeLa13 and through ERα in T47D-KBluc cells were measured in duplicate. Toxic 
effects of the chosen leads, if any, on the HeLa cells were determined using MTS reagent. The 
data from all the above assays was used to further shortlist AR inhibitor leads. 
Analysis- The effect of each compound on luciferase activity was determined by comparison 
to the positive and negative control wells of each plate. Compounds showing >65% inhibition of 
luciferase activity in the AR containing cell lines, which were also >75% viable and had minimal 
inhibitory effects on ER, were selected for further study. Approximately 120 small molecules 
were shortlisted at this stage for further study.  
 
TERTIARY HIGH-THROUGHPUT SCREENING 
We tested the selected 280 (120+160) compounds in two batches at various doses on the 
HeLa13 cells and determined the extent of inhibition of luciferase activity in 96-well plates. This 
was compared to inhibition of each compound on ER-mediated and GR-mediated luciferase 
activity in T47D cells. The growth inhibitory effects of all the compounds were tested in 
triplicate assays in AR-dependent LNCaP cells. Finally, 37 small molecules from the first batch 
and 12 small molecules from the second batch were selected for purchase from ChemBridge or 
acquired from the NIH (Developmental Therapeutics Program). Due to cost considerations, the 
number of small molecules purchased was kept to a minimum.  
 
LEAD DEVELOPMENT 
The 37 compounds obtained in the first batch were assayed for inhibition of AR-dependent 
growth in LNCaP cells, luciferase expression, and for AR-independent toxic effects in DU145 
cells. Table 3.1 represents the data obtained from testing 10 µM of each compound in the various 
assays. Highlighted in red are the reasons for eliminating that particular compound. Only two 
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compounds (*:AR19 and AR33) showed the desirable qualities of reducing AR-dependent cell 
growth and transactivation, without intrinsically effecting luciferase enzyme activity. From the 
dozen small molecules in the second batch purchased from ChemBridge, two compounds (AR45 
and AR54) inhibited AR-dependent transactivation and proliferation with reasonable IC50s. We 
evaluated a total of 4 lead compounds, AR19 (CPIC), AR33, AR45 and AR54. AR33 and AR45 
were later dropped from mechanistic studies due to their toxicity profile in AR-independent cell 
lines. Extensive mechanism of action studies were performed for AR19 (CPIC) detailed in 
Chapters 4 and 5, and AR54 described in Chapter 6.  
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TABLES & FIGURES  
Table 3.1: Analysis of the effects of 10 µM of the compounds purchased from ChemBridge. 
Compound 
(10µM) 
DU145 
% Viability 
LNCaP 
% Growth 
HeLa13 
% Luc Activity 
Luciferase Enzyme 
% Activity 
DMSO 100.0 100.0 100.0 100.0 
AR1 122.9 70.7 45.3 94.7 
AR2 71.7 55.4 8.4 41.1 
AR3 107.0 63.2 10.8 17.3 
AR4 85.6 78.7 15.3 13.0 
AR5 76.7 83.5 17.7 102.2 
AR6 104.4 70.5 178.5 13.7 
AR7 145.3 52.4 41.7 106.0 
AR8 147.4 64.4 30.4 19.7 
AR9 113.0 64.9 14.2 12.6 
AR10 31.0 36.1 30.6 102.9 
AR11 109.7 69.7 203.1 97.9 
AR 12 95.1 87.5  52.5 
AR 13 2.0 12.8 64.1 56.1 
AR 14 89.4 70.0 3.7 12.8 
AR 15 93.9 69.9 50.9 18.0 
AR 16 6.1 5.2 11.6 89.6 
AR 17 100.0 108.0  22.0 
AR 18 85.5 84.8  90.9 
AR 19* 62.9 42.4 2.8 99.8 
AR 20 93.3 90.8 103.6 33.3 
AR 21 85.5 62.1 86.0 102.7 
AR 22 71.7 104.3 12.6 105.6 
AR 23 81.7 77.3 2.3 100.8 
AR 24 96.0 126.6 46.0 27.9 
AR 25 97.8  106.7 99.2 
AR 26 93.6  170.2 95.8 
AR 27 79.7  91.6 95.8 
AR 28 93.0  104.1 96.4 
AR 29 57.6  35.1 92.0 
AR 30 90.0  106.3 88.3 
AR 31 92.5  78.2 92.3 
AR 32 79.1  92.2 94.3 
AR 33* 82.9 1.9 20.5 98.8 
AR 34 120.1  75.8 99.9 
AR 35 15.1  11.8 105.2 
AR 36 12.6  5.4 105.8 
AR 37 10.0  9.8 101.3 
Bic  35.0 24.0  
  * Represents lead inhibitors 
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Figure 3.1 
 
FIGURE 3.1. Schematic representation of FAMA analysis of AR:DNA and AR:DNA-
inhibitor interactions.   
When excited with polarized light of 494 nm, the fluorescein-labeled androgen response 
elements, fl-ARE, tumbles rapidly in solution and the emitted light is largely depolarized to the 
parallel and perpendicular detectors (520 nm). Binding of DHT (T)-bound AR to the fl-ARE 
results in a much larger, less mobile complex. Therefore, the emitted light is mostly polarized. 
Binding of small molecule inhibitors that disrupt the AR:fl-ARE complex reverses this 
polarization, resulting in emitted light that is more depolarized and a decrease in fluorescence 
anisotropy. 
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Figure 3.2 
 
FIGURE 3.2. FAMA analysis of the binding of AR to different hormone-response elements 
(HREs). Increasing amounts of purified AR were incubated with 1nM of the indicated 
fluorescein-labeled probe in the binding buffer. The apparent KD for AR is ~25 nM under these 
conditions. Typical anisotropy values for free probe range from 40-45 mA and the probe bound 
to AR is ~100 mA.The probes used were fl-cARE, 5’fl-CTA GAT TAC GGT ACA TGA TGT 
TCT TAC TCA-3’, fl-c3ARE, 5’fl-CTA GAT TAC AGT ACG TGA TGT TCT TAC TCA-3’, 
and fl-PRE/GRE, 5’-fl- CTA GAT TAC AGA ACA ATC TGT TCT TAC TCA. 
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Figure 3.3 
 
FIGURE 3.3. A sample plate of FAMA based HTS for AR.  
45 nM AR was bound to 1 nM flcARE to obtain ~80% of maximum binding. 100 nl each of the 
small molecules from the library were added using a pin transfer apparatus to a final 
concentration of 2.5 µM and incubated for 15 minutes at room temperature. The effect of each 
compound, measured in % inhibition or % activation was calculated with respect to the DMSO 
control wells with AR:flcARE that were set at 0%. The black bars represents % inhibition 
calculated for individual wells. The first 16 wells contain various controls. Wells 1-5 contain 1 
nM flcARE probe alone.Wells 6-10 have 45 nM AR with 1 nM flcARE. The next six wells are 
positive control wells spiked with 10 mM, 5 mM and 2.5 mM BPS, a zinc-chelator in duplicate. 
Intrinsic fluorescence intensity of some of the small molecules (red circles, % intensity), which is 
measured as part of each assay, is responsible for several of the most dramatic changes seen in 
the screening data.
 66 
Figure 3.4 
 
FIGURE 3.4. Structure and dose response curve for 4457, in FAMA and cells.  
A. Chemical structure of 4457 compared to trinitrotoluene (TNT).  B. Fluorescence anisotropy 
assays were carried out at concentrations of AR and ERα that exhibit ~80% of maximal binding 
(~2X KM; 40 nM AR and 5 nM ERα). The indicated concentrations of 4457 were incubated with 
AR (filled circles), or ERα (open triangles) in reactions containing 1 nM flcARE or 1 nM flcERE 
for 15 min. and anisotropy was measured. Anisotropy in the DMSO control was set equal to 
100%. The anisotropy change without inhibitor is ~60 mA for assays containing AR and ~35 mA 
for assays containing ER. The data represents the average of 4 independent experiments ± SEM. 
C. Effects of 20 and 30 µM 4457 on transactivation by AR in cells. HeLa cells were transfected 
with 10 ng pCMVhAR and 0.25 µg PSA-Enh-Luc using FuGENE-6 (Roche). Cells were 
incubated in serum-free medium in the presence or absence of 1 nM DHT and 4457 for 24 h and 
luciferase activity determined using a BMG Labtech Lumistar Galaxy automated luminometer.  
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Figure 3.5 
 
     
FIGURE 3.5. Theophylline derivatives 95869 and 95899, reduces AR transactivation by 
competing with androgen for binding AR. A. HeLaA6 cells were seeded in 24-well plates and 
maintained for 24 h in medium containing 80 pM DHT and the indicated concentrations of 
compounds 95869 or 95899. Data represent the average of triplicate experiments ± SEM. B. 
Competitive radioligand binding assay in COS cells. Relative binding affinity of various ligands 
for AR was determined using 5 nM [3H]R1881 and a range of ligand concentrations (1-20,000 
nM). Data are the average of duplicate experiments ± mean error.  
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Figure 3.6 
 
 
FIGURE 3.6. A Hit map comparing both luciferase activity and cell viability of compounds 
from a single HTS library plate assayed using Methods 1 and 2. Compounds on this 
representative 384-well plate that exerted >50% inhibition of luciferase activity are highlighted 
in yellow, while those that caused >20% reduction in cell viability are shown in blue. Wells 
treated with 5 nM DHT + DMSO (vehicle) were set to 100% in both assays. Luciferase 
inhibition and toxicity exerted by the small molecules were similar when the compounds were 
added after the cells had had one day to attach and recover (Method 1), or when the compounds 
were added along with the cells (Method 2). We chose Method 2 for large-scale screening. 
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Figure 3.7 
 
 
FIGURE 3.7. Comparison of AR level and activity between HeLaA6 and HeLa13 cell lines.  
Various cells were plated in medium containing 5% CD-FBS and stripped for at least 3 days. 
Treatment medium containing ethanol (vehicle) or 10 nM DHT was then added to the cells, 
incubated for 24 hours and protein extracted. Equal amounts of protein were loaded on 10% 
polyacrylamide gels, analyzed by western blotting using AR antibody. 
Data in figure 3.7: Elizabeth M Wilson 
AR 
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Figure 3.8 
 
 
FIGURE 3.8. Schematic diagram of the various steps involved in cell-based HTS for 
identification and characterization of small molecule inhibitors of AR action. 
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CHAPTER 4 
A SMALL MOLECULE INHIBITOR THAT REDUCES RECRUITMENT OF 
ANDROGEN RECEPTOR TO ANDROGEN RESPONSIVE GENES2§ 
 
The androgen receptor (AR) has a critical role in the growth and progression of androgen-
dependent and castration-resistant prostate cancers. To identify novel inhibitors of AR 
transactivation that block growth of prostate cancer cells, a luciferase-based high throughput 
screen of ~160,000 small molecules was performed in cells stably expressing AR and a prostate-
specific antigen (PSA)-luciferase reporter. CPIC (1-(3-(2-chlorophenoxy) propyl)-1H-indole-3-
carbonitrile) was identified as a small molecule that blocks AR transactivation to a greater extent 
than other steroid receptors. CPIC inhibited AR-mediated proliferation of androgen-sensitive 
prostate cancer cell lines, with minimal toxicity in AR-negative cell lines. CPIC treatment also 
reduced the anchorage-independent growth of LAPC-4 prostate cancer cells. CPIC functioned as 
a pure antagonist by inhibiting the expression of AR-regulated genes in LAPC-4 cells that 
express wild-type AR, and exhibited weak agonist activity in LNCaP cells that express the 
mutant AR-T877A. CPIC treatment did not reduce AR levels or alter its nuclear localization. We 
used chromatin immunoprecipitation to identify the site of action of CPIC. CPIC inhibited 
recruitment of androgen-bound AR to the PSA promoter and enhancer sites to a greater extent 
than bicalutamide. CPIC is a new therapeutic inhibitor that targets AR-mediated gene activation 
with potential to arrest the growth of prostate cancer. 
 
INTRODUCTION 
Androgens, such as testosterone and dihydrotestosterone (DHT), mediate their biological  
effects through the nuclear androgen receptor (AR). Binding of high-affinity androgens to the 
ligand-binding domain of AR induces the interdomain amino and carboxy-terminal (N/C) 
interaction (1-3). Activated AR translocates and accumulates in the nucleus, where it binds to 
specific androgen response elements (AREs) in the promoter and enhancer regions of androgen-
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2  This research was originally published in Journal of Biological Chemistry. MT Cherian, EM Wilson and DJ 
Shapiro, “A competitive inhibitor that reduces recruitment of androgen receptor to androgen responsive genes”, J. 
Biol. Chem., 2012 © the American Society for Biochemistry and Molecular Biology. 
§ Disclosure: The University of Illinois at Urbana-Champaign has filed a novel use patent that claims CPIC.  
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regulated genes, and initiates transcription by recruiting multiple coregulators and the basal 
transcription machinery in a sequential and cyclic fashion (4, 5). Inhibitors of AR-mediated 
transcription include selective AR modulators (SARMs) such as the prostate cancer therapeutic, 
bicalutamide (Casodex) and the experimental drug MDV3100. Bicalutamide (Bic) and 
MDV3100 inhibit AR transcriptional activity by competing with androgens for binding to the 
ligand-binding domain of AR (6, 7). Bicalutamide can exhibit some agonist activity in cells 
containing mutant AR or expressing high AR levels (8, 9). 
Androgens play a central role in the growth and development of the normal prostate gland 
and in the proliferation and progression of prostate cancers (10, 11). Patients with low-grade 
tumors benefit from primary therapies for prostate cancer, including radical prostatectomy and 
androgen deprivation or anti-androgen therapy. However, these treatment strategies are much 
less effective for long-term treatment of high-grade tumors (Gleason score ≥7) with elevated 
recurrence rates after primary therapy. In castration-resistant (or castration-recurrent) prostate 
cancer (CRPC), there may be higher levels of AR (12), increased expression of AR-regulated 
genes (13-15), and AR coregulators such as MAGE-A11 and SRC/p160 coactivators  (16-19), 
suggesting that these cancers remain dependent on AR. Several types of evidence support the 
continuing role of AR in CRPC. Many of the genes induced by androgens in androgen-
dependent prostate cancer xenografts become elevated in CRPC (20). Recent studies show that 
many advanced prostate cancers fuel their growth by synthesizing their own androgens (21). AR 
continues to be a focus for new drug development and it remains important to identify 
antagonists that block AR transcriptional activity (22). The importance of new approaches to 
targeting androgens and AR in CRPC is illustrated by Abiraterone acetate/Zytiga, an androgen 
synthesis inhibitor that prolongs survival in patients with advanced prostate cancer (23). 
To search for new AR antagonists, we developed and implemented a cell-based high-
throughput screen of ~160,000 small molecules using HeLa cells that stably express AR and an 
androgen-inducible PSA-luciferase reporter. The relatively high levels of AR in these cells and 
the high concentration of androgen we used in the screens, rendered bicalutamide largely 
ineffective as an AR antagonist. Here we describe 1-(3-(2-chlorophenoxy)propyl)-1H-indole-3-
carbonitrile (CPIC), a lead compound that emerged from our screen. CPIC is a potent and 
selective AR antagonist that inhibits expression of endogenous AR-regulated genes and the 
androgen-dependent growth of prostate cancer cells. Chromatin immunoprecipitation (ChIP) 
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assays using the synthetic androgen methyltrienolone (R1881), showed that CPIC decreased AR 
occupancy at AREs of two prominent AR-regulated genes PSA and TMPRSS2, without affecting 
AR protein levels or AR nuclear translocation. In LNCaP cells that express a mutant AR-T877A 
and in LAPC-4 cells with wild-type AR, CPIC inhibited binding of R1881-AR to the PSA 
promoter and enhancer. The ability of CPIC to reduce recruitment of AR to multiple regulatory 
regions of androgen-responsive genes to a greater extent than bicalutamide suggests a new mode 
of action.  
 
EXPERIMENTAL PROCEDURES 
Chemical Libraries- The libraries screened were the ChemBridge MicroFormat small 
molecule library obtained from ChemBridge™ containing ~150,000 small molecules, the Marvel 
library developed at the University of Illinois by K. Putt and Hergenrother containing ∼9,700 
small molecules (24) and the NCI Diversity Set from NIH with ~1,990 small molecules. 
Plasmids- Expression vectors used have been previously described (25). pCMV-AR-(507–
919) codes for the human AR DNA and ligand-binding domains, pCMV-AR-(1–503) codes for 
the AR NH2-terminal domain. PSA-Enh-Luc containing the PSA upstream enhancer region was 
generously provided by Michael Carey (University of California, Los Angeles). 
Cell Culture- AR-positive cell lines included LNCaP and LAPC-4 human prostate cancer 
cells maintained in phenol-red free RPMI 1640 with 10% fetal bovine serum (FBS, Atlanta 
Biological, GA). LAPC-4 growth medium was routinely supplemented with 1 nM of the 
synthetic androgen R1881. Cells were transferred to RPMI 1640 containing 5% charcoal-dextran 
stripped FBS (CD-FBS) at least three days prior to plating for an experiment. CWR-R1 cells 
were grown in modified iMEM (GIBCO#10488-001) containing 2.5 g/l of glucose, 1.2 g/l 
niacinamide, 0.5 ml of insulin-transferrin-selenium (ITS, Roche #11074547001), 10 ng/mL 
epidermal growth factor (EGF) and 2% FBS. The cells were transferred to medium containing 
2% CD-FBS without EGF 3-4 days before the experiment.   
HeLa-AR1C-PSA-ARE-Luc-A6 (HeLaA6) cells selected with hygromycin and geneticin 
(G418) stably express human AR and a PSA-luciferase reporter gene containing the 5.8 kb PSA 
upstream enhancer and promoter region linked to the luciferase gene (26). HeLa-AR3A-PSA-
ARE4-Luc-13 (HeLa13) cells selected with hygromycin and G418 stably express human AR and 
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a PSA-luciferase reporter gene containing a 4X multimerized PSA upstream enhancer ARE1 
linked to the E4 TATA box and luciferase gene. Both HeLa-AR cell lines were maintained in 
MEM supplemented with 10% FBS. HeLaA6 cells were maintained under selection with 0.1 
mg/ml hygromycin B and 0.5 mg/ml geneticin. HeLa13 cells were maintained under selection 
with 0.05 mg/ml hygromycin B and 0.5 mg/ml G418. Cells were transferred to medium 
containing 5% CD-FBS 3-4 days before the experiment. AR-negative cell lines included PC-3 
human prostate cancer cells maintained in RPMI 1640 with 10% FBS, and DU145 human 
prostate cancer cells and MDA-MB-231 human breast cancer cells grown in MEM with 10% 
FBS. 
Other cell lines included estrogen receptor α (ERα)-containing T47D-KBluc breast cancer 
cells expressing an (ERE)3-luciferase reporter gene (27), maintained in RPMI 1640 containing 
10% FBS. Three days before induction with 17β-estradiol (E2), cells were transferred to medium 
containing 5% CD-FBS. T47D/(A1-2) cells stably express the human glucocorticoid receptor 
(GR) and contain a mouse mammary tumor virus (MMTV)-luciferase reporter (28) and were 
maintained in MEM, 5% FBS and 0.2 mg/ml G418. MMTV-Luc reporter is inducible by AR, PR 
and GR depending on the activating ligand used. Before the experiment, cells were transferred to 
the above medium containing 5% CD-FBS.  
The RPMI base medium was supplemented with 2 mM L-glutamine, 1.5 g/l sodium 
bicarbonate, 4.5 g/l glucose, 10 mM Hepes, pH 7.5, and 1 mM sodium pyruvate. MEM was 
supplemented with 10 mM HEPES, pH 7.4 and 2 mM L-glutamine. All cells were maintained at 
37˚C in 5% CO2 in growth medium containing 1% penicillin and streptomycin and 2-10% fetal 
bovine serum (FBS) (Atlanta Biological, Atlanta, GA) without phenol-red. 
Soft-agar colony formation assay- To assay anchorage-independent cell growth in soft agar, 
1% and 0.7% Select Agar (Invitrogen) were prepared in water and warmed at 40°C before use. 
1.5 ml of 0.5% bottom agar diluted in 2X RPMI 1640 medium was added to each well of a 6-
well cell culture plate and allowed to solidify at room temperature. Top agar was prepared by 
dilution in warm medium. LAPC-4 cells were resuspended in 1.5 ml of 0.35% top agar at 5000 
cells/well and plated in 3 wells for each condition. The plates were kept at room temperature for 
30 min until the top agar solidified then 0.5 ml of medium containing the respective treatments 
was added on top of the agar. Culture medium containing the various treatments was changed 
every 3-4 days. Colonies were visible after 2 weeks in the hormone treated wells and counted at 
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day 28 using a dissecting microscope. Photographs of colonies were taken using a Zeiss 
AxioImager2 imaging system at 5X magnification. 
Reporter Gene Assays- At least 3 days before each experiment, cells were transferred to 
medium containing CD-FBS as described above. HeLaA6 and HeLa13 cells (50,000 cells/well) 
and T47DA/1-2 or T47D-KBluc cells (200,000 cells/well) were plated in 1 ml of medium in 24-
well plates. After 24 h the indicated concentrations of E2, DHT or dexamethasone (Dex) were 
added along with each inhibitor or DMSO (vehicle). After 24 h of treatment, cells were lysed in 
100 µl of Passive Lysis Buffer (Promega, Madison WI) and luciferase activity was determined 
using BrightGlo firefly luciferase reagent (Promega). Unless otherwise mentioned, total DMSO 
(vehicle) concentration in all assays was maintained at or below 0.1%. 
Cell Growth and Viability Assays- To assay cell growth, 2,000 cells/well were plated in 96 
well plates. LNCaP and LAPC-4 cells were maintained in CD-treated serum for at least 2-4 days 
prior to each experiment. All AR negative cell lines, MDA-MB-231, DU145 and PC-3, were 
plated in growth medium 24 h prior to treatment. Treatment medium containing vehicle or the 
indicated concentrations of R1881, with or without inhibitor compounds was added to the cells 
and incubated for the indicated number of days. Cell viability was determined using Promega 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS). 
Transient Transfection- LAPC-4 cells were plated (200,000 cells/well in 1 ml) in 24-well 
plates in 5% CD-FBS 3 days prior to transfection. On the day of transfection, the medium was 
changed to 0.2 ml OPTI-MEM. DNA and Lipofectamine2000 (Invitrogen) were diluted in OPTI-
MEM and incubated together for 20 min before adding to the well. A total of 500 ng DNA (400 
ng PSA-Luc and 100 ng Renilla-Luc) was transfected into cells in each well at a 
DNA:Lipofectamine2000 ratio of 1:3. 24 h after transfection, 1 nM R1881 and the indicated 
concentrations of each inhibitor in DMSO, were added to the cells and incubated for 48 h. Cells 
were lysed in 100 µl of Passive Lysis Buffer (Promega, Madison WI) and luciferase activity was 
determined using Dual-Luciferase Reporter Assay (Promega #E1910). Transfections in HeLa 
cells were performed as described (29). 
Radioligand Binding Assay- Competitive radioligand binding assays were performed by 
expressing pCMV-AR in monkey kidney COS cells and incubating cell cultures for 2 h at 37˚C 
with [3H]R1881 (17α-methyl-[3H] methyltrienolone, 82 Ci/mmol) in the absence and presence of 
competitor ligands (30, 31).  
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Endogenous Gene Expression- LNCaP and LAPC-4 cells were seeded into 6-well plates 
and grown for 3-4 days in medium containing 5% CD-FBS. Cells were then treated with ethanol 
or R1881, along with the indicated concentrations of the inhibitor for 24 h. RNA was extracted 
and purified using the Qiagen RNeasy kit. cDNA was prepared from 1 µg of RNA with M-
MuLV reverse transcriptase from New England BioLabs. Diluted cDNA was used to perform 
quantitative RT-PCR using SybrGreen (ABI Thermocycler) with actin as the internal standard. 
Primers for qRT-PCR were: β-actin forward primer 5’- TGT CAC CAA CTG GGA CGA CA 
and reverse primer 5’- GGG GTG TTG AAG GTC TCA AA; PSA (kallikrein 3) forward primer 
5’- GGT GAC CAA GTT CAT GCT GTG and reverse primer 5’- GTG TCC TTG ATC CAC 
TTC CG; TMPRSS2 forward primer 5’- TAG TGA AAC CAG TGT GTC TGC and reverse 
primer 5’- AGC GTT CAG CAC TTC TGA GGT CTT (6). 
Western Blot- Cells were plated at 300,000 cells/well in 6-well plates in medium containing 
5% CD-FBS. The medium was changed on day 2, and on day 4 the cells received fresh medium 
containing the indicated treatments. Whole cell extracts were prepared after 24 h of treatment 
using 1X RIPA buffer (Millipore, CA) containing complete mini protease inhibitor cocktail 
(Roche, Germany). 30 µg of protein per lane was analyzed on 10% SDS-PAGE gels and 
transferred to nitrocellulose membranes (GE Healthcare). AR protein was detected using AR 
antibody AR (441) (sc-7305, Santa Cruz, CA), internal control α-tubulin was detected using 
monoclonal antibody T1699 (Sigma) and β-actin was detected using antibody A1978 (Sigma). 
Chromatin Immunoprecipitation (ChIP) - LNCaP or LAPC-4 cells were grown in 5% CD-
FBS for 4 days and pretreated with 10 µM CPIC, Bic or DMSO as control for 1 h before 
treatment with 1 nM R1881 or vehicle (ethanol) for 4 h. Proteins were cross-linked with 1% 
formaldehyde for 10 min. Cell extracts were digested for 10 min with 50 U of Micrococcal 
Nuclease (New England BioLabs) at 37ºC and further sonicated to yield sheared DNA fragments 
with an average length of 200-1000 base pairs. The sonicated samples were pelleted by 
centrifugation and the supernatant was diluted 5-fold with ChIP dilution buffer (0.01% SDS, 1.1 
% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCl and protease 
inhibitor cocktail). 50 µl of diluted supernatant was reserved as input (10%) for each treatment. 
The samples were precleared with 50 µl of Protein A-Sepharose™ 4 Fast Flow (GE Healthcare) 
in ChIP dilution buffer (1:1), pre-blocked with 200 µg/ml sheared herring sperm DNA and 500 
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µg/ml BSA. The samples were then divided and the remaining proteins were incubated with 
either 2 µg of anti-AR (C19), 2 µg of anti-RNA polymerase II (clone CTD4H8, Millipore), or 
control mouse IgG overnight at 4˚C. The antibody-protein-DNA complex was precipitated by 
incubating with 50 µl Protein A-Sepharose™ beads for 2 h at 4˚C. The protein-DNA complex 
was eluted from the beads with elution buffer (1% SDS, 0.1 M NaHCO3). Cross-links were 
reversed and DNA was eluted from the protein-DNA complexes by adding 200 mM NaCl and 
incubating overnight at 65˚C. Protein was digested using Proteinase K and incubating at 45˚C for 
2 h. DNA was recovered and purified. Quantitative RT-PCR was performed to determine the 
change in AR and RNA polymerase II (RPol II) occupancy at various sites of AR binding. The 
double negative controls were nonspecific antibody (normal mouse IgG) and primers coding for 
intergenic regions that do not interact with AR. Thermal cycling conditions were 95ºC for 10 
min, followed by 50 cycles of 25 s at 95ºC, 30 s at 60ºC and 30 s at 72ºC. Primers used were: 
PSA enhancer ARE forward primer 5’- ACC TGC TCA GCC TTT GTC TCT GAT and reverse 
primer 5’- AGA TCC AGG CTT GCT TAC TGT CCT; PSA promoter ARE forward primer 5’- 
CCT AGA TGA AGT CTC CAT GAG CTA CA and reverse primer 5’- GGG AGG GAG AGC 
TAG CAC TTG; Middle region forward primer 5’- CTG TGC TTG GAG TTT ACC TGA and 
reverse primer 5’- GCA GAG GTT GCA GTG AGC C (32-34). 
Statistical Analysis- Results are expressed as mean ± SEM of at least three independent 
experiments. Significance was established when p<0.05. Student’s T-test was used for 
comparison of the means between two groups.    
 
RESULTS 
Establishment of Stable HeLa Cell Lines - For this work, HeLaA6 (26) and HeLa13 cells 
were established to stably express PSA-ARE-Luc reporter genes and AR at levels similar to or 
greater than LNCaP and LAPC- 4 cells. HeLaA6 cells express considerably more AR protein 
than prostate cancer cell lines like LNCaP or LAPC-4 (35) (Fig. 4.1A). The higher level of AR 
results in 10-40 µM bicalutamide acting as an agonist in HeLaA6 cells (Supplemental Fig. 
4S.1A) and in this regard they resemble castration-resistant prostate cancer (CRPC). To more 
nearly mimic the environment of early-stage prostate cancer, we established the HeLa13 cell line 
that stably expresses AR protein at levels similar to LNCaP and LAPC-4 cells (Fig. 4.1A). There 
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is a 20-fold difference in the dose response curves between the two cell lines. The half-maximal 
effective DHT concentration (EC50) was ~50 pM in the HeLaA6 cells compared to ~1 nM in the 
HeLa13 cells (Fig. 4.1B). 
Cell-based High-throughput Screening- Feasibility for the cell-based high-throughput 
screen was established using a combination of manual and robotic steps. Details of the screening 
procedure are elaborated in Chapter 3. To identify new small molecule inhibitors of AR action, 
we performed a luciferase-reporter based high-throughput screen using HeLaA6 cells and 
~160,000 small molecules in several libraries at the University of Illinois High-Throughput 
Screening Facility.  
Identification of CPIC as a Lead Compound - To minimize the detection of moderate 
affinity competitor ligands, HeLaA6 cells were assayed in the presence of 5 nM DHT to fully 
saturate AR (see Fig. 4.1B). The lead inhibitor to emerge from our studies, CPIC (Fig. 4.2A), 
was subsequently shown to be a competitive inhibitor of androgen binding to AR. We evaluated 
the potency of CPIC in cells expressing high (HeLaA6) and moderate (HeLa13) levels of AR. 
The potency of CPIC in HeLaA6 and HeLa13 cells was compared to bicalutamide, a competitive 
AR antagonist that inhibits androgen binding to AR. CPIC elicited a concentration dependent 
inhibition of AR-induced luciferase activity in the HeLaA6 cells with an IC50 of 5 µM, and was 
much more effective in HeLa13 cells with an IC50 of 0.09 µM (Fig. 4.2B). In contrast to 
bicalutamide, which had substantial agonist activity in HeLaA6 cells in the absence of DHT, 
CPIC lacked agonist activity in these cells (Supplemental Fig. 4S.1) and thus functioned as a 
pure antagonist. 
To evaluate the potency of CPIC in prostate cancer cells containing wild-type AR, LAPC-4 
human prostate cancer cells were transfected with PSA-luciferase reporter. CPIC effectively 
inhibited luciferase activity induced by R1881-AR with an IC50 of 1-5 µM (Fig. 4.2C). 
CPIC Competes with Androgen for Binding to AR and Disrupts the AR N/C Interaction- 
The ability of CPIC to compete with R1881 binding to AR was evaluated in cell-based assays. In 
competitive radiometric binding assays performed using 5 nM [3H]R1881, CPIC competed for 
binding to AR (Fig. 4.3A). If CPIC is a competitive inhibitor of AR, increasing the hormone 
concentration should reduce the ability of CPIC to bind AR and block its action. To test this, we 
varied the DHT concentration by 100-fold and tested the ability of CPIC to inhibit PSA-Luc in 
HeLaA6 cells. Increasing the concentration of DHT from 0.1 nM to 10 nM increased the IC50 for 
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inhibiting DHT-AR induced PSA-Luc transcription by ~20 fold (Fig. 4.3B). These data 
demonstrate that one mechanism for CPIC inhibition of AR-mediated transcription is by 
competing with androgen binding to AR. 
To evaluate the effect of CPIC on the interdomain AR N/C interaction, we performed 
mammalian 2-hybrid assays using constructs containing the N- and C-terminal regions of AR. 
Transfections were performed in HeLa cells using pCMV-AR-(1-503) (the AR NH2-terminal 
region), pCMV-AR-(507-919) (NH2-terminal deletion of AR) and PSA-Enh-Luc reporter 
plasmids in the absence and presence of 10 nM DHT. Bicalutamide and other antagonists that 
bind to the ligand-binding pocket of AR disrupt this crucial interaction and alter receptor 
structure and function (36, 37). CPIC was substantially more effective than bicalutamide in 
inhibiting the androgen-induced AR N/C interdomain interaction (Fig. 4.3C).  
CPIC is a Relatively Specific Inhibitor of AR-Mediated Transactivation- The AR ligand-
binding domain shares >50% sequence homology with the GR ligand-binding domain (38). We 
therefore evaluated the effect of CPIC on transcription by GR and ERα in cell lines stably 
expressing reporter genes. Inhibition of ERα was evaluated in T47D-KBluc cells that express 
endogenous ERα and are stably transfected to express an (ERE)3-luciferase reporter. Inhibition 
of GR was evaluated in T47D/(A1-2) cells that stably express GR and a mouse mammary tumor 
virus (MMTV)-luciferase reporter gene. Fig. 4.4 shows that CPIC did not inhibit GR 
transcriptional activity and modestly inhibited ERα activity at 20 µM CPIC. The results suggest 
that CPIC is a relatively specific inhibitor of AR-mediated transcription. 
CPIC Inhibits AR-Dependent Proliferation of Prostate Cancer Cells- We evaluated the 
effect of CPIC on the proliferation of AR positive prostate cancer cell lines. LAPC-4 cells 
contain wild-type AR. LNCaP cells, the most widely used androgen-sensitive cell line, contain 
high levels of the mutant AR-T877A and CWR-R1 cells contain mutant AR-H874Y, both of 
which are highly inducible by androgens and other steroids (9, 39). CPIC inhibited androgen-
mediated AR-dependent growth of all 3 cell lines, with an IC50 of ~2 µM in LNCaP cells (Fig. 
4.5A), ~0.3 µM in LAPC-4 cells (Fig. 4.5B) and ~5 µM in CWR-R1 cells (Fig. 4.5C).  
The specificity of CPIC inhibition of AR-mediated cell growth was tested using AR-
negative PC-3 and DU145 prostate cancer cells and MDA-MB-231 breast cancer cells. CPIC had 
little effect on the growth of PC-3 or MDA-MB-231 cells (Fig. 4.5D). However at high 
concentrations, CPIC slowed, but did not arrest the proliferation of DU145 cells. Thus, 
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functional concentrations of <5 µM CPIC were relatively specific for inhibition of AR-mediated 
cell growth. We also evaluated several small molecules structurally related to CPIC. These small 
molecules lacked the combined potency and specificity of CPIC. One member of this structural 
family, PIC19.7, exhibited an excellent toxicity profile (Supplemental Fig. 4S.2), but had 
substantially lower potency than CPIC and inhibited ER mediated transactivation at high 
concentrations. 
 CPIC Inhibits Anchorage-Independent Growth of LAPC-4 cells- Anchorage-independent 
growth is a hallmark of cancer cells. Growth in soft agar is often used to evaluate anchorage-
independence of human prostate cancer cells. We tested the ability of CPIC to inhibit colony-
formation of wild-type AR containing LAPC-4 cells grown in soft agar. LAPC-4 cells 
supplemented with medium containing 1 nM R1881 formed large colonies (>0.5 mm) after 4 
weeks (Fig 6, R1881). The growth of these cells was completely inhibited in the presence of 10 
µM CPIC as well as 10 µM Bic (Fig. 4.6). When colonies from all the wells of each treatment 
condition were counted, the R1881 treated plate contained 77 colonies/well mostly >0.5 mm in 
diameter. In comparison, there were no colonies >0.5 mm in diameter in the R1881+ CPIC 
treated wells, and on average 2 small colonies/well less than 0.5 mm in diameter. A similar effect 
was seen in the R1881+ Bic treated wells. The data indicate that CPIC inhibits androgen-
stimulation of anchorage-dependent (Fig. 4.5) and anchorage-independent (Fig. 4.6) growth of 
prostate cancer cells. 
CPIC Inhibits Expression of Endogenous AR-Regulated Genes- To evaluate the effect of 
CPIC on endogenous gene expression, the levels of mRNAs for several well characterized 
androgen-regulated genes were measured in LNCaP and LAPC-4 cells. The PSA and TMPRSS2 
genes are highly induced by androgens acting through AR. In LNCaP cells, 10 µM CPIC 
exhibited weak agonist activity and blocked AR-mediated transcription of PSA and TMPRSS2 
mRNAs in a dose-dependent manner with IC50s of ~0.5 µM and 0.3 µM, respectively (Fig. 
4.7A). In contrast to LNCaP cells, in LAPC-4 cells that express wild-type AR, CPIC was a pure 
antagonist and was more effective than bicalutamide in inhibiting induction of PSA and other 
genes (Fig. 4.7B and Supplemental Fig. 4S.3B). TMPRSS2 mRNA was minimally induced by 
androgen in LAPC-4 cells, and thus the effect of CPIC could not be evaluated (data not shown). 
CPIC also inhibited androgen-regulated expression of other genes including kallikrein 2 (KLK2) 
and TMEPAI in LNCaP and LAPC-4 cells (Supplemental Fig. 4S.3).  
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The AR-T877A mutant in LNCaP cells is activated by adrenal androgens, estrogens, and 
progestins, as well as many antiandrogens (39) which may explain the weak agonist activity of 
CPIC. Alternatively, higher levels of AR in LNCaP cells compared to LAPC-4 cells (Fig. 4.1A) 
or cell type specificity might be responsible for the weak agonist activity of CPIC. To test the 
effect of the AR-T877A mutation, transient transfections were performed in HeLa cells. For both 
wild-type AR and AR-T877A, CPIC did not induce luciferase activity above the no hormone 
control (Supplemental Fig. 4S.4). Since CPIC did not exhibit weak agonist activity in HeLaA6 
cells containing high levels of wild-type AR (Supplemental Fig. 4S.1B), or in HeLa cells 
transfected with AR-T877A (Supplemental Fig. 4S.4), it seems likely that cell context 
contributes to the weak agonist activity of CPIC in LNCaP cells. 
 CPIC Does Not Decrease AR Levels or Reduce Nuclear Translocation- CPIC could 
inhibit AR-mediated gene expression through multiple mechanisms (40) that include (a) 
increased AR degradation, (b) reduced nuclear localization of liganded-AR, (c) inhibition of AR 
recruitment to response elements on DNA, and (d) altered coregulator recruitment. Western blot 
analysis showed that CPIC had little or no effect on intracellular levels of AR (Fig. 4.8A).  
We used fluorescent polyclonal antibody to visualize intracellular AR in LNCaP and LAPC-
4 cells. AR was predominantly nuclear in the presence of 10 nM R1881. In LNCaP cells, when 
10 µM CPIC or Bic was present for either 4 or 24 h, AR was predominantly localized in the 
nucleus (Fig. 4.8B and Supplemental Fig. 4S.5A). Staining DNA with DAPI showed nuclear co-
localization of CPIC-bound AR in LAPC-4 cells (Supplemental Fig. 4S.5B). These data suggest 
that CPIC promotes nuclear localization of AR and might influence AR association with DNA. 
CPIC Inhibits AR Binding to Androgen-Responsive Genes- ChIP was used to evaluate the 
effect of CPIC on AR recruitment to regulatory regions of androgen-responsive genes in LNCaP 
and LAPC-4 cells. PSA and TMPRSS2 are two well-characterized androgen-regulated genes with 
defined AREs in their promoter and enhancer regions (41, 42). In LNCaP cells, R1881 increased 
AR recruitment to the PSA enhancer and promoter regions (Fig. 4.9A&B) and the TMPRSS2 
enhancer (Supplemental Fig. 4S.6A). RNA polymerase II was also recruited to these AREs in the 
presence of androgen-bound AR. Consistent with its weak agonist activity in LNCaP cells, with 
10 µM CPIC alone, there was a small increase in association of AR with the PSA enhancer and 
promoter (Fig. 4.9A&B). Although there is diversity in the reported effects of bicalutamide on 
AR binding to the PSA enhancer in LNCaP cells (6, 43, 44), most reports suggest that 
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bicalutamide interferes with androgen action at the PSA promoter by altering AR interaction 
with coregulators rather than inhibiting AR DNA binding (34, 45, 46). We found that 
bicalutamide inhibited recruitment of R1881-bound AR to the PSA enhancer to a greater extent 
than the PSA-promoter (Fig. 4.9A&B). CPIC strongly inhibited recruitment of R1881-AR to the 
PSA-promoter, PSA-enhancer and the TMPRSS2-enhancer (Fig. 4.9A&B and supplemental Fig. 
4S.6A). 
Since CPIC has no effect on AR levels or nuclear localization (Fig. 4.8), the decrease in AR 
occupancy is likely an effect of CPIC on AR binding to AREs and not a result of reduced levels 
of nuclear AR. Consistent with its ability to reduce AR binding to the promoter and enhancer 
regions of PSA and TMPRSS2, CPIC also reduced recruitment of RPol II (Fig. 4.9C&D and 
Supplemental Fig. 4S.6B). The results suggest that CPIC inhibits AR binding to AREs. 
In LNCaP cells, 10 µM CPIC exhibits weak agonist activity at the PSA gene (Figs. 7A and 
9). To evaluate the effect of CPIC in cells in which it acts as a pure antagonist, we performed 
ChIP in LAPC-4 cells. Because LAPC-4 cells contain lower levels of AR relative to LNCaP 
cells, there are few instances of ChIP performed using these cells. In LAPC-4 cells, 10 µM CPIC 
in the absence of R1881 did not increase AR occupancy at the PSA enhancer or promoter (Fig. 
4.10A&B) or the KLK2-enhancer (Supplemental Fig. 4S.6C). Bicalutamide had no effect on 
R1881-AR recruitment at the PSA promoter, whereas CPIC strongly inhibited R1881-AR 
recruitment to the PSA promoter (Fig. 4.10B). CPIC was somewhat more effective than Bic in 
reducing AR recruitment to the PSA enhancer (Fig. 4.10A). Consistent with its inhibition of AR 
binding at the PSA regulatory regions, CPIC also prevents recruitment of RPol II (Fig. 4.10C&D 
and Supplemental Fig. 4S.6D).  
To investigate the effect of CPIC on interaction of coactivators to AR, we used mammalian 
2-hybrid assays. Since this assay uses GAL4 DNA binding domain, we investigated the effects 
of CPIC on coactivator recruitment independent of its effects on AR binding to AREs in 
responsive genes. Previous work showed that TIF2 (GRIP1/SRC2) interacts with the AR ligand 
binding domain through its LXXLL motifs (1). In mammalian two-hybrid assays in HeLa cells, 
CPIC moderately reduces the interaction between the AR ligand-binding domain and the TIF2 
fragment required for interaction with AR (Supplemental Fig. 4S.7). There was essentially no 
effect on TIF2 interaction at 5 µM CPIC and 50% inhibition at 10 µM CPIC. 
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We evaluated the relationship between the weak agonist activity of CPIC in LNCaP cells 
that induced PSA and TMPRSS2 mRNAs, and the extent to which CPIC enhances AR 
occupancy at regulatory sites in PSA and TMPRSS2. CPIC alone induced TMPRSS2 mRNA to 
~24% of maximum and AR binding to the TMPRSS2 enhancer to ~26% of maximum (Fig. 4.7 
and Supplemental Fig. 4S.6). There was also a correlation between the ability of CPIC to inhibit 
R1881 induction of PSA and TMPRSS2 mRNAs and its ability to inhibit binding of AR to the 
regulatory regions of these genes. These results suggest that CPIC acts by decreasing AR binding 
to AREs in androgen-responsive genes. 
 
DISCUSSION 
The importance of AR in the development and growth of prostate cancer make AR an 
important therapeutic target. AR has properties unique among the steroid receptor family that 
influence androgen-dependent gene regulation. The AR interdomain interactions and a more 
limited role of coactivator LxxLL motifs (1, 3) highlight significant differences between AR and 
other steroid receptors. One way to probe the mechanism of AR action is by identification and 
characterization of novel small molecule inhibitors. The identification of a new coactivator 
binding surface on AR using low potency small molecule inhibitors, unrelated to CPIC, 
identified by screening (47) supports the utility of using small molecules as probes of AR 
actions. New small molecule inhibitors also have the potential to be therapeutically relevant. 
Molecular mechanisms leading to the development of prostate cancer resistance to 
antagonists are not fully understood. In a limited number of cases, AR mutations such as AR-
T877A can confer resistance to antiandrogens that function as weak agonists (39). To identify 
new small molecule AR inhibitors, we developed and implemented a cell-based high-throughput 
screen. Since LNCaP cells contain mutant AR-T877A, and LAPC-4 cells contain wild-type AR 
but have a doubling time of ~3 days, these cell lines were unsuitable for a luciferase-based 
screen. Although assays for androgen-stimulated proliferation of LNCaP and LAPC-4 cells work 
well in a 96-well format, they did not reach the requisite level of precision and reproducibility 
needed for a high-throughput screen in 384-well plates. For both the primary screen and 
preliminary analysis of hits, HeLa cells stably expressing wild-type AR and a PSA-luciferase 
reporter were used. The classical approach to cell-based screening involves adding the test 
compounds to cells that are previously plated. We found a simpler approach, in which the 
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inhibitor and cells are added at the same time produced equivalent results and could be readily 
automated. Consistent with its properties in LNCaP cells stably transfected to express elevated 
levels of wild-type AR (6), bicalutamide was an agonist in the HeLaA6 cells that express high 
levels of AR compared to minimal agonist activity in HeLa13 cells with moderate levels of AR 
similar to prostate cancer cells. In contrast to bicalutamide, which did not inhibit the androgen-
induced AR N/C interaction at the sub-micromolar concentrations tested, CPIC potently 
disrupted the androgen-dependent interdomain AR N/C interaction. 
Based on our assays CPIC was selected for detailed evaluation. An effective small molecule 
inhibitor of AR should exhibit high potency and specificity. Our studies show that CPIC inhibits 
AR transcriptional activity, with little or no effect on GR or ERα under the same conditions 
where other small molecules robustly inhibited ERα and GR (26, 48). CPIC effectively inhibited 
androgen-AR-dependent proliferation of LNCaP, LAPC-4 and CWR-R1 prostate cancer cells. At 
relevant concentrations, CPIC had little or no effect on the proliferation of several AR negative 
cell lines. Anchorage-independent colony-formation is a characteristic of many cancers and 
CPIC nearly abolished the AR-dependent proliferation of LAPC-4 prostate cancer cells in soft-
agar. Our studies therefore suggest that CPIC is a potent and selective inhibitor of AR action in 
prostate cancer cells.  
Radioligand binding assays and gene expression studies using stably transfected cell lines 
indicate that high levels of CPIC compete with androgen binding. By far the most 
straightforward explanation of this data is that CPIC is a competitive inhibitor of androgen 
binding to AR. However, our data do not exclude the possibility that CPIC binds to AR outside 
of the ligand-binding pocket and induces an inactive AR conformation opposed to androgen 
binding. When very high concentrations of androgens are present, AR is predominantly in the 
active conformation, which suggests a competitor phenotype. 
Although radioligand binding and cell-based assays show that CPIC competes with 
androgen for binding to AR, the weak agonist activity of CPIC in LNCaP cells did not result 
from the AR-T877A mutation. Cell context and high AR-T877A are likely responsible for the 
weak agonist activity of CPIC. 
Interestingly, CPIC has a different site of action than two experimental competitive 
inhibitors of AR, MDV3100 (6) and ARN-509 (49). In part because MDV3100 required a 
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relatively high 100 mg/kg/d dose to elicit a maximum in vivo response, ARN-509 was produced 
that elicited a maximum response at 30 mg/kg/d. A major site of action of both MDV3100 and 
ARN-509 is inhibition of AR nuclear localization (6, 49). In contrast, CPIC has no effect on 
nuclear localization, and acts at the level of AR binding to regulatory regions in responsive 
genes. 
CPIC exhibited weak agonist activity in LNCaP cells and modestly induced PSA and 
TMPRSS2 mRNAs in the absence of androgen. However, 10 µM CPIC and 10 µM bicalutamide 
alone had similar minimal effects on the proliferation of LNCaP cells. Tamoxifen, which 
competes with estrogens for binding to ER, exhibits partial agonist activity in stimulating gene 
expression in MCF-7 human breast cancer cells (50, 51), but is widely used in breast cancer 
therapy. Since the weak agonist activity of CPIC in LNCaP cells does not stimulate of LNCaP 
cell proliferation, CPIC has therapeutic potential.  
The inability of CPIC to influence AR levels or block agonist-induced AR nuclear 
localization together with the results from ChIP assays indicate that the inhibitory effects of 
CPIC occur at the gene level. R1881 induced a ~27 fold increase in AR occupancy at the PSA 
enhancer, ~11 fold increase in occupancy at the PSA promoter and a ~18 fold increase in 
occupancy at the TMPRSS2 regulatory region. The extent to which CPIC acts as a weak agonist 
in LNCaP cells and induced PSA and TMPRSS2 mRNAs correlated with the extent to which 
CPIC enhanced AR occupancy at regulatory sites in PSA and TMPRSS2. These data suggest that 
CPIC-bound AR at the PSA and TMPRSS2 genes is transcriptionally competent.  
Consistent with the mRNA data, CPIC does not exhibit any weak agonist activity in LAPC-
4 cells. In these cells, CPIC significantly reduced androgen-induced AR recruitment, and 
consequently reduced RNA polymerase II recruitment to the PSA promoter and enhancer 
regions. In contrast, bicalutamide in the presence of androgen did not inhibit AR occupancy at 
the PSA promoter in LNCaP cells (5), and has been reported to recruit corepressors to the 
promoter region (34, 45). Our data indicate that CPIC functions as an AR inhibitor by decreasing 
the interaction of AR with regulatory regions of androgen-responsive genes.  
AR and other steroid receptors exhibit a high level of conformational flexibility. Small 
molecules such as CPIC and bicalutamide may elicit different AR conformations. Our analysis 
suggests that although CPIC is similar to bicalutamide in its ability to inhibit androgen-induced 
transcription at the PSA gene locus, they may evoke different conformational changes when 
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bound to AR and have different mechanisms of action. CPIC was much more effective than 
bicalutamide in the inhibition of R1881-AR binding to the PSA promoter. The weak agonist 
activity of CPIC in LNCaP cells could be due to an AR conformation in which binding to AREs 
is reduced but not eliminated, an altered coactivator population that stabilizes weak binding of 
CPIC-AR to AREs, or the existence of multiple CPIC-AR conformations, one of which binds 
DNA and one of which is unable to bind DNA. With its unique mode of action, CPIC is a new 
potential inhibitor of prostate cancer growth.  
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FIGURES 
Figure 4.1 
 
FIGURE 4.1. Comparison of AR level and activity in HeLaA6 and HeLa13 cells. A, Western 
blot showing AR levels in HeLaA6 and HeLa13 cells. After at least 3 days in medium containing 
5% CD-FBS, ethanol (-) or 10 nM DHT (+) was added. After 24 h, the cells were harvested, 
protein was extracted and equal amounts of protein were fractionated on 10% polyacrylamide 
gels, analyzed by western blotting. Tubulin served as a loading control. B, Shown are the DHT 
dose-response curves for HeLaA6 and HeLa13 cells. HeLaA6 or HeLa13 cells were plated one 
day prior to treatment with the indicated concentrations of DHT or ethanol (vehicle) control. 
After 24 h of incubation, lysates were prepared and PSA luciferase activity measured in extracts 
from 3 wells of cells (Mean ± standard error of mean (SEM)). Activity in the presence of 
saturating DHT was set to 100%. 
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Figure 4.2 
  
FIGURE 4.2. CPIC inhibits androgen induction of PSA-luciferase activity. A, Structure of 
CPIC. B, Dose-response studies of CPIC inhibition of DHT-AR induced PSA-luciferase in 
HeLaA6 and HeLa13 cells. Cells were seeded in 24-well plates and treated with medium +/- 10 
nM DHT containing DMSO (Veh), the indicated concentrations of CPIC, or 10 µM  
bicalutamide (Bic) for 24 h and assayed for PSA luciferase activity. Activity of the reporter in 
the presence of 10 nM DHT and DMSO vehicle was set to 100%. Data represent the mean of 3 
experiments ±SEM. C, LAPC-4 cells transiently transfected with 400 ng of PSA-Enh-luciferase 
plasmid and 100 ng CMV-Renilla luciferase were treated with the indicated concentrations of 
CPIC or DMSO in the presence of 2 nM R1881 for 48 h. Cell lysates were assayed for firefly-
luciferase and normalized with Renilla-luciferase activity. Bars represent the mean of 3 
experiments ±SEM.  
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Figure 4.3  
 
FIGURE 4.3. CPIC competes with androgens for binding to AR and reduces the AR N/C 
interaction. A, Competitive radioligand binding assay. Relative binding affinity of CPIC for AR 
was determined using 5 nM [3H]R1881 and a range of CPIC concentrations as described (31). 
Data are the average of duplicate experiments. B, Effect of DHT concentration on CPIC 
inhibition of AR induced luciferase activity. HeLaA6 cells were seeded in 24-well plates and 
maintained for 24 h in medium containing 0.1 nM DHT (circle) or 10 nM DHT (triangle) and the 
indicated concentrations of CPIC. Data represent the average of triplicate experiments ± SEM. C, 
HeLa cells were transfected with 100 ng PSA-Enh-Luc reporter plasmid, 50 ng pCMV-AR-(1-
503) and 50 ng pCMV-AR-(507-919). Cells were incubated in the absence or presence of 10 nM 
DHT and the indicated concentrations of CPIC or bicalutamide (Bic). Luciferase units of DHT-
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treated wells were set at 100%. The luciferase activity is representative of two independent 
experiments. 
Experimental Data in Figure 4.3C: EM Wilson 
Figure 4.4  
 
FIGURE 4.4. Partial inhibition of ERα activity at high concentrations of CPIC. T47D-KBluc 
and T47D/(A1-2) cells were seeded in 24-well plates in medium containing 5% CD-FBS. After 
the cells attached, treatment medium was added with 5 nM of 17β-estradiol for ER in T47D-
KBluc cells, and 5 nM dexamethasone for GR in T47D/(A1-2) cells and the indicated 
concentrations of CPIC (or DMSO vehicle). After 24 h cell lysates were analyzed for luciferase 
activity. Data are the average of triplicate experiments ± S.E.M. 
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Figure 4.5 
 
FIGURE 4.5. Effects of CPIC on prostate cancer cell growth. A, LNCaP cells, B, LAPC-4 
cells, and C, CWR-R1 cells were treated with the indicated concentrations of CPIC in the 
presence or absence of 1 nM R1881. After 4 days of treatment for LNCaP and CWR-R1 cells, 
and 8 days for slow-growing LAPC-4, cell proliferation was measured using MTS. Cell growth 
in R1881+DMSO was set to 100%. D, AR-negative PC-3, MDA-MB-231 and DU145 cells were 
inoculated at 2,000 cells/well in 96-well plates and treated with 100 µl medium containing the 
indicated concentrations of CPIC or DMSO (vehicle). Growth of the cells was evaluated after 3 
days. DMSO wells were set to 100%. Data points represent the mean of 8 wells ± SEM. 
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Figure 4.6  
 
FIGURE 4.6. CPIC inhibits anchorage-independent growth of LAPC-4 prostate cancer cells 
in soft agar. 5,000 LAPC-4 cells were plated into top agar. Cells were treated with medium 
containing DMSO (vehicle), 1 nM R1881, 1 nM R1881 + 10 µM CPIC or 1 nM R1881 + 10 µM 
Bic, and replenished every 3-4 days. After 28 days colonies were counted and photographed at 
5X magnification. Inset, Bar graph represents the average of the total number of colonies 
counted in each well of the treatments. Photographs are representative of the entire well and of 
triplicate experiments.  
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Figure 4.7  
 
FIGURE 4.7. CPIC inhibits expression of endogenous AR-regulated genes. A, LNCaP and B, 
LAPC-4 cells were seeded in 6-well plates at 300,000 cells/well in medium containing 5% CD-
FBS for at least 3 days. Cells were treated with or without 1 nM R1881 and the indicated 
concentrations of CPIC or bicalutamide (Bic) for 24 h before RNA extraction. mRNA was 
quantitated using qRT-PCR and normalized to β-actin. Data represent the mean of 3 independent 
experiments ±SEM.  
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Figure 4.8  
 
 
 
FIGURE 4.8. CPIC does not decrease AR levels or alter nuclear localization of AR. A, 
Western blot of AR levels in LNCaP cells treated with CPIC. LNCaP cells were plated in 
medium containing 5% CD-FBS and maintained for at least 3 days. Treatment medium with (+) 
or without (-) 10 nM DHT containing DMSO (vehicle) or the indicated inhibitor was added to 
the cells. After 24 h, cell lysates were prepared and equal amounts of protein were analyzed by 
western blotting and tubulin used as a loading control. B, Visualization of intracellular AR in 
LNCaP cells. LNCaP cells were incubated with 10 nM R1881, 10 µM Bic, or 10 µM CPIC for 
24 h and intracellular AR was visualized by fluorescent microscopy using AR polyclonal 
antibody (Abcam, ab3510). Objective magnification, 40X. 
Experimental Data in Figure 4.8B: EM Wilson 
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Figure 4.9  
 
FIGURE 4.9. CPIC inhibits R1881-AR occupancy at AREs in LNCaP cells. Prior to ChIP, 
LNCaP cells were maintained for 3 days in medium containing 5% CD-FBS. After 1 h 
incubation with DMSO, 10 µM CPIC or 10 µM Bic, the cells were treated with 1 nM R1881 or 
ethanol and incubated for 4 h. Protein complexes were cross-linked and AR (A) or RPol II (B) or 
control IgG antibody was used to pull-down protein bound chromatin fragments. Occupancy at 
the PSA-enhancer, PSA-promoter and a control ARE-free region (middle region) between the 
two sites was determined using qRT-PCR. Fold enrichment over IgG control was plotted. Data 
represent the mean of 3 PCRs ± SEM and are representative of other experiments. Significance 
of the differences between CPIC and the DMSO control was tested using Student’s T-test. 
p<0.01 when compared to the respective controls.
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Figure 4.10  
 
FIGURE 4.10. CPIC inhibits R1881-AR occupancy at AREs in LAPC-4 cells. LAPC-4 cells 
were maintained for 3 days in medium containing 5% CD-FBS and ChIP was carried out as 
described in Fig. 4.9 and Experimental Procedures. AR (A, B) and RPol II (C, D) occupancy at 
the PSA-enhancer, PSA-promoter and a control ARE-free region (middle region) between the 
two sites were determined using qRT-PCR. Fold enrichment over IgG control was plotted. Data 
represent the mean of 3 PCRs ± SEM. Significance of the differences between CPIC and the 
DMSO control was tested using Student’s T-test and p <0.05 when compared to the respective 
controls. For AR recruitment to the PSA-promoter, R1881+10 µM Bic was not significantly 
different from R1881+DMSO. 
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SUPPLEMENTAL FIGURES 
 
Supplemental Figure 4S.1 
 
 
SUPPLEMENTAL FIGURE 4S.1. Bicalutamide is an agonist in HeLaA6 cells but not CPIC. 
Dose-response studies of (A) bicalutamide and (B) CPIC activation of AR-induced PSA-
luciferase in HeLaA6 and HeLa13 cells in the absence of added androgen. The cells were seeded 
in 24-well plates and treated with medium containing DMSO (vehicle), 10 nM DHT, or the 
indicated concentrations of Bic or CPIC for 24 h and assayed for luciferase activity. Activity of 
the reporter in the presence of 10 nM DHT was set to 100%. Data represent the mean of 3 
experiments ±SEM. 
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Supplemental Figure 4S.2 
 
SUPPLEMENTAL FIGURE 4S.2. PIC19.7 is a less potent analogue of CPIC. A, Structure of 
PIC19.7. B, PIC19.7 inhibits androgen-mediated luciferase activity in androgen-treated HeLaA6 
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and HeLa13 cells. C and D, PIC19.7 inhibits androgen-dependent growth of LAPC-4 cells 
without exerting toxic effects on the AR-negative PC3, MDA-MB-231 and DU145 cells. E, 
PIC19.7 is a specific inhibitor of AR and has minimal effects on GR or ERα induced luciferase 
activity. F, PIC19.7 inhibits AR mediated gene expression in LNCaP cells. G, In LNCaP cells, 
AR protein is not degraded in the presence of PIC19.7. 
 
Supplemental Figure 4S.3 
SUPPLEMENTAL FIGURE 4S.3. Effect of CPIC on androgen-regulated gene expression. 
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(A) LNCaP or (B) LAPC-4 cells were treated with or without 1nM R1881 and DMSO (vehicle), 
or 10 µM CPIC, or bicalutamide (Bic) for 24 h. qRT-PCR was performed to measure the levels 
of several known androgen-regulated mRNAs. Levels of mRNA were normalized to levels of β-
actin mRNA and presented as a ratio to control wells (no R1881, DMSO). Bars represent the 
mean of 3 experiments ± SEM.  
Primers used were: KLK2 forward primer 5’- TGT GTG CTA GAG CTT ACT CTG and reverse primer 
5’- CCA CTT CCG GTA ATG CAC CA; TMEPAI forward primer 5’- AAC GCT CTT TGT TCC AGA 
GCA TGG and reverse primer 5’- TCA CCA CCA CCA TCA CCA TCA TCA; PDZRN3 forward primer 
5’- AAT GGG ATA GAG GTG CAG AAC CGT and reverse primer 5’- ATG TCC ATG TGC AGG 
TCA TCC AGA; MMP16 forward primer 5’- TCT CCT CAG GGA GCA TTT GT and reverse primer 5’- 
TCC TTG AGG ATG GAT CTT GG. 
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Supplemental Figure 4S.4 
SUPPLEMENTAL FIGURE 4S.4. CPIC does not exhibit partial agonist activity in HeLa 
cells transfected with AR-T877A mutant or wt-AR. HeLa cells were transiently transfected 
with pCMV-hAR or pCMV-AR-T877A and PSA-luciferase reporter plasmids (as described in 
(29)), and treated with indicated nM concentrations of ligands DHT, R1881 or CPIC. The 
average of duplicate experiments is shown.  
Experimental Data in Supplemental Figure 4S.4: EM Wilson 
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 Supplemental Figure 4S.5 
 
SUPPLEMENTAL FIGURE 4S.5. CPIC does not alter nuclear translocation of AR in 
LNCaP or LAPC-4 cells. (A) LNCaP or (B) LAPC-4 cells were incubated with 1 nM R1881, 10 
µM Bic, or 10 µM CPIC for 4 or 24 h, respectively.  AR was visualized by fluorescent 
microscopy using AR polyclonal antibody (Abcam, ab3510). Intracellular DNA was visualized 
by DAPI staining. Objective magnification, 40X. 
Experimental Data in Supplemental Figure 4S.5: EM Wilson 
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Supplemental Figure 4S.6 
 
SUPPLEMENTAL FIGURE 4S.6. CPIC inhibits AR and RNA polymerase II (RPol II) 
occupancy at TMPRSS2 and KLK2 genes in LNCaP and LAPC-4 cells. LNCaP and LAPC-4 
cells were maintained for at least 3 days in 5% CD-FBS medium prior to ChIP. After one hour 
incubation with DMSO or 10 µM CPIC, cells were treated with 1 nM R1881 or ethanol and 
further incubated for 4 h. Protein complexes were cross-linked and (A,C) AR antibody, (B,D) 
RPol II antibody or control normal mouse IgG was used to pull-down protein bound chromatin 
fragments. Occupancy at the TMPRSS2-enhancer site in LNCaP cells and KLK2-enhancer site 
in LAPC-4 cells was determined using qRT-PCR. Fold enrichment over IgG control was plotted. 
Primers used were: KLK2 forward primer 5’- GTT GAA AGC AGA CCT ACT CTG GA and reverse 
primer 5’- CTG GAC CAT CTT TTC AAG CAT; TMPRSS2-Enh-ARE forward primer 5’- TGG TCC 
TGG ATG ATA AAA AAA GTT T and reverse primer 5’- GAC ATA CGC CCC ACA ACA GA 
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Supplemental Figure 4S.7 
 
SUPPLEMENTAL FIGURE 4S.7. High concentrations of CPIC interrupt TIF2 interaction 
with AR-LBD in two-hybrid assays. HeLa cells were plated in 12-well plates at 50,000 
cells/well and transfected with 100 ng 5XGAL4Luc3 reporter plasmid, and either 50 ng GAL-
AR-658-919 and 50 ng VP-TIF2.1 or 50 ng GAL-VP16 control plasmid. Cells were incubated in 
the presence or absence of 10 nM DHT and the indicated concentrations of CPIC. The mean and 
S.E. of luciferase activity are representative of two independent experiments.  
Experimental Data in Supplemental Figure 4S.7: Elizabeth M Wilson 
Plasmids: VP-TIF2.1 coding for TIF2 residues 624–1287 as a fusion protein with the VP16 activation 
domain was generously provided by Heinrich Gronemeyer (Institute of Genetics and Molecular and 
Cellular Biology) and the GAL4 luciferase reporter 5XGAL4Luc3 containing five tandem GAL-4 binding 
sites and the luciferase coding sequence was from Donald P. McDonnell (Duke University).  
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CHAPTER 5 
CPIC INHIBITS TRANSACTIVATION BY THE AMINO-TERMINAL DOMAIN OF 
THE ANDROGEN RECEPTOR 
 
The androgen receptor (AR) is unusual in the critical role of its N-terminal domain (NTD). 
While the C-terminal ligand-binding domain is the primary site for coactivator binding in other 
steroid receptors, the N-terminal domain plays a key role in coactivator binding to AR. Also, AR 
action is dependent on a strong interdomain N/C interaction. Our earlier work (see Chapter 4) 
suggested that CPIC was extremely effective in inhibiting the AR N/C interaction. We therefore 
looked in more detail at the ability of CPIC to inhibit the AR N/C interaction and its ability to 
inhibit transactivation by a constitutively active AR fragment that contains the N-terminal 
domain and the DNA binding domain but lacks the ligand binding domain. CPIC, potently 
inhibited transactivation by truncated AR. In contrast, the classical ligand binding competitors, 
bicalutamide and hydroxyflutamide had no effect on transactivation by truncated AR. CPIC also 
inhibited androgen-independent proliferation of CWR22RV1 cells, in which proliferation is 
stimulated by an AR splice variant that lacks the ligand-binding domain. CPIC shows a 
competitive ligand phenotype but is also able to act at the N-terminus. CPIC reduces the AR N/C 
interaction, presumably by interacting with the AR-NTD. We hypothesize that CPIC binding 
disallows androgens from binding the receptor at the LBD. CPIC could bind near the N-terminus 
to stabilize an inactive AR conformation that opposes ligand binding. There is a slight possibility 
that CPIC binds at two sites on AR, one in the ligand binding pocket and one in the N-terminal 
region. Alternatively, it remains to be seen if CPIC inhibits some unknown external factors (like 
cytokines, kinases or growth factors), the activity of which might be crucial for AR 
transactivation in most cell types. CPIC represents a class of compounds with properties that 
make them suitable candidates for further therapeutic development in CRPC. 
 
INTRODUCTION 
Androgens, such as dihydrotestoserone, and the synthetic androgen R1881, exert their 
actions by binding to the androgen receptor (AR). AR has modular functional domains with an 
amino-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region, and a C-terminal 
ligand-binding domain (LBD). Non-liganded full-length AR is found associated with a complex 
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of molecular chaperones in the cytoplasm. Binding of androgen to the LBD of the AR induces an 
intramolecular conformation change in the receptor that brings the amino and carboxy termini 
into close proximity, resulting in an N/C terminal interaction (1). Activated AR translocates and 
accumulates in the nucleus, where it can effectively bind to specific androgen response elements 
(AREs) in the promoter and enhancer regions of androgen-regulated genes to initiate 
transcription. The intra-domain N/C terminal interaction within the receptor and interactions of 
each of the domains with coactivators, corepressors, and DNA are essential for the regulation of 
transcription elicited by androgen-bound AR at responsive genes. The N-terminal region of AR 
contains the major activation domains (AF1 and AF5). Even in the absence of androgen, AR can 
also be activated by signaling pathways acting through the N-terminal region via c-AMP 
activated kinase (PKA), IL-6 or bone-derived factors (2).  
AR plays a key role in the growth and progression of prostate cancer (2-4). After primary 
treatment by surgical removal of the tumor or radiation, about 1/3rd of prostate tumors will 
eventually recur and are highly malignant (Gleason Score ≥7). These tumors are currently treated 
using endocrine therapies that either block production of androgens (surgically or chemically) or 
using anti-androgens such as Casodex (bicalutamide), hydroxyflutamide and the experimental 
drug MDV3100 that act by competing with androgens for binding to androgen receptor. Usually 
the tumor will begin to regrow in the absence of testicular androgens and in spite of anti-
androgen treatment. These tumors are called castration recurrent (or castration resistant) prostate 
cancer (CRPC). Therapeutic options for CRPC patients are very limited.  
It is widely accepted that CRPC remains dependent on AR action. Prostate specific antigen 
(PSA) and other androgen-AR induced genes which are detected in primary prostatic tumors are 
also elevated in CRPC (5). AR is the most commonly overexpressed protein in CRPC (6). 
Generation of gain of function mutations in the receptor, and altered action of coregulatory 
proteins, increased cross talk with other signaling pathways or the action of constitutively active 
AR splice variants can all contribute to disease progression in CRPC (7).  
The amino (N)-terminal region of the androgen receptor plays an important role in its ability 
to regulate gene expression. A regulatory protein, called MAGE-11 is overexpressed in many 
prostate cancers (8), and activates androgen receptor activity by binding to the N-terminal 
region. Also, some prostate cancers contain short forms of the androgen receptor protein that 
contain the N-terminal region and lack the part of the AR that binds androgens but continue to be 
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transcriptionally active. Because they are missing the site that binds androgens, they do not 
respond to agents that act by competing with androgens for binding to the androgen receptor. 
Recently, naturally occurring splice variants containing only the N-terminal region of AR and the 
DNA binding domain and some C-terminal extensions have been identified in CRPC (9-12). 
These constitutively active variants of AR retain transcriptional activity similar to that of full-
length receptor. Since they lack the binding site for androgens, they are not activated by 
androgens and are insensitive to inhibition by anti-androgens that compete with androgens for 
binding to the AR, such as bicalutamide and hydroxyflutamide. The AR NTD, with its high 
intrinsic disorder and flexibility, has not yet been crystallized and has traditionally not been 
targeted for structure-based drug design. But targeting the AR NTD would allow us to block in 
vivo prostate tumor growth in the presence of androgens in androgen-sensitive tumors and in the 
absence of androgens as seen in CRPC. 
Most recent inhibitors of prostate cancer progression have targeted activation of the AR, 
either directly or through co-regulators, or concentrated on the reduction of androgen synthesis 
by inhibiting 17,20-lyase/CYP17 activity. Of the androgen synthesis inhibitors, abiraterone 
acetate (Zytiga) has been approved for clinical use in the treatment of hormone-refractory 
prostate cancer while TOK-001 and TAK-700 (13, 14) are in various stages of clinical trials. 
New investigational drugs MDV3100 and a close analogue ARN-509 are antiandrogens that 
have shown great promise in clinical trials of CRPC. Current therapeutics bicalutamide and 
hydroxyflutamide (OHF) demonstrate agonist properties in cells containing mutant AR or 
expressing high AR levels (15, 16). 
To identify small molecules that inhibit the growth of cancer cells that contain androgen 
receptor, we carried out high throughput screening (HTS). We used the ~160,000 compounds in 
the libraries in the UIUC High Throughput Screening Center and carried out a cell-based assay 
measuring the ability of the small molecules to inhibit androgen-AR-induced expression of an 
easily assayed “reporter gene” consisting of a regulatory region controlling expression of PSA, 
driving production of the easy to assay luciferase. Serum PSA is a widely used diagnostic and 
prognostic indicator in prostate cancer. Small molecule “hits” were then validated by re-testing, 
evaluated for potency (the amount of the small molecule required to produce an effect), for 
efficacy (the maximum effect seen) and for specificity as an inhibitor of AR and not the closely 
related steroid hormone receptor, the estrogen receptor (ER) and for the absence of toxicity in 
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cells that do not contain AR. Then verified hits were tested for the ability to inhibit proliferation 
of AR-containing prostate cancer cells with low toxicity to AR-negative cells. By far the most 
effective compound to emerge from the screen and follow-up studies was CPIC (1-(3-(2-
chlorophenoxy)propyl)-1H-indole-3-carbonitrile)  as described previously in Chapter 4. CPIC is 
able to: 
 (i) Inhibit androgen-AR action, even in cells in which bicalutamide/casodex is ineffective  
(ii) Block the induction of endogenous androgen regulated genes (TMPRSS2, PSA and 
others) in multiple cell lines 
(iii) CPIC acts primarily by inhibiting binding of androgen-AR to regulatory regions of 
responsive genes 
(iv) Inhibit anchorage-dependent and anchorage-independent androgen-stimulated growth of 
prostate cancer cells with little effect on AR-negative cell lines  
(v) At 0.5 µM CPIC, completely inhibits the AR N/C interaction  
Here we describe CPIC as a small molecule inhibitor of androgen receptor that is effective 
against both the full-length androgen receptor and against a short truncated androgen receptor 
that does not respond to current drugs. CPIC completely inhibits constitutively active truncated 
AR1-660 that lacks the ligand-binding domain at concentrations as low as 0.5 µM. CPIC blocks 
androgen-dependent and androgen-independent growth of CWR22Rv1 prostate cancer cells. The 
sub-micromolar potency of CPIC against truncated AR is especially impressive compared to 
other small molecules that target AR (17). CPIC exhibits a wide therapeutic window. CPIC 
represents a class of compounds with properties that make them suitable candidates for further 
therapeutic development in CRPC. 
 
MATERIALS & METHODS 
Plasmids: Expression vectors used have been previously described (18). pCMV-AR-(507–
919) codes for the human AR DNA and ligand-binding domains, pCMV-AR-(1–503) codes for 
the AR amino-terminal domain. PSA-Enh-Luc containing the PSA upstream enhancer region 
was generously provided by Michael Carey (University of California, Los Angeles). The pCMV-
AR-1-660 codes for the AR amino terminal domain and DBD with parts of the hinge region 
(Exons 1/2/3) and is constitutively active in the absence of androgens. pCMV-hAR and pCMV-
hGR express full-length androgen and glucocorticoid receptors, respectively, and binds to the 
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PSA-Enh-Luc to induce luciferase activity in the presence of their respective hormone ligands 
dihydrotestosterone (DHT) or dexamethasone (Dex). 
Expression plasmids for a chimeric protein encoding the GAL4 DNA binding domain fused 
to the C-terminal AR ligand binding domain (GAL -AR-658-919) and the N-terminal region of 
AR fused to the powerful VP16 transcription activation domain (VP-AR-1-660) interact with 
each other and induces luciferase enzyme activity through the 5X-GAL4 DNA element, in the 
presence of androgens. The GAL-VP16 plasmid is used as a control.  
Transient transfections: Transfections in HeLa cells were performed as described (19). 
Briefly, human epithelial cervical carcinoma HeLa cells were maintained in Eagle's minimum 
essential medium supplemented with 10% fetal bovine serum, penicillin, streptomycin, and 2 
mM-glutamine. HeLa cells were plated at 5 × 104 cells/well in 12-well plates and 24 h later 
transfected using FuGENE 6 transfection reagent (Roche Applied Science) with indicated 
amounts of expression vectors and luciferase reporter plasmid to determine androgen-induced or 
androgen-independent AR transactivation. The next day cells were washed with PBS, and 1 
ml/well serum-free medium containing the indicated treatments was added and incubated at 37 
°C. Twenty four hours later cells were washed with PBS and assayed for luciferase activity after 
harvesting in 0.25 ml of lysis buffer using a Lumistar Galaxy (BMG Labtech) automated multi-
well plate reader luminometer. 
Cell proliferation assay: CWR22Rv1 cells were obtained from ATCC and maintained in 
RPMI 1640 supplemented with 10% FBS and 1% penicillin and streptomycin at 37˚C in 5% 
CO2. 4 days prior to experiments the cells were shifted to media containing 5% CD-treated FBS 
for removal of any trace androgens. 2,000 cells/well were plated in 96-well plates and allowed to 
plate for a day. Treatment medium containing indicated concentrations of inhibitor compounds 
was added to the cells, with or without 1 nM DHT and incubated for 6 days. Cell viability was 
determined using Promega CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS). 
 
RESULTS 
CPIC disrupts the AR N/C interaction 
Interaction between the amino (N) terminal region of AR and the ligand-binding domain (C-
terminal region) plays a critical role in AR activity. To evaluate the effect of CPIC on the 
interdomain AR N/C interaction, we performed mammalian 2-hybrid assays using constructs 
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containing the N- and C-terminal regions of AR. Transfections were performed in HeLa cells 
using pCMV-AR-(1-503) (the AR NH2-terminal region), pCMV-AR-(507-919) (NH2-terminal 
deletion of AR) and PSA-Enh-Luc reporter plasmids in the absence and presence of 10 nM DHT. 
Bicalutamide and other antagonists that bind to the ligand-binding pocket of AR disrupt this 
crucial interaction and alter receptor structure and function at higher concentrations (1, 20). 
CPIC was substantially more effective than bicalutamide in inhibiting the androgen-induced AR 
N/C interdomain interaction (Fig. 5.1). 
CPIC is able to reduce the recruitment of AR to DNA regulatory sites on target genes (Fig 
4.9 and 4.10). To eliminate the possibility that the reduction we see in luciferase activity in the 
above assay is due to a poor recruitment of the interacting AR fragments to the PSA-enhancer-
luciferase, we tested the ability of CPIC to disrupt N/C interaction by using GAL4-VP16 two-
hybrid constructs. In these constructs, GAL4-DBD not AR-DBD is responsible for DNA 
binding. Expression plasmids for a chimeric protein encoding the Gal4 DNA binding domain 
fused to the C-terminal AR ligand binding domain (Gal-AR-658-919) and the N-terminal region 
of AR fused to the powerful VP16 transcription activation domain (VP-AR-1-660) were used. 
Treatment with 10 nM DHT results in robust transcription of the luciferase reporter. CPIC 
elicited a dose-dependent inhibition of the reporter with an IC50 of ~0.7 µM and complete 
inhibition at 10 µM (Fig. 5.2). CPIC inhibition was specific for the AR N/C interaction. Control 
transfections with GAL-VP16, which activates the same reporter, showed no effect of CPIC at 
all concentrations tested (0.1-10 µM). These data show that CPIC potently inhibits the N/C 
interaction of AR. 
CPIC potently inhibits transcription by the truncated N-terminal AR 
Truncated AR variants that contain the NTD and DBD but lack the LBD are constitutively 
active in the absence of androgens. Dose-response studies in transfected cells showed that CPIC 
potently inhibited AR1-660 constitutive activity, with IC50 = ~0.2 µM and >90% inhibition at 0.5 
µM (Fig. 5.3). AR1-660 lacks the AR LBD and does not bind androgens, and thus bicalutamide 
(Bic) and hydroxyflutamide (OHF) are unable to inhibit activity of this truncated form of AR.  
In control experiments, CPIC was able to down regulate the transcriptional activity of full-
length AR transfected into COS cells (Fig 5.4A) or HeLa cells (Fig 5.4B), but not that of full-
length glucocorticoid receptor (GR). This inhibition is not due to non-specific toxicity. In the 
same cell line, HeLa cells transfected with GAL-VP16 and treated with 10 µM CPIC show no 
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inhibition (Fig. 5.2). CPIC can directly target the N-terminal region in full-length or truncated 
forms of AR and potently inhibit AR variants often seen in aggressive prostate cancers. 
CPIC inhibits androgen-dependent and androgen-independent proliferation of 
CWR22Rv1 cells 
CWR22Rv1 is a human prostate cancer cell line derived from a transplanted xenograft that 
relapsed after castration-induced androgen ablation (21). CWR22Rv1 cells express both the full-
length AR and two AR isoforms (10, 11). One of these variants, AR-V7 consists of the AR NTD, 
DBD and a C-terminal extension region (cryptic exons) (Figure 5.5A). AR-V7 is constitutively 
active and drives androgen-independent growth of the 22Rv1 cells and therefore, could play a 
role in castration resistance (9-12, 21). CPIC but not OHF inhibited androgen-independent 
proliferation of 22Rv1 cells, while both CPIC and OHF were able to reduce the androgen-
dependent proliferation of 22Rv1 cells in 1 nM DHT (Fig 5.5B). Inhibition was similar to that 
reported for EPI-001, a compound derived from marine sponge which is also capable of 
interacting with the AR-NTD (Fig. 4D in (17)). CPIC represents a class of novel AR inhibitors 
that inhibit the proliferation of 22Rv1 cells, a model for CRPC, in the presence or absence of 
androgens by targeting the AR NTD rather than the LBD. 
 
DISCUSSION 
Constitutively active AR variants have been identified in aggressive prostate cancers and are 
associated with early recurrence and poor prognosis (22). These AR variants lack the hormone 
binding domain but are transcriptionally active in the absence of androgens, and elicit castration-
recurrent growth of prostatic tumors. Using a cell-based high-throughput screen we identified the 
small molecule AR inhibitor, CPIC. Initially CPIC was thought to be a competitive antagonist of 
AR, much like bicalutamide and hydroxyflutamide. In radioligand binding assays, CPIC 
competed with 5 nM [3H]-R1881 for binding AR at least as well as bicalutamide. Further 
analysis revealed that CPIC inhibits the AR N/C interaction much more potently than 
bicalutamide. The N/C interaction of AR plays a major role in the stabilization of the ligand-
receptor complex as well as in AR dimerization and reduces receptor degradation (23). This 
raises the possibility that CPIC allosterically binds the AR NTD resulting in reduced N/C 
interaction and subsequently opposing androgen binding to the LBD. 
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We directly test this theory by analyzing the effects of CPIC on transactivation mediated by 
a constitutively active AR variant lacking the LBD. CPIC potently inhibits activities of AR that 
involve the N-terminal region. Inhibition of the constitutively active N-terminal AR was also 
seen using the less potent structurally related PIC19.7. In contrast, existing drugs Casodex 
(Bicalutamide) and Eulexin (hydroxyflutamide) are completely ineffective against this form of 
AR due to the absence of the LBD. Thus CPIC represents a family of compounds capable of 
directly targeting the N-terminal region in full-length or truncated forms of AR and potently 
inhibit AR variants often seen in CRPCs. 
Another compound reported to target the N-terminal region of AR is EPI-001, identified 
from marine sponge by a group of scientists at the University of British Columbia, Vancouver 
(17). CPIC is at least 20 times more potent than EPI-001 in its ability to inhibit transactivation of 
N-terminal AR. Although through personal communications with Dr. Marianne Sadar, it is 
known that EPI-001 has gone through a rigorous process of lead optimization and a more potent 
analogue has been synthesized.  
CPIC represents a potentially new class of therapeutics for castration recurrent prostate 
cancer. CPIC is active against the highly active truncated form of androgen receptor found in a 
significant percentage of the most aggressive and lethal prostate cancers. CRPC may contain 
primarily full-length AR, a mixture of full-length and truncated AR or exclusively truncated AR 
lacking the ligand-binding domain. CPIC is also very effective against full-length AR and 
inhibits the proliferation of AR positive cells. Because there are few therapeutic options for 
CRPC, interest in small molecule AR inhibitors with therapeutic potential is intense. 
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FIGURES 
 
Figure 5.1 
 
FIGURE 5.1. CPIC inhibits transactivation by 2 fragments of AR linked by N/C 
interaction. 50,000 HeLa cells/well were plated in 12-well plates. The cells were maintained in 
CD-FBS and transiently transfected with 50 ng of AR-507-919 and 50 ng of AR-1-503, and 100 
ng of the androgen inducible PSA Enhancer-luciferase reporter. Transfected cells were 
maintained in the absence (-) or presence (+) of 10 nM DHT and the indicated concentrations (0-
1 µM) of CPIC, PIC19.7 or bicalutamide/Casodex (Bic) and assayed for luciferase activity 
(Luciferase Units). Data is the average of 2 experiments performed in duplicates ± error. 
(Parts of this experiment are shown in Chapter 4, Figure 4.3C)
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Figure 5.2 
 
FIGURE 5.2. CPIC inhibits the AR N/C interaction in 2-hybrid assays. Mammalian 2-hybrid 
assays were carried out in transiently transfected HeLa cells. 50,000 HeLa cells/well were seeded 
in 6-well plates, maintained in CD-FBS and subjected to transient transfection using 50 ng/well 
of GAL-AR-658-919, 50 ng of VP-AR-1-660 and 100 ng of (GAL4)5-luciferase reporter, or as a 
control for non-specific effects of CPIC 50 ng of GAL-VP16 and 100 ng of (GAL4)5-luciferase. 
Transfected cells were maintained in the absence (--) or presence (+) of 10 nM DHT and the 
indicated concentrations of CPIC (0-10 µm) and assayed for luciferase activity (luciferase units). 
Data is the average of 2 experiments performed in duplicates ± Error.
 123 
Figure 5.3 
 
 
FIGURE 5.3. CPIC potently inhibits the constitutively active N-terminal AR. To compare 
the ability of CPIC, bicalutamide (Bic) and hydroxyflutamide (OHF) to inhibit transcription by 
the N-terminal AR, 50,000 HeLa cells/well were plated in 12-well plates and maintained in CD-
FBS. The cells were transfected with 50 ng/well of AR-1-660 (contains the A, B and C domains 
of AR; the N-terminal region and the DNA-binding domain but lacks the ligand-binding domain) 
and 100 ng of the PSA Enhancer-luciferase reporter. Transfected cells were maintained with no 
added DHT and the indicated concentrations (0-10 µM) of CPIC, bicalutamide (Bic), or 
hydroxyflutamide (OHF) and assayed for luciferase activity (Luciferase Units). Data is the 
average of 2 duplicate experiments ± error.
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Figure 5.4 
 
 
 
 
 
 
FIGURE 5.4. CPIC 
specifically inhibits AR 
but not GR mediated 
luciferase activity. 
A. 50,000 COS cells/well 
were plated in 12-well 
plates and maintained in 
CD-FBS. The cells were 
transfected with 10 ng/well 
of pCMV-hAR or pCMV-
hGR along with 250 ng of 
the PSA Enhancer-
luciferase reporter. B. 
50,000 HeLa cells/well 
were plated in 12-well 
plates and maintained in 
CD-FBS. The cells were transfected with 10 ng/well of pCMV-hAR along with 250 ng of the 
PSA Enhancer-luciferase reporter or 10 ng/well pCMV-hGR and 100 ng of the MMTV-
luciferase reporter. Transfected cells were maintained in the absence (--) or presence (+) of 1 nM 
DHT for AR or 10 nM Dex for GR and the indicated concentrations (0-10 µM) of CPIC and 
assayed for luciferase activity (Luciferase Units). Data is the average fold induction of 2 
duplicate experiments. 
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Figure 5.5 
 
FIGURE 5.5. CPIC inhibits androgen-dependent and androgen-independent proliferation 
of 22Rv1 cells.  
A. Schematic diagram of the domains of full-length AR and the splice variant AR-V7 expressed 
in 22Rv1 cells. B. 22Rv1 cells were stripped for 4 days in 5% CD-FBS containing media and 
plated at 2000 cells/well in 96-well plates. Cells were maintained without added androgens (no 
DHT) or with 1 nM DHT and the indicated concentrations of CPIC or OHF and assayed using 
MTS after 6 days. Cell growth in DMSO after 6 days was set to 100% and data points represent 
the mean of at least 3 wells ± SEM. Significance was tested using Student’s T-test and p <0.05. 
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CHAPTER 6 
A SMALL-MOLECULE INHIBITOR THAT REDUCES THE LEVEL OF ANDROGEN 
RECEPTOR 
  
Androgen receptor (AR) remains a key target in castration-recurrent prostate cancer 
(CRPC). The molecular mechanisms driving the reactivation of AR in this malignant state are 
not fully understood. Some potential causes for the CRPC phenotype includes the expression of 
AR splice variants or gain of function mutants of AR, which are constitutively active in the 
absence of ligands. This underscores the need to identify new molecules not only able to bind to 
the full-length AR, but also capable of inhibiting transactivation by AR splice-variants and 
mutants.  
We performed a stringent high-throughput screen using an androgen-induced luciferase-
reporter system in a stable HeLa cell line, which allowed us to identify AR54 (2-(pyrimidin-2-
ylthio)-1-(2,2,4-trimethyl-4-phenyl-3,4-dihydroquinolin-1(2H)-yl)ethanone) as a novel non-
competitive inhibitor of AR action. In LAPC-4 prostate cancer cells, AR54 blocks cell 
proliferation, reduces the level of AR mRNA and subsequently down-regulates AR protein 
levels. We have not yet determined whether AR54 reduces the production of AR transcripts or 
increases the rate of mRNA degradation. AR54 is able to inhibit both androgen-dependent and 
androgen-independent proliferation of CWR22Rv1 cells, presumably by inhibiting the 
transactivation potential of both full-length AR and constitutively active AR variants present in 
these cells.  
 
INTRODUCTION  
Androgens, acting through the androgen receptor (AR), play a key role in the development 
and progression of prostate cancer (PCa). Antiandrogen and androgen deprivation therapy have 
been standard therapies for metastatic and recurrent prostate cancer since Huggins and Hodges 
(1) reported the effect of castration on PCa. Although most patients initially respond favorably, 
over time tumors recur as aggressive castration-resistant or castration-recurrent prostate cancer 
(CRPC) with limited therapeutic options in approximately 25% of patients (2). The mechanisms 
underlying castration-resistant androgen receptor (AR)–mediated signaling remain unclear, 
although several possible mechanisms have been proposed including AR gene mutation, 
 
127 
increased AR expression, or increased androgen biosynthesis in prostate tumors (3-8). In spite of 
intensive androgen-depleting therapies used to mitigate the cancer at the initial stages of 
progression, continued AR signaling is a common feature of CRPC and AR remains a key 
therapeutic target (2, 3). A thorough understanding of the how AR activity promotes tumor 
growth and survival is the need of the hour.  
As a transcription factor, the AR regulates the expression of many coding and noncoding 
RNA targets. In CRPC, transactivation by AR can occur through a number of interdependent 
mechanisms, including increased expression of the receptor, generation of mutations in the 
receptor, and altered action of coregulatory proteins, through cross talk with other signaling 
pathways or through the action of constitutively active splice variants (6). Current antiandrogens 
used in the clinic, including bicalutamide (Casodex) and flutamide (Eulexin), specifically act by 
competing with androgens for binding the AR. Blockage of androgen binding results in 
inhibition of AR-mediated gene expression and cell proliferation, but transactivation of the 
receptor by other factors renders these treatments ineffective in advanced PCa. In model settings 
of CRPC bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity and 
prostate tumor cell growth (9). There is also some evidence to demonstrate that AR mutations are 
selected in response to strong selective pressure from flutamide treatment (10). The continued 
viability of AR as a therapeutic target is illustrated by the recent approval of the inhibitor of 
androgen biosynthesis, abiraterone, which prolongs survival in late-stage metastatic prostate 
cancer (11), MDV3100 which acts by competing with androgens for binding in the ligand-
binding pocket of AR and by the ongoing efforts to develop ARN-509, also a competitive 
antagonist with a better dose-response profile in mouse xenograft tumors (9, 12). Most efforts to 
target AR action focus on inhibition of androgen synthesis, or on improved antiandrogens. 
Efforts have also been intensified in finding natural chemicals that can act as ligand inhibitors of 
therapeutic targets like AR. C Chang and colleagues describe such an AR inhibitor, ASC-J9, 
which is a curcumin derivative capable of enhancing AR degradation (13). In our hands, ASC-J9 
was a potent inhibitor of AR action but it also exerted substantial indiscriminate toxic effects in 
AR-negative environments in the same concentration range (data not shown).  
Because there are several mechanisms by which AR retains its ability to act in CRPC (14), 
we were interested in identifying noncompetitive small-molecule inhibitors that reduce AR 
levels. After screening a library of about ~160,000 small molecules, we identified a potent 
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noncompetitive inhibitor of AR in prostate cancer cells. This compound, AR54 (2,2,4-trimethyl-
4-phenyl-1-[(2-pyrimidinylthio)acetyl]-1,2,3,4-tetrahydroquinoline), was able to down-regulate 
AR protein levels in prostate cells. A dozen small molecules that were structurally related to 
AR54 were also tested for potency, specificity and toxicity. By reducing AR levels, our non-
competitive small molecule inhibitor AR54 should be able to target most known mechanisms by 
which AR can act in CRPC.  
 
EXPERIMENTAL PROCEDURES: 
Chemical Libraries- The libraries screened were the ChemBridge MicroFormat small 
molecule library obtained from ChemBridge™ containing ~150,000 small molecules, the Marvel 
library, developed at the University of Illinois by K. Putt and P. Hergenrother containing ∼9,700 
small molecules (15, 16) and the NCI Diversity Set from NIH containing ~1,990 small 
molecules. 
Cell Culture- AR-positive cell lines included LNCaP and LAPC-4 human prostate cancer 
cells maintained in phenol-red free RPMI 1640 with 10% fetal bovine serum (FBS; Atlanta 
Biological, GA). LAPC-4 growth medium were routinely supplemented with 1 nM of the 
synthetic androgen methyltrienolone (R1881). Cells were transferred to RPMI 1640 containing 
5% charcoal-dextran stripped (CD) FBS at least three days prior to plating for an experiment. 
CWR-R1 cells (17) were grown in modified iMEM (GIBCO#10488-001) containing 2.5 g/l of 
glucose, 1.2 g/l Niacinamide, 0.5 ml of Insulin-Transferrin-Selenium (ITS; Roche 
#11074547001), 10 ng/mL epidermal growth factor (EGF) and 2% FBS. The cells were 
transferred to medium containing 2% CD-FBS without EGF 3-4 days before the experiment. 
CWR22Rv1 cells were obtained from ATCC and maintained in RPMI 1640 supplemented with 
10% FBS for growth flasks or 5% CD-FBS for the treatment flasks and experimental plates.  
AR-negative cell lines included PC3 human prostate cancer cells maintained in RPMI 1640 
with 10% FBS, and DU145 human prostate cancer cells and MDA-MB-231 human breast cancer 
cells grown in MEM with 10% FBS. 
Other cell lines included estrogen receptor α (ERα)-containing T47D-KBluc breast cancer 
cells (18) expressing an (ERE)3-luciferase reporter gene , maintained in RPMI 1640 containing 
10% FBS. Three days before induction with 17β-estradiol (E2), cells were transferred to medium, 
containing 5% CD-FBS. T47D/(A1-2) cells stably express the human glucocorticoid receptor 
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(GR) and contain a mouse mammary tumor virus (MMTV)-luciferase reporter (19) were 
maintained in MEM, 5% FBS and 0.2 mg/ml G418. The MMTV-Luc reporter is inducible by 
AR, progesterone receptor (PR) and GR depending on the activating ligand used. Before the 
experiment, cells were transferred to the above medium containing 5% CD-FBS.  
The RPMI Base medium was supplemented with 2 mM L-glutamine, 1.5 g/l sodium 
bicarbonate, 4.5 g/l glucose, 10 mM Hepes, and pH 7.5, 1 mM sodium pyruvate. MEM was 
supplemented with 10 mM HEPES, pH 7.4 and 2 mM glutamine. 
All cells were maintained at 37˚C in 5% CO2 in growth medium containing 1% penicillin 
and streptomycin and 2-10% fetal bovine serum (FBS) (Atlanta Biological, Atlanta, GA) without 
phenol-red. 
Reporter Gene Assays- At least 3 days before each experiment cells were transferred to 
medium containing CD-FBS as described above. T47D/(A1-2) and T47D-KBluc cells (200,000 
cells/well) were plated in 1 ml of medium in 24-well plates. After 24 h the indicated 
concentrations of E2, or dexamethasone (Dex) were added along with each inhibitor or DMSO 
(vehicle). After 24 h, cells were lysed in 100 µl of Passive Lysis Buffer (Promega, Madison WI) 
and luciferase activity was determined using BrightGlo firefly luciferase reagent (Promega). 
Unless otherwise mentioned, total DMSO (vehicle) concentration in all assays was maintained at 
or below 0.1%. 
Cell Growth and Viability Assays- To assay cell growth, 2,000 cells/well were plated in 96 
well plates. LNCaP and LAPC-4 cells were maintained in CD-treated serum for at least 2-4 days 
prior to each experiment. All AR negative cell lines, MDA-MB-231 and PC3, were plated in 
growth medium 24 hours prior to treatment. Treatment medium containing vehicle or the 
indicated concentrations of R1881, with or without inhibitor compounds was added to the cells 
and incubated for the indicated number of days. Cell viability was determined using Promega 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS). 
Radioligand Binding Assay- Competitive radioligand binding assays were performed by 
expressing pCMV-AR in monkey kidney COS cells and incubating cell cultures for 2 h at 37˚C 
with [3H]R1881 (17α-methyl-[3H] methyltrienolone, 82 Ci/mmol) in the absence and presence of 
competitor ligands (20).  
Endogenous Gene Expression- LNCaP, LAPC-4 and MCF-7 cells were seeded into 6-well 
plates and grown for 3-4 days in medium containing 5% CD-FBS. Cells were then treated with 
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ethanol or hormone, along with the indicated concentrations of the inhibitor for 24 hours. RNA 
was extracted and purified using the Qiagen RNeasy kit. cDNA was prepared from 1 µg of RNA 
with M-MuLV reverse transcriptase from NEB. Diluted cDNA was used to perform quantitative 
RT-PCR using SybrGreen (ABI Thermocycler) with actin as the internal standard. Primers for 
qRT-PCR were: β-actin forward primer 5’- TGT CAC CAA CTG GGA CGA CA and reverse 
primer 5’- GGG GTG TTG AAG GTC TCA AA; PSA (kallikrein 3) forward primer 5’- GGT 
GAC CAA GTT CAT GCT GTG and reverse primer 5’- GTG TCC TTG ATC CAC TTC CG; 
TMPRSS2 forward primer 5’- TAG TGA AAC CAG TGT GTC TGC and reverse primer 5’- 
AGC GTT CAG CAC TTC TGA GGT CTT; PS2 forward primer 5’- ACC GGA CAC CTC 
AGA CAC G 3’ and reverse primer 5’- CTG TGT TGT GAG CCG AGG C 3’and ERα forward 
primer 5’- GCG AAG AGG GTG CCA GGC TTT 3’ and reverse primer 5’- ATG GAG CGC 
CAG ACG AGA CCA 3’.  
Western Blot- Cells were plated at 300,000 cells/well in 6-well plates in medium containing 
5% CD-FBS. The medium was changed on day 2, and on day 4 the cells received fresh medium 
containing the indicated treatments. Whole cell extracts were prepared after 24 h of treatment 
using 1X RIPA buffer (Millipore, CA) containing complete mini protease inhibitor cocktail 
(Roche, Germany). 30 µg of protein per lane was analyzed on 10% SDS-PAGE gels and 
transferred to nitrocellulose membranes (GE Healthcare). AR protein was detected using AR 
antibody AR (441) (sc-7305, Santa Cruz, CA) and β-actin was detected using monoclonal 
antibody A1978 (Sigma).  
Statistical Analysis- Results are expressed as mean ± SEM of at least three independent 
experiments. Significance was established when p<0.05. Student’s t test was used for 
comparison of the means between two groups. 
 
RESULTS 
AR54 is a Novel non-ligand Small-molecule Inhibitor of AR in Prostate Cancer Cells- To 
identify small molecules that inhibit the growth of AR positive cancer cells we carried out high-
throughput screening (HTS) of a ~160,000 small molecule library at the UIUC HTS Center. 
Validated small molecule “hits” were evaluated for potency, efficacy, specificity and toxicity. 
AR54 (Fig 6.1A) is one of the most effective novel small-molecule inhibitor to emerge from this 
study. The ability of AR54 to compete with R1881 binding to AR was evaluated in COS cells 
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transfected with wt-hAR. In competitive radiometric binding assays AR54 did not compete with 
the synthetic radiolabeled androgen R1881 for binding at the AR ligand-binding domain (Fig 
6.1B). Therefore AR54 most probably acts outside of the ligand-binding pocket of AR. 
Interestingly, in analyzing a cohort of 13 compounds sharing >85% structural similarity with 
AR54(Supplemental Table 6S.1), we found that one compound ARD67 competes with 
androgens for binding AR and shows the phenotype of an AR inhibitor (Supplemental Fig 6S.1). 
Comparisons of the activities of these analogues on AR dependent and independent proliferation 
of various cell lines are summarized in Supplemental Fig 6S.2 and may serve as a limited 
structure-activity correlation study.  
AR54 Inhibits Growth of AR Positive LAPC-4 Prostate Cancer Cells and Exhibits Low 
Toxicity in AR Negative Cells- We evaluated the effect of AR54 on the androgen-dependent 
proliferation of some AR-positive cell lines. LAPC-4 cells contain wild-type AR. In dose 
response studies, AR54 inhibited androgen-dependent growth of LAPC-4 cells with an IC50 of 
3.5 µM (Fig 6.2A). In 7-day experiments with 10 µM and 20 µM AR54 in the absence of R1881, 
the final number of cells were similar to that seen in LAPC-4 cells grown with vehicle DMSO 
without R1881. This indicates indirectly that AR54 does not elicit an indiscriminate toxic effect 
in cells.  
Fig 6.2B compares AR54 with other known inhibitors of AR and shows that in these cells 
AR54 was more effective than the competitive AR inhibitor ASC-J9, which also causes AR 
degradation (13).  
In PC3 cells, AR54 did not inhibit cell growth at 10 µM and did not reach 50% inhibition at 
the highest concentration tested, 30 µM (Fig 6.2C). We showed that MDA-MB-231 cells are 
highly susceptible to non-specific damage (15) and AR54 was less toxic than the competitive AR 
inhibitor ASC-J9 (Fig 6.2D). The results indicate that at concentrations of AR54 sufficient for 
inhibition of AR-mediated proliferation of AR-positive prostate cancer cells, it exerts minimal 
toxicity on AR-negative cells. 
AR54 specifically inhibits AR action- AR sequence has substantial structural homology 
with other steroid receptors namely the GR and PR. Therefore, from a therapeutic and 
mechanistic point of view, it is important for an inhibitor to exhibit specificity in binding AR 
without affecting the ubiquitously expressed GR.  
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We evaluated the effect of AR54 on transcription mediated by other steroid receptors in cell 
lines stably transfected to express reporter genes. Inhibition of ERα, was evaluated in T47D-
KBluc cells that express endogenous ERα and are stably transfected with an estrogen (E2) 
inducible (ERE)3-luciferase reporter gene. Inhibition of glucocortioid receptor (GR) was 
evaluated in T47D/(A1-2) cells that are stably transfected to express GR and a mouse mammary 
tumor virus (MMTV)-luciferase reporter gene. In these cells treatment with the synthetic 
glucocorticoid, dexamethsone (Dex) activates the MMTV reporter through GR. 10 µM AR54 
treatment results in minimal inhibition of ERα and GR mediated transactivation but 20 µM 
AR54 reduces ERα mediated luciferase activity (Fig 6.3A).  
To ensure AR54 specificity for AR inhibition at concentrations ≤10 µM, it was also probed 
in MCF-7 cells that contain abundant ERα, transactivation by which is inducible by E2. 
Treatment with 10 µM AR54 for 24 hours did not alter the expression of the ERα-regulated PS2 
gene transcripts (Fig 6.3B).  
At concentrations sufficient for inhibition of AR action, AR54 had little effect on two other 
members of the family of ligand activated nuclear receptors, GR or ERα. The results suggest that 
AR54 is a relatively specific inhibitor of AR-mediated transcription at or below 10 µM.  
AR54 inhibits Expression of Endogenous Androgen-regulated Genes - To evaluate the 
effect of AR54 on endogenous gene expression, the levels of mRNAs for several well–
characterized androgen-related genes were measured in LNCaP and LAPC-4 cells. In LNCaP 
cells, the PSA and TMPRSS2 genes are highly induced and RDC1 gene transcripts are down 
regulated by androgens working through AR. In LNCaP cells treated for 24 h, 10 µM AR54 
strongly inhibited the induction of PSA and TMPRSS2 mRNAs (Fig 6.4A) while reversing the 
androgen-induced reduction of RDC1 mRNA (Fig 6.4B). We also note that in the absence of 
androgens, AR54 treatment does not result in AR transactivation in LNCaP cells, thus indicating 
that it is a pure antagonist of AR action.  
AR54 also reduced the expression of PSA mRNA in a dose-dependent manner with an IC50 
of ~3 µM in LAPC-4 cells (Fig 6.4C). In summary, AR54 is able to inhibit AR-dependent 
proliferation and gene expression in LAPC-4 cells with a half maximal concentration of ~3 µM. 
AR54 Down-regulates AR Levels- Hypothetically, reduction of all AR signaling in tissue 
can be achieved by treatment with a small molecule that specifically and potently increases AR 
degradation. We analyzed AR protein levels from LAPC-4 cells treated with AR54. Western blot 
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analysis shows that in the presence and absence of androgen, 10 µM AR54 (Fig 6.5A, B, C) 
down-regulates AR protein levels. AR54 is at least as effective as ASC-J9, a curcumin derivative 
shown to increase AR degradation (13). Other AR inhibitors we identified, AR45 and AR52 did 
not down-regulate AR and serve as controls (Fig 6.5A). A time-course performed with 10 µM 
AR54 also shows reduced amounts of total AR when compared to R1881 treated control wells as 
early as 4 h after treatment (Fig 6.5C). 
Further analysis revealed that AR54 reduces AR mRNA levels in LAPC-4 cells (Fig 6.5D). 
This down regulation of AR mRNA is presumably responsible for the reduction in AR protein 
levels and seems to be specific for AR when compared to ERα. AR54 is unable to alter the levels 
of ERα mRNA in MCF-7 cells treated with estradiol (Fig 6.5E). We have tried to use 
actinomycin-D in LAPC-4 cells to dissect whether AR54 causes an increased degradation of AR 
mRNA, but have been unsuccessful in these experiments so far possibly due to the cell-damage 
elicited by actinomycin-D.  
AR54 Modestly Reduces Androgen-Independent Proliferation of CWR22Rv1 Cells- 
CWR22Rv1 is a CRPC cell line derived from the CWR22R subline, which was isolated from the 
recurrent tumor of the androgen-dependent CWR22 cells in castrated mice (21). This cell line 
contains full-length AR along with LBD-truncated AR splice variants. Some of these AR splice 
variants have been shown to have transactivation capacity similar to the full-length AR and are 
capable of eliciting androgen-independent proliferation in 22Rv1 cells.  
We also assessed the effects of treating 22Rv1 cells with 10 µM AR54. The results also 
showed that 1 nM DHT can promote cell growth modestly and AR54 suppressed the DHT-
induced cell growth (Fig 6.6A). Although the inhibitory effect of AR54 on 22Rv1 cell 
proliferation is slight, we are encouraged by the fact that these are comparable to what other 
researchers have observed in these cells (22, 23).  
We also examined the effects of AR54 on full-length AR and truncated AR-mediated 
targeted gene expression. 1 nM DHT modestly induced the expression of some AR-targeted 
genes in 22Rv1 cells. Addition of 10 µM AR54 suppressed PSA and KLK2 gene-expression in 
both DHT-mediated and androgen-independent environments.  
 
DISCUSSION 
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The AR remains a key target in CRPC. AR54, a novel compound, which acts by down-
regulating AR gene transcripts, has potential to show effectiveness against all AR-mediated 
actions in CRPC. AR54 is relatively specific for down-regulation of AR. Due to the substantial 
structural homology of the AR sequence with other steroid receptors, it is important for an 
inhibitor to exhibit specificity in binding AR without affecting the ubiquitously expressed GR, 
from a therapeutic and mechanistic point of view. For example, the last decade saw renewed 
interest in the ansamycin antibiotic 17-allylamino, 17-demethoxygeldanamycin (17-AAG) which 
was discovered to be an anti-tumor agent that binds and inhibits Hsp90. 17-AAG is able to 
disrupt the Hsp90-protein complexes and lead to the degradation of the associated proteins. A 
growing number of Hsp90 client proteins have been shown to be important for the development, 
proliferation and survival of several types of cancer, including prostate cancer. Inhibition of 
Hsp90 leads to the degradation of known oncogene products, such as Her2, BRAF, Erk1/2 and 
others, leading to the simultaneous blockade of multiple oncogenic transduction pathways (24). 
But the nonspecific disruption by 17-AAG of the interaction between Hsp90 and most of its 
associated proteins leads to extensive adverse and unwanted side effects including anorexia, 
diarrhea, nausea, fatigue, vomiting and the reversible elevation of liver enzymes and therefore 
limits the applicability of 17-AAG as a therapeutic molecule. 
If AR54 exhibited general toxicity in cells it might be expected to indiscriminately block 
R1881-bound AR induced target gene expression. The ability of AR54 to reverse both R1881-
AR mediated up regulation of target mRNAs (PSA and TMPRSS2) and down regulation of 
RDC1 mRNA provides evidence that AR54 is acting as a specific inhibitor of AR and not 
through non-specific toxic mechanisms. 
Importantly, by reducing AR mRNA levels, AR54 is likely to enhance effectiveness of 
current agents in resistant cells. Bicalutamide is a potent agonist in LNCaP/AR cells that 
overexpress AR, but is a full antagonist in the parental LNCaP cells expressing several fold less 
AR. By reducing AR levels, it is possible that AR54 could restore the antagonist activity of 
bicalutamide in some resistant cells.  
It remains unclear whether AR54 directly binds AR at all. Some evidence points to the 
possibility of AR54 suppressing AR action by altering some crucial signaling pathway. The 
possibility that AR54 changes the activity of certain microRNAs, resulting in reduced AR 
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transcript levels cannot be ruled out either. We are encouraged to pursue further mechanistic 
studies of AR54 action by its specificity for AR compared to ERα and GR. 
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FIGURES: 
 
Figure 6.1 
  
 
FIGURE 6.1. AR54 does not compete with androgens for binding to AR. A, Structure of 
AR54. B, Radioligand competition assay. Ligand-competition assays were performed using 5 nM 
[3H]-R1881 and indicated concentrations of unlabeled small molecules. In contrast to R1881 and 
the antiandrogens hydroxyflutamide (OHF) and bicalutamide, AR54 did not compete with 
labeled R1881 for binding to AR.  
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Figure 6.2 
 
FIGURE 6.2. Inhibition of R1881-dependent prostate cancer cell growth by AR54. Dose-
response study of AR54 inhibition of cell growth in LAPC-4 cells (A and B), PC3 cells (C), and 
MDA MB-231 cells (D). Adaptation to R1881-free medium, growth and calculation of cell 
numbers and MTS assays were as described in Chapter 3. LAPC-4 cells were maintained in 
medium containing 5% CD-FBS with (filled circles) or without (open circle, vehicle only) 1 nM 
R1881. PC3 and MDA-MB-231 cells were cultured in medium containing 10% FBS. Data is the 
average of 8 wells of cells ± S.E.M. The number of cells in 1 nM R1881+DMSO was set at 
100%. The IC50 for inhibition of LAPC-4 cell growth was calculated using Sigma Plot.  
(Data in Figure 6.2A: Khin Khin Soe H Wu) 
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Figure 6.3 
FIGURE 6.3. AR54 does not inhibit other steroid receptors at 10 µM.  
A, Two different stably transfected T47D stable cell lines were used to gauge the effect of AR54 
on ERα and GR mediated luciferase activity. Data is the mean of 3 independent experiments ± 
SEM. B, MCF-7 cells were plated in medium containing 5% CD-FBS, treated with 10 nM 
estradiol (E2) and 10 µM of the indicated inhibitors for 24 h before RNA extraction. mRNA was 
quantitated using qRT-PCR and normalized to β-actin. Data represent the mean of 3 independent 
experiments ± SEM.   
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Figure 6.4 
  
FIGURE 6.4. AR54 inhibits induction of AR-regulated genes. Hormone-depleted LNCaP 
(A,B) and LAPC-4 (C) cells were treated for 24 h and mRNA levels determined by qRT-PCR 
using β-actin to normalize. Data is the mean of 3 independent experiments ±SEM. 
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Figure 6.5 
 
FIGURE 6.5. AR54 down-regulates AR. A, Hormone-depleted LAPC-4 cells were maintained 
with or without R1881 with DMSO or 10 µM inhibitor for 24 hours. 10% polyacrylamide gel 
wells were loaded with equal amounts of protein in each lane, fractionated and analyzed by 
western blotting. B, LAPC-4 cells were treated with 5, 10 or 20 µM AR54 or 10 µM 
hydroxyflutamide (OHF) in the absence (-) or presence (+) of 1 nM R1881. Equal amounts of 
protein was loaded on 10% polyacrylamide gels, fractionated and analyzed by western blotting. 
C, LAPC-4 cells were treated with 10 µM AR54 or DMSO (--) in the presence (+) of 1 nM 
R1881 for the indicated amount of time (4 h, 8 h, 12 h, 24 h, and 48 h). Cells were lysed and 
protein analyzed by western blotting. The antibody used to detect AR was AR441 monoclonal 
antibody (NeoMarkers, Freemont, CA). D, Hormone-depleted LAPC-4 cells were treated for 24 
h and AR mRNA levels determined by qRT-PCR using β-actin to normalize. Data is the mean of 
3 independent experiments ±SEM. E, MCF-7 cells were treated with 10 nM estradiol (E2) for 24 
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h in the presence of 10 µM of indicated AR inhibitors (AR54, ARD67 or bicalutamide (Bic)). 
ERα mRNA levels determined by qRT-PCR and normalized to β-actin. Data is the mean of 3 
independent experiments ±SEM. 
 
Figure 6.6 
 
FIGURE 6.6. AR54 suppresses proliferation of 22Rv1 cells and inhibits AR-mediated gene 
expression. A, 22Rv1 cells were maintained for 4 days in 5% CD-FBS containing medium and 
plated at 5000 cells/well in 96-well plates. Cells were maintained without added androgens (no 
DHT) or with 1 nM DHT and the indicated concentrations of AR54 or hydroxyflutamide (OHF) 
and assayed using MTS after 5 days. Cell growth in DMSO after 5 days was set to 100% and 
data points represent the mean of 6 wells ± SEM. B, 22Rv1 cells were plated in 6-well plates and 
treated with indicated ligands and inhibitors for 24 h. PSA and KLK2 mRNA levels determined 
by qRT-PCR using β-actin to normalize.	  Significance of the differences between CPIC and the 
DMSO control was tested using Student’s T-test and p <0.05	  when compared to the respective 
controls. 
*	  
*	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SUPPLEMENTAL TABLES3 
Table 6S.1 
TABLE 6S.1. AR54 and some structural analogues. A common chemical scaffold of the 
compounds is shown, with R1, R2, R3, and R4 used for labeling the different substituents in the 
structure. Compounds were grouped into three categories based on a commonality indicated by 
the presence of phenyl, methoxy, methyl or none of the above groups at R1, R3 or R4.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  The supplemental tables and figures in Chapter 6 were prepared by Khin Khin So H. Wu and are used here with 
her permission. These were part of an independent study conducted by Ms. Wu. I express my sincerest gratitude to 
Ms. Wu for her assistance and support in completing this work.    
	  
Group 1: Phenyl 
Compound R1 R2 R3 R4 
AR54 Phenyl 
 
- - H - - H 
ARD61 Phenyl 
 
- - H - - H 
ARD55 Phenyl 
 
- - H - - H 
ARD53 Phenyl 
 
- - H - - H 
ARD03 Phenyl 
 
- - H - - H 
ARD42 Phenyl 
 
- - H - - H 
	  
Group 2:  No Phenyl, with methoxy 
 R1 R2 R3 R4 
ARD30 --H 
 
-OCH3 - - H 
ARD35 - - H 
 
- - H -OCH3 
ARD45 - - H 
 
-OCH3 - - H 
	  Group 3:  No Phenyl, with methyl 
 R1 R2 R3 R4 
ARD79 --H 
 
--H - - H 
ARD67 - - H 
 
--H --H 
ARD94 - - H 
 
-CH3 --H 
ARD279 - - H 
 
-CH3 --H 
 
145 
The actual structures of the analogues from Table 6S.1 are depicted below. 
 
Structures of AR54 analogues. These chemicals that are structurally related to AR54 were 
purchased from ChemBridge for structure-activity relationship studies.  
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Table 6S.2 
 
 
 
TABLE 6S.2. Properties of AR54 and analogues. MTS assays were performed to measure cell 
growth and inhibitory effects of compounds in different cell-lines. LAPC-4 and LNCaP are 
prostate cancer cell lines. MCF-10A is an AR-negative breast cancer cell line, and PC-3 is an 
AR-negative prostate cancer cell line. A luciferase reporter assay was performed with stable 
Compound 
LAPC4 
MTS 
(Potency) 
LNCaP 
MTS 
(Potency) 
MCF-10A MTS  
(Toxicity) 
PC-3 MTS 
(Toxicity) 
T47D-KBLuc 
(Specificity) 
G
R
O
U
P 
1 
AR54 IC50 ≈ 1 -2 µM IC50 ≈ 4µM 
Toxic at ≥20µM. 
(Drastic decline 
from 10 to 20 µM) 
Toxic. 60% cell 
viability at 30µM.  
65% inhibition at 
30µM 
ARD61 IC50 ≈ 1.5µM 
IC50 ≈ 
11.5µM 
Very toxic at 
≥10µM.  
10% cell viability 
at 20µM. 
54% inhibition at 
30µM 
ARD55 IC50 ≈ 1.5µM 
IC50 ≈ 
12µM 
Very toxic at 
≥20µM. 
40% cell viability 
at 20µM. 
40% inhibition at 
30µM 
ARD53 IC50 ≈ 6.5µM     
ARD03 IC50 ≥ 10.0µM     
ARD42 IC50 ≈ 2.5µM  
50% cell viability at  
≥ 5 µM. 
55% cell viability 
at 20µM.  
G
R
O
U
P 
2 
ARD30 IC50 ≈ 9µM 
IC50 > 
15µM 
No toxicity seen 
until 30µM. (85% 
cell viability) 
Minimal toxicity. 
80% cell viability 
at 30µM. 
 
ARD35 IC50 ≈ 10µM  
No toxicity seen up 
to 30µM.   
ARD45 IC50 ≈ 9.5µM  
No toxicity seen up 
to 30µM.    
G
R
O
U
P 
3 
ARD79 IC50 < 1µM 
IC50 ≈ 
14µM 
49% cell viability at 
20µM. 
49% cell viability 
at 30µM. 
25% inhibition at 
30µM 
ARD67 IC50 < 1µM IC50 ≈ 7µM 
73% cell viability at 
30µM. 
70% cell viability 
at 30µM.  
22% inhibition at 
30µM 
ARD94 IC50 ≈ 3.75µM 
IC50 > 
15µM 
No toxicity seen up 
to 30µM 
64% cell viability 
at 30µM. 
20% inhibition at 
30µM 
ARD279 IC50 ≈ 1µM 
IC50 ≈ 
9.5µM 
42% cell viability at 
30µM. 
46% cell viability 
at 20µM. 
No inhibition of 
activity up to 
30µM. 
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T47D-KBluc cells. The gray blocks indicate that the assay was not performed for that compound 
with that particular cell line, because the compound failed to show potential as an effective 
inhibitor. 
 
Figure 6S.1 
 
 
FIGURE 6S.1. ARD67 is a competitive inhibitor of AR. We analyzed the effect of DHT 
concentration on ARD67 inhibition of AR induced luciferase activity. HeLaA6 cells were seeded 
in 24-well plates and maintained for 24 h in medium containing 0.1 nM DHT (white bars) or 10 
nM DHT (black bars) and the indicated concentrations of ARD67. Luciferase units of DHT-
treated wells were set at 100%. Data represent the average of triplicate experiments ± SEM. 
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CHAPTER 7 
DISCUSSION 
 
Steroid hormone receptors play an important role in physiological development and in 
maintaining a healthy constitution. The significance of androgen and estrogen receptor action is 
emphasized by the fact that any deviation from their normal modus operandi can result in a range 
of chronic to morbid disorders. The androgen and estrogen receptors are unique among steroid 
receptors in their proliferative capacity; a trait that has serious ramifications in the context of 
prostate and breast cancer progression. For the past few years, our laboratory has been involved 
in efforts aimed at identifying and characterizing new small molecule inhibitors of androgen and 
estrogen receptor action. These inhibitors could then serve as starting points for the development 
of therapeutically relevant drugs and additionally be useful as probes to improve our 
understanding of steroid hormone receptor signaling. We performed a few moderate-to-high 
throughput screens to help us identify applicable chemical scaffolds. This document elaborates 
on screening methodologies and mechanistic studies performed to better understand the ‘lead’ 
chemicals we identified from each screen. 
 
High throughput screening 
HTS is a repetitive procedure once the steps required for implementation are designed. But it 
requires a fair amount of initial groundwork before assembly into a fully feasible high-
throughput screen. Since the screen for AR inhibitors was the first cell-based high throughput 
screen carried out on this campus, there was no template to follow. Every step in the screen was 
carefully planned and executed on a pilot scale before the actual screen. There were quite a few 
challenging hurdles before each segment of the screen was set up. For example, the liquid-
handling systems could only dispense certain fixed volumes of compounds and we had to make 
sure to design the screen in the most ‘pocket-friendly’ way possible. These constraints 
challenged us to devise new non-traditional ways, especially for cell-based screening and 
analysis.  
The first screen we set-up was a relatively easy biochemical assay. We tried to identify 
small molecules that interfere with the DNA binding function of full-length androgen receptor 
(AR). This fluorescence-based assay contained very few components and hence raised fewer 
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technical concerns. The most pertinent concern we had was regarding the intrinsic fluorescence 
activities of certain small molecules. These chemicals had to be eliminated as false positives, 
even though there was no telling whether any of them were real inhibitors. The screen had a 
robust Z’-factor value of 0.8, which makes it a very strong assay for HTS. We were able to 
execute the screen using 2.5 µM of each compound, a low concentration, in hopes of identifying 
only potent inhibitors. By comparing the results of the AR screen to similar screens performed 
using estrogen and progesterone receptors, we were able to eliminate most of the non-specific 
inhibitors. Everything seemed fine until we tested these chemicals in cell-based assays. With the 
exception of one, all the small molecules failed to suppress androgen-mediated luciferase 
expression, presumably due to their lack of cell permeability. We were unable to pursue the only 
viable compound identified by this screen due to lack of availability and challenging synthesis 
protocols involving explosives (1).  
Our experience made us reevaluate our approach and we decided to set up a cell-based HTS 
of a much larger chemical library with the hope that individual hits will be identified with better 
potency, efficacy and specificity. A significant part of HTS success is dependent on the design 
and execution of the primary screening procedure. The more stringent and rigorous screens are 
rewarded with fewer false positives and false negatives. Cell-based assays combine the 
biological complexity of live cell responses with the scalability and process adaptation of HTS 
but it is an inherently challenging operation. The high degree of crosstalk between signaling 
pathways in a cell makes it biologically complex and increases potential sources of noise and 
variability. But on a positive note, it also makes the screen unbiased to a certain degree and 
allows of the identification of small molecules with different modes of action. 
Many months were spent in validating the individual steps in the cell-based HTS screen. Just 
for comparison, the FAMA screen took one week for the primary screen with ~4 weeks of assay 
development. The cell-based HTS assay development took a few months to establish and the 
primary screen itself spanned several months. During the assay development phase, we designed 
a new way for performing cell-based screening as detailed in Chapter 3.  
One major drawback of the screen was the increased incidence of false-positives, which in 
reality were cytotoxic chemicals. It would have been advantageous to couple the luciferase 
reporter-based primary screen to a toxicity screen in AR-negative cells. We tried to circumvent 
this issue by selecting a larger pool of compounds for secondary screening. Generally a hit rate 
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of 1-2 compounds/384-well plate is considered to be ideal after primary screening, but we 
selected about 5-6 compounds/plate. 
The screen was implemented using a stable HeLa cell line that expresses luciferase enzyme 
robustly in response to androgens, working through the stably expressed AR. Although, it is 
known that most well-studied prostate cancer cell lines are unsuitable for HTS (LNCaP, attach 
poorly to wells while LAPC-4 cells have a long doubling time) it might still have been 
advantageous to use a prostate cancer derived cell line for the purpose of the primary screen. 
This might have ensured that the small molecules are able to work in signaling network and co-
regulator environment mimicking actual prostate tissue. 
The most common potential alternative to HTS is to identify hits using rational design or 
virtual screening. These approaches require significant structural information that is not currently 
available for much of AR. The N-terminal region of AR plays a critical role in transactivation. 
This unstructured region has been elusive to structural studies. Until the crystal structure for the 
AR amino-terminal domain is solved, it remains difficult to predict chemical scaffolds that could 
interact successfully at this domain and inhibit AR transactivation. Thus rational design and 
virtual screening are presently not feasible and HTS is the only realistic approach for identifying 
novel inhibitors that act outside the ligand binding domain of AR.  
In spite of the reasonable success of our AR HTS, it remains puzzling that we found no 
specific AR inhibitor with potency in the nanomolar range, unlike the ER screen performed by 
others using the same set-up in different cells. Is ER easier to inhibit than AR? It is certainly 
possible, and what we observed in practice, but real proof for such a hypothesis is not available 
at this time. One point to note is the shorter and comparatively less active amino terminal domain 
of ER, which makes it a much more structured protein than AR. The flexible AR NTD 
constitutes more than half this protein and could be contributing to being harder to inhibit by 
requiring higher affinity small molecule binding. 
 
AR54  
We are only at the preliminary stages of lead development of this small molecule. Listed 
below are some experiments to shed light on the mechanism of action of AR54 and to enable us 
to tap into its long-term therapeutic potential, if any. 
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Does AR54 directly bind AR? - As AR54 is not a competitive ligand, it is of utmost 
importance that we show conclusively whether or not it binds the androgen receptor. Recently, 
Anderson et al. used alterations in fluorescence emission patterns to help show that EPI-001 a 
small molecule AR inhibitor binds specifically to the AR N-terminal domain (2). Steady-state 
fluorescence emission spectra of full-length AR bound to AR54 could be performed if large 
amounts of purified androgen receptor are available. By analyzing fluorescence emission from 
tryptophan (λmax 343 nm) and tyrosine (λmax 305 nm) residues in the receptor, and by 
comparing the spectra resulting from solutions containing DMSO, AR54, or an inactive analogue 
of AR54, it is possible that we can deduce whether AR54 truly binds AR. Using synthetic 
chemistry, if a successful fluorescent analogue of AR54 is developed, it will be feasible to use 
that for binding studies (As demonstrated for EPI-001 in a talk by Dr. Marianne Sadar at the 
ENDO2011 Conference).  
How does AR54 decrease AR mRNA levels?- Experiments in LAPC-4 cells using 
actinomycin-D, an inhibitor of transcriptional initiation, have been unsuccessful so far. The 
concentrations of actinomycin-D used in these experiments were in the highest range possible 
without killing cells, and yet were incapable of reducing AR mRNA levels in the control 
treatments. AR54 at concentrations ≤10 µM are specific for AR mRNA suppression when 
compared to ERα. The major mechanisms to probe for would include transcriptional control by 
regulators at the AR gene level or translational repression and gene silencing resulting from 
microRNA action.  
The long-term goal of this study is the development of potent small molecule inhibitors, 
capable of enhancing AR degradation at the molecular level that translates into increased 
survival in various models of prostate cancer.  
 
CPIC; a promising new inhibitor of AR action  
We aspire to advance this promising AR inhibitor or one of its putative analogues, from 
mechanistic studies in the laboratory through preclinical studies. Although discussed here, these 
long-term goals are beyond the scope of this thesis.  
Identify the site(s) on AR that interact with CPIC - We recently showed that CPIC robustly 
inhibits transactivation by the N-terminal AR-1-660. Based on our data, the IC50 for CPIC 
inhibition of AR-1-660 is likely in the range of 200 nM. This inhibition is not due to non-specific 
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toxicity as transfections with GAL-VP16 in the same cell line treated with 10 µM CPIC show no 
inhibition. In addition to its actions at the N-terminus of AR, CPIC also exhibits properties 
consistent with action as a competitive inhibitor of androgen binding to full-length AR (Chapter 
4). This suggests that the inhibitory effects of CPIC may be mediated through multiple regions of 
AR, or by inhibiting AR binding to DNA response elements. Competition assays with purified 
AR LBD can be used to determine whether CPIC retains the ability to exhibit a competitor 
phenotype without the AR N-terminus. Alterations in the fluorescence spectrum of expressed AR 
NTD, LBD and DBD  can also be used to identify the site(s) on AR that interact with CPIC. 
CPIC reduces the AR N/C interaction, presumably by interacting with the AR-NTD. One 
possibility is that CPIC binding induces an AR conformation that disfavors androgen binding 
and is inactive. Androgen binding induces an alternative active conformation that opposes the 
effect of CPIC. In this model, CPIC binding in the N-terminal region exhibits a “competitor 
phenotype”- even though it does not directly compete with androgens for binding in the ligand-
binding domain. The major effect of this model is that in cases of CRPC when androgens are 
either absent or present at post-castration low concentrations, CPIC will be a considerably more 
effective inhibitor of AR action than it is in our early tests conducted at very high saturating 
concentrations of androgens. Alternatively, it remains possible that CPIC inhibits some unknown 
external factors (such as cytokines, kinases or growth factors), the activity of which might be 
crucial for AR transactivation in all cell types. Since CPIC is relatively specific for inhibition of 
AR and not other steroid receptors, this seems less likely. 
Determine the mechanism by which CPIC inhibits transactivation by constitutively active 
AR - It might be interesting to determine whether CPIC inhibits constitutive AR N-terminal 
activity in the same way as it inhibits full-length AR. These studies could include nuclear 
compartmentalization, DNA binding and coregulator recruitment, coimmunoprecipitation, RNAi 
knockdown, protein expression, mammalian two-hybrid assays, ChIP, microarrays and 
bioinformatics. They could establish whether CPIC uses the same mechanism to inhibit truncated 
and full-length AR, and whether N-terminal and full-length AR use the same pathway and 
coregulators to activate target genes.  
Lead optimization of CPIC using limited structure-activity relationships (SAR) - A dozen 
commercially available structural analogues of CPIC were evaluated as part of optimization 
studies. One small molecule PIC19.7 was identified to have partially activity in inhibiting AR 
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transactivation, while all the other analogues of this chemical family tested were inactive (data 
not shown). This limited structural data could serve as a guide for synthesis of CPIC derivatives 
with improved potency and specificity. Promising compounds that emerge from optimization can 
be evaluated for specificity in cell-proliferation studies using multiple AR and AR N-terminal 
positive and negative cell lines, tested for effectiveness against AR1-660 and constitutively 
active splice variants ARv567es reported in CRPC. Microarrays studies or on a more ambitious 
note, multiplex gene expression studies (using platforms like the Luminex FlexGene LDA assay 
or L1000) can test for off-target effects and a genome-wide transcriptional profiling of CPIC 
treatment. 
Test CPIC in mouse xenograft models- The in vivo effectiveness of CPIC (or the best 
compound to emerge from optimization) has to be determined before we can ascertain that it has 
potential for use in human therapy. This could be tested in the androgen-dependent CWR22 
human prostate cancer xenografts. There are no widely accepted xenograft models whose growth 
is driven by an AR splice variant. The CWR22 human prostate cancer xenograft resembles the 
majority of prostatic cancers. The tumor secretes PSA, regresses after castration and recurs as a 
palpable, growing, and ultimately fatal tumor.  
In the long-term, CPIC might be suitable for further optimization and development as a 
potential therapeutic for aggressive late-stage prostate cancers resistant to current therapies. 
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